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Abstract 
 
Cystic fibrosis (CF) is a debilitating disease caused by mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene, which codes for the CFTR anion 
channel. ΔF508, the most common CF-associated mutation, causes both a gating and a 
trafficking defect in the CFTR protein. 
This thesis describes the optimisation and use of two fluorescence assays, capable of 
measuring the two defects caused by the ΔF508 mutation. 
Yellow fluorescent protein (YFP)-CFTR, in which halide sensitive YFP is tagged to the N-
terminal of the CFTR coding sequence, is a functional assay, used to test for ΔF508-CFTR 
potentiator activity. CFTR-pHTomato, in which the pH sensor is tagged to the fourth 
extracellular loop of CFTR, is used to measure membrane density and internal CFTR 
expression. 
Human embryonic kidney cells (HEK293 cells), expressing YFP-ΔF508-CFTR were used to 
screen a pilot library of compounds with some structural similarity to known potentiator VX-
770. Ligand-based virtual screening was then used to construct two further libraries, based 
on VX-770 and the lead hit compound from the pilot screen. A number of novel ΔF508-CFTR 
potentiators were identified in each of the screens. 
Recently published studies suggest that chronic treatment with VX-770 decreases ΔF508-
CFTR density at the plasma membrane, potentially limiting its clinical effectiveness. ΔF508-
CFTR-pHTomato was used to show that a number of hit compounds from our screens did 
not decrease membrane density of ΔF508-CFTR. 
The YFP-CFTR assay was also used for studies investigating the mechanism of potentiation 
by VX-770. We provide evidence that WT-CFTR does not require phosphorylation for 
potentiation by VX-770, which has not been reported previously. Additionally, studies using 
gating mutations do not support the current hypothesis that VX-770 stabilises the post-
hydrolytic open state in the CFTR gating cycle. 
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Chapter 1 
Introduction 
 
1.1 Cystic fibrosis disease overview 
1.1.1 Cystic Fibrosis 
Cystic fibrosis (CF) is the most common life-threatening hereditary disease in the Caucasian 
population, affecting approximately 10,500 patients in the UK (UK CF Registry annual report 
2014). The disease is caused by mutations in the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene, which codes for the CFTR chloride (Clˉ) channel. To 
date, over 2,000 mutations have been identified in the CFTR gene (www.cftr2.org).  
Due to widespread expression of CFTR in the body, CF manifests as a multi-organ disease, 
although the severity of specific symptoms varies between patients. Clinically, the most 
prevalent symptom of CF is lung disease - characterised by persistent coughing, wheezing 
and repeated chest infections. Colonisation of lung epithelium by bacteria such as 
Pseudomonas aeruginosa, which forms antibiotic-resistant biofilms (Singh et al., 2000), 
induces a chronic infection and inflammation cycle, leading to progressive organ 
degeneration. 85% of CF patients have pancreatic insufficiency, causing malnutrition and 
poor weight gain, and an abnormality of the vas deferens development leaves most male 
patients infertile (Lubamba et al., 2012). Life expectancy of CF patients has improved 
dramatically since the disease was first described in the 1930s, from infancy to a projected 
survival age of 50 for children born with CF since 2000 (Dodge et al., 2007). However, the 
increased age of the patient population has exposed multiple CF co-morbidities, such as CF-
related diabetes, osteoporosis and arthritis.  
With no cure available, the majority of CF patients are treated only for symptoms. Despite 
vast improvements in care, the life of a CF patient is still blighted by a daily treatment 
regimen of physiotherapy, antibiotics, bronchodilators, and enzyme tablets.  
1.1.2 CF pathophysiology 
The CFTR anion channel is expressed on the apical membrane of epithelial cells, where it 
plays a role in regulating transepithelial fluid flow in many organs. In CF, Clˉ transport 
through CFTR is reduced or eliminated. Although this is known to be the basis of the 
disease, the order of events leading to the development of symptoms is not entirely 
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understood. Many theories exist as to how mutations in CFTR contribute to progression of 
CF pathology. 
1.1.2.1 Dehydrated airway surface liquid hypothesis 
Airway surface liquid (ASL) is a film of fluid lining the airway lumen, covering the epithelial 
surface. It is composed of the airway mucus layer, separated from the epithelium by the 
watery periciliary liquid layer. In healthy lungs, the periciliary liquid layer allows beating of 
cilia, resulting in mucus movement towards the pharynx and eventual clearance, defending 
from infection by removing particles which become trapped in the mucus layer. In CF, 
mucociliary clearance is impaired, making airways more vulnerable to infection and 
inflammation, ultimately leading to respiratory failure (Boucher, 2007).  
 
One widely accepted theory claims that reduced mucociliary clearance in CF is due to 
dehydration of the ASL. Decreased apical Clˉ efflux via CFTR and increased sodium (Na+) 
absorption via epithelial Na+ channels (ENaC) reduces the water content of the ASL (Figure 
1.1). Dehydrated, heavy mucus lining the airways of CF patients is difficult to shift by 
coughing, and prone to infection.  
Figure 1.1 ASL regulation in healthy and CF airways. Left: In healthy airways, 
transepithelial Clˉ transport via CFTR (apical) and NKCC1 (basolateral), and Na+ transport 
via ENaC (apical) and the Na+/K+ ATPase (basolateral) regulates the water content of the 
ASL. A sufficiently large volume of watery ASL allows mucociliary clearance of the airways. 
Right: In CF, Clˉ transport via CFTR is reduced or eliminated, Na+ transport via ENaC is 
increased, and the volume of watery ASL is reduced. Dense mucus prevents cilia from 
beating. 
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Nasal potential difference (NPD) measurements are used to assess the apical Clˉ and Na+ 
permeability of nasal cells, providing useful information for CF diagnosis. As well as reduced 
Clˉ permeability, CF patient NPD recordings show transepithelial potentials very strongly 
altered by the ENaC channel blocker amiloride (Middleton and House, 2010), suggesting 
increased ENaC activity. It is not clear whether this is due to direct regulation of ENaC by 
CFTR (Stutts et al., 1995), or an indirect effect, for example mediated by reduced Clˉ 
permeability (Bachhuber et al., 2005).  
1.1.2.2 Bicarbonate and pH hypothesis 
CFTR is also permeable to bicarbonate ions (HCO3ˉ), with a permeability ratio of 0.14 
compared to Clˉ (calculated from bi-ionic reversal potential shifts; Linsdell et al., 1997). 
CFTR function, therefore, has the capacity to influence local pH on epithelial surfaces. The 
pH of the ASL in CF airways is ~0.5 pH units lower than that of healthy epithelia (Coakley et 
al., 2003). This has the potential to affect pH-dependent processes on the apical membrane. 
For example, secreted protein short palate, lung, and nasal epithelial clone 1 (SPLUNC1), a 
regulator of ENaC, is unable to interact with ENaC in the acidic pH of CF ASL (Garland et 
al., 2013). Dysregulation of ENaC allows hyperabsorption of Na+, and likely contributes to 
dehydration of the ASL. Low pH-ASL also has reduced bactericidal properties, which 
contributes to the chronic airway infections associated with CF (Pezzulo et al., 2012) 
1.1.2.3 Immune response hypothesis 
Upon exposure to bacteria, a large inflammatory response is launched in the CF lung. 
However, this response is ineffective in eradicating infections. It remains unclear whether 
chronic inflammation is a secondary symptom of the disease, caused by increased pathogen 
exposure, or a primary defect in CF (Ratner and Mueller, 2012). 
CFTR mutations have been associated with constitutive inflammatory status and neutrophil 
accumulation in the naive CF airway (Tirouvanziam et al., 2000). This suggests that even 
before pathogen exposure, CF airways are in an inflammatory state. An intrinsic inability to 
eradicate bacteria, as seen in the newborn pig, has been suggested as the defect which 
initiates the inflammatory pathology seen in CF (Stoltz et al., 2010).  
It has also been hypothesised that expression of CFTR on immune cells is the cause of 
irregularities in the immune response (Mueller et al., 2011). The fact that CF patients do not 
suffer with widespread infections casts doubt upon this theory.  
The progression of CF disease is likely to be influenced by some, or all, of the events 
discussed here, but the respective weight of these factors is disputed. Whilst multiple 
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theories of CF disease aetiology exist, most would agree that correction of Clˉ transport via 
CFTR would be, at least somewhat, successful in treating the disease. Indeed, the clinical 
success of Ivacaftor (Vertex Pharmaceuticals; Ramsey et al., 2011), the first approved drug 
to target CFTR directly, supports this concept. 
1.1.2.4 CF-causing mutation classes 
CFTR mutations are grouped into classes I to VI, according to the nature of the effect on the 
CFTR protein (Figure 1.2). Class II includes deletion of phenylalanine at position 508 
(ΔF508), which is the most common CF-causing mutation, found on at least one allele in 
~90% of patients (UK CF Registry annual report 2014). 
The native mutation carried by ΔF508-CF patients is not a straightforward loss of the triplet 
encoding F508. Rather, it is the loss of the last one or two nucleotides of the triplet encoding 
isoleucine 507 (ATC), and of the first one or two nucleotides of the triplet encoding 
phenylalanine 508 (TTT). The loss of these three nucleotides, therefore, also results in a 
synonymous codon change at I507 (ATC to ATT). The synonymous mutation itself 
contributes to the ΔF508-CFTR phenotype by changing the rate of cotranslational folding 
and CFTR:chaperone interactions, which affects endoplasmic reticulum (ER)-associated 
degradation (ERAD) (Lazrak et al., 2013; Shah et al., 2015).  
Due to the prevalence of this mutation in the patient population, this project focussed on CF 
caused by ΔF508, and the associated drug discovery effort. All ΔF508-CFTR work was 
carried out using plasmids encoding the native human ΔF508-CFTR, including the 
synonymous I507-ATT mutation. 
1.2 WT-CFTR gating 
CFTR is a member of the ATP-binding cassette (ABC) transporter superfamily, unique in 
that it functions as an ion channel rather than as an active transporter. Two membrane 
spanning domains (MSDs), formed of 12 transmembrane helices (TMs), form an anion 
selective pore in the plasma membrane (Figure 1.3). TMs are linked by intracellular loops 
(ICLs) and extracellular loops (ECLs). Gating is controlled by intracellular domains: two 
nucleotide binding domains (NBDs) and the regulatory (R)-domain. Protein kinase A (PKA)-
dependent phosphorylation of multiple sites on the R-domain is generally thought to be 
necessary as a pre-requisite for CFTR gating. Once phosphorylated, gating of the pore is 
controlled by adenosine triphosphate (ATP)-dependent NBD dimerisation and separation. 
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Figure 1.2 CFTR mutation classes. Modified from Boyle & De Boeck 2013. Top left: WT-
CFTR is processed at the ER and trafficked to the Golgi, where it undergoes complex 
glycosylation. Mature CFTR is expressed at the membrane with a long half-life (~16 h; 
Sharma et al., 2004). Top right: Class I mutations introduce premature stop codons, which 
produce unstable partial mRNA strands, incapable of undergoing translation. Class II 
mutations cause a folding defect, recognised by quality control mechanisms and targeted for 
proteasomal degradation. Bottom left: Classes III and IV cause functional defects, either by a 
gating defect (class III), or reduced single-channel conductance (class IV). Bottom right: 
Class V mutations are mostly splicing defects, which reduce the amount of correct CFTR 
mRNA, so protein expression is reduced. Class VI mutations reduce stability at the 
membrane.  
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The NBDs form a head-to-tail dimer, creating two ATP-binding sites at the interface: non-
catalytic site 1 and catalytic site 2 (Figure 1.4). ATP binds and remains bound at site 1 
throughout many gating cycles (Tsai et al., 2010). Upon ATP binding at site 2, NBD 
dimerisation is favoured, and a conformational change is transmitted to the TMs, such that 
the CFTR pore opens (O1 state; Vergani et al., 2005). The channel remains open until ATP-
hydrolysis occurs at site 2, whereby CFTR enters a short-lived post-hydrolytic open state (O2 
state), and eventually closes (Jih et al., 2012b; Jih and Hwang, 2013). Due to the stability of 
the O1 state, very few wild type (WT)-CFTR gating events terminate via the non-hydrolytic 
pathway (Csanády et al., 2010). 
The mechanism by which phosphorylation of the R-domain regulates CFTR gating is not 
entirely clear. The R-domain is a ~200 amino acid, intrinsically disordered structure, unique 
to CFTR. Crystal structures of other members of the ABC transporter superfamily do not 
contain the R-domain and flexibility of the domain means crystallisation has so far been 
impossible. Low resolution 3D structural studies suggest the R-domain lies in close proximity 
to the ICLs, in unphosphorylated CFTR (Zhang et al., 2011). Little else is known about the 
location of the R-domain in inactive and gating CFTR, which makes deduction of the 
regulatory mechanism challenging.  
Fifteen phosphorylation sites have been identified on the R-domain, with no specific site 
critical for activation, but rather phosphorylation of multiple sites has a cumulative effect 
(Chang et al., 1993). It appears that the unphosphorylated R-domain has an inhibitory effect 
on the channel, as CFTR with the R-domain missing (CFTR-ΔR) is capable of normal gating 
in the absence of phosphorylation (Chan et al., 2000). Studies of the isolated R-domain have 
Figure 1.3 CFTR topology. CFTR is formed of two MSDs, each formed of six TMs. The two 
MSDs are linked by NBD1, and the R-domain, unique to CFTR. The C-terminal of MSD2 is 
followed by NBD2. CFTR activation is regulated by PKA-dependent phosphorylation of the 
R-domain.  
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demonstrated dynamic interdomain interactions in CFTR. For example, the 
unphosphorylated R-domain interacts strongly with NBD1, whereas the phosphorylated R-
domain interacts with the C-terminal (Kanelis et al., 2010; Bozoky et al., 2013).  
One hypothesis for regulation is that the R-domain is located in an inhibitory position, 
physically preventing NBD dimerisation. Upon phosphorylation, a conformational shift 
causes the R-domain to move away from NBD1 and bind either another domain, such as the 
C-terminal, or an accessory protein, to allow NBD dimerisation and gating (Kanelis et al., 
2010; Bozoky et al., 2013).  
 
 
 
 
 
1.3 ΔF508-CFTR: Causes of the gating defect 
The ΔF508 mutation affects the folding of CFTR during biosynthesis, causing production of 
an aberrant protein, which is recognised by quality control mechanisms and targeted for 
proteasomal degradation. There are ways in which this can be overcome in the laboratory to 
enable the study of ΔF508-CFTR ion channel function at the plasma membrane. 
Figure 1.4 WT-CFTR gating mechanism. Following phosphorylation of the R-domain by 
PKA, ATP binds the two ATP-binding sites located at the interface of the NBD dimer (C2-
ATP). ATP remains bound at non-catalytic site 1 (see inset) for many gating cycles. Upon 
ATP binding at site 2, and NBD dimerisation, the channel opens (C2-ATP ↔ O1). Channel 
closure is triggered by ATP hydrolysis at site 2 (O1 ↔ C2, via the short-lived O2). Orange = 
ATP. 
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Single channel patching of rescued ΔF508-CFTR showed a ~15-fold reduction in open 
probability (Po), caused mainly by a decrease in the opening rate (Dalemans et al., 1991; 
Miki et al., 2010). The cause of the gating defect is unknown. It is unlikely to be caused by a 
disruption of ATP binding, because although F508 is located in NBD1, homology models 
suggest that it is not positioned at the NBD dimer interface (Serohijos et al., 2008). Strong 
phosphorylation of ΔF508-CFTR demonstrates that normal gating can be achieved. In these 
conditions, the dose-response curve to ATP is not shifted, suggesting that indeed affinity for 
ATP binding is unchanged (Wang et al., 2000). Moreover, isolated NBDs do not display 
reduced ATP binding affinity when ΔF508 is introduced (Rabeh et al., 2012).  
Homology models suggest the functional defect is more likely caused by altered interdomain 
interactions. One such interaction is at the NBD1:ICL4 interface, an interaction which is 
modified in ΔF508-CFTR (Serohijos et al., 2008). It is possible that the trigger for opening, 
which comes from NBD dimerisation, is not effectively transmitted to the TMs that form the 
pore, due to disruption at this interface. Cross-linking residues on either side of the interface 
abolishes gating (Serohijos et al., 2008). This suggests that dynamic interaction between the 
two domains is necessary to allow CFTR gating.  
The slow opening rate associated with ΔF508-CFTR is indicative of a higher energetic 
barrier to opening, i.e. a higher-energy transition state with respect to the closed state. It has 
recently been shown that the transition state of CFTR contains dimerised NBDs, but the pore 
remains closed (Sorum et al., 2015). This suggests that a great deal of molecular strain 
exists between the NBDs and the pore, likely at the interface at which F508 is located, 
underlying the high-energy transition state of CFTR gating. It is likely that loss of F508 
creates extra strain at this interface, destabilising the transition state with respect to the 
closed state, to slow opening (Sorum et al., 2015). Indeed comparing gating characteristics 
of F508C, before and after reacting with an aromatic sulfhydryl reactive reagent (Cui et al., 
2006), suggests that partially repairing this interaction goes some way to correcting the 
gating defect.  
Phosphorylation of the R-domain also appears to contribute to the ΔF508-CFTR gating 
defect. As mentioned, high concentrations of PKA can overcome the defect resulting in 
gating with a Po similar to that of WT-CFTR (Wang et al., 2000). In these conditions, 
macroscopic ΔF508-CFTR patches are much slower to reach steady state activation 
following exposure to PKA. Others have recently shown that there is a reduction in 
phosphorylation at specific sites when comparing activated ΔF508-CFTR and WT-CFTR 
(Pasyk et al., 2015).  These studies suggest that ΔF508-CFTR is not as good a substrate for 
PKA as WT-CFTR, but if maximal phosphorylation is obtained, gating is not abnormal.  
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As discussed below, loss of F508 induces a global conformational change in CFTR. Such a 
change is expected to impact many interactions, some of which are likely to be involved in 
gating. It seems probable that the gating defect is caused by both a change in 
phosphorylation propensity, and altered interdomain interactions required for opening of the 
pore. 
1.3.1 ΔF508-CFTR potentiator compounds 
A number of CFTR potentiators have been identified, with Ivacaftor (in which the active 
component is VX-770) approved in 2012 for the treatment of CF caused by G551D and a 
number of other gating mutations (Van Goor et al., 2009, 2013; Yu et al., 2012). This class of 
mutations (class III, Figure 1.2) is the most promising group for treatment by CFTR 
potentiators, because, for these mutant CFTR molecules, trafficking and maturation is 
normal (Gregory et al., 1991; Bompadre et al., 2007). As the only approved CFTR 
potentiator, VX-770 was used throughout this project as a benchmark compound and 
positive control. 
Successful clinical trials using VX-770 to treat G551D-CF patients - 15% improvement in 
lung function (measured by forced expiratory volume in one s; FEV1), sweat Clˉ levels 
reduced to below that which indicates CF, and increased weight gain (Ramsey et al., 2011; 
Davies et al., 2013) – led to the approval of VX-770 for the treatment of G551D-CF patients.  
Following promising in vitro data (Van Goor et al., 2009), VX-770 was tested as a treatment 
for ΔF508-CF, but failed to have a clinical effect (Flume et al., 2012), presumably because 
an insufficient number of ΔF508-CFTR molecules are located at the membrane (class II, 
Figure 1.2). Therefore, combination treatment using VX-770 alongside processing corrector 
compound Lumacaftor (Vertex Pharmaceuticals; active component VX-809), which promotes 
trafficking of ΔF508-CFTR to the membrane, was tested in clinical trials (Wainwright et al., 
2015). In 2015, Orkambi (Vertex Pharmaceuticals; VX-770/VX-809 combination treatment) 
was approved for the treatment of ΔF508-CF homozygous patients, despite much smaller 
clinical gains than those obtained by VX-770 treatment of G551D-CF patients. 
The mechanism by which VX-770 exerts potentiator effects is only partially understood. 
Generally, compounds stabilise the open state or increase the opening rate in order to 
potentiate CFTR gating. For example, slowing ATP hydrolysis (as seen with VRT-532; 
Wellhauser et al., 2009), or stabilising the NBD dimer (e.g. with non-hydrolysable ATP 
analogues), potentiates CFTR gating.  
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Single channel patch traces of WT-CFTR and G551D-CFTR show an increase in Po in the 
presence of VX-770, achieved mainly by an increase in mean open time (Van Goor et al., 
2009; Yu et al., 2012). Whilst open time of WT-CFTR is dependent on ATP-hydrolysis, 
G551D-CFTR does not undergo ATP-hydrolysis, and gates only via infrequent ATP-
independent events (possibly via C2 ↔ O2; Li et al., 1996; Bompadre et al., 2007). 
Stabilisation of the O2 state has been proposed as a mechanism by which both ATP-
dependent and ATP-independent open events could be prolonged (Figure 1.4; Jih and 
Hwang, 2013).  
1.4 WT-CFTR folding and trafficking 
Although potentiation of ΔF508-CFTR gating is a key step in reversing the molecular defect 
caused by the mutation, this method has so far been ineffective in the clinic (Flume et al., 
2012). Assuming this is caused by a lack of ΔF508-CFTR at the plasma membrane, effective 
trafficking correctors (such as VX-809) might enable potentiators to exert a clinical effect. 
The ΔF508-CFTR folding defect is complex and first requires a description of WT-CFTR 
folding and trafficking. 
Full length WT-CFTR exists in three distinct forms: unglycosylated, core-glycosylated, and 
complex-glycosylated CFTR. The three glycosylation states can be clearly identified by size 
when visualised on an immunoblot, and are often referred to as bands A, B and C, 
respectively. Core-glycosylation occurs at the ER, and thus represents immature, ER-
associated CFTR. Complex-glycosylation occurs at the Golgi, and therefore is present only 
on mature, membrane-associated CFTR (Cheng et al., 1990). Due to cotranslational 
glycosylation, band A is not detected in cellular extracts. 
CFTR folding takes place both cotranslationally within the ER membrane (Lu et al., 1998), 
and posttranslationally (Du et al., 2005). Individual domain folding, interdomain interactions 
and domain swapping must occur in a precise manner, in order to influence each other 
appropriately. A mutation in one domain can therefore influence the folding and structure of 
other domains, or even the entire protein (Du and Lukacs, 2009). Figure 1.5A shows the 
interdomain interactions that occur during WT-CFTR folding. During translation, NBD1 
interacts with MSD1 and MSD2, to form a compact, four domain unit (MSD1, NBD1, R-
domain and MSD2) capable of export from the ER. NBD2 is incorporated posttranslationally 
to form a folded, functioning channel inserted in the plasma membrane. WT-CFTR remains 
at the membrane with a half-life of ~16 h (Sharma et al., 2004), where it is maintained via 
endosomal recycling, or targeted to lysosomes for degradation (Ameen et al., 2007).  
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1.5 ΔF508-CFTR – the folding defect 
The loss of phenylalanine at position 508 prevents maturation to complex-glycosylated, 
membrane-associated CFTR (Cheng et al., 1990). A global misfolding of the protein causes 
retention of ΔF508-CFTR at the ER, from where it is degraded by ERAD mechanisms. Any 
ΔF508-CFTR which escapes ERAD to acquire plasma membrane localisation has a short 
half-life (< 4 h; Lukacs et al., 1993) due to increased degradation and reduced recycling 
(Okiyoneda et al., 2010). 
The ΔF508 mutation destabilises the NBD1 domain, where it is located, and disrupts 
interdomain interactions with MSD1 (via ICL1) and MSD2 (via ICL4) during cotranslational 
folding. This, in turn, prevents posttranslational incorporation of NBD2. NBD1 destabilisation 
and interface disruption are the two primary folding defects associated with ΔF508-CFTR 
(Figure 1.5B). 
CFTR homology models, based on crystal structures of ABC exporters, indicate that F508 is 
located on the surface of NBD1, at the proposed interface between NBD1 and ICL4 
(Serohijos et al., 2008). Initially, this lead to the assumption that the mutation did not perturb 
NBD1 structure, but rather the defect was caused by defective interdomain assembly. Repair 
of the NBD1:ICL4 interaction using revertant mutation R1070W, which introduces an 
alternative aromatic residue to the interface, increases the appearance of mature ΔF508-
CFTR. Additionally, introducing the R1070W mutation in the WT-CFTR background 
decreases maturation, presumably by disrupting the NBD1:ICL4 interaction (Thibodeau et 
al., 2010). This suggests that the NBD1:ICL4 interaction is necessary for proper folding, and 
disturbance of the interface causes a folding defect similar to that of ΔF508-CFTR.  
ΔF508-CFTR/R1070W also improves the Po compared to ΔF508-CFTR (Rabeh et al., 2012). 
This again highlights the importance of the NBD1:ICL4 interface in determining the energetic 
barrier to CFTR gating (Sorum et al., 2015). 
Publication of the ΔF508-NBD1 crystal structure, which was similar to WT-NBD1, supported 
the interface theory, as the only noticeable difference was seen at the proposed ICL4 
interface (Lewis et al., 2005). However, it has since been shown that ΔF508 also impacts on 
both the thermodynamic and kinetic stability of isolated NBD1 (Hoelen et al., 2010; Rabeh et 
al., 2012). It is possible that the similarity of the ΔF508-NBD1 and WT-NBD1 crystal 
structures was caused by greatly reduced protein dynamics at the low temperature required 
for crystallisation.  
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Further to interdomain interactions, many chaperones interact with CFTR during folding and 
trafficking. Interactions with accessory proteins, such as calnexin (Farinha and Amaral, 
2005) and heat shock protein (Hsp)70/Hsp90 (Yang et al., 1993; Loo et al., 1998), decide 
the fate of CFTR molecules, depending upon the protein conformation.  
Figure 1.5 Simplified CFTR folding model. Modified from Cui et al. 2007 and Okiyoneda et 
al. 2013. A) WT-CFTR: NBD1 interacts with MSD1 and MSD2 during cotranslational folding. 
This four domain unit can be glycosylated and exported from the ER. NBD2 is incorporated 
posttranslationally. B) ΔF508-CFTR: Due to the ΔF508 mutation (red star), NBD1 cannot 
interact appropriately with either MSD1 (via ICL1) or MSD2 (via ICL4). Improper folding 
prevents export from the ER and NBD2 folding and incorporation. 
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Multiple chaperone interactions are altered by ΔF508, due to misfolding of CFTR. For 
example, normally buried arginine framed tripeptides (which act as ER retention signals) are 
exposed in ΔF508-CFTR, promoting retention in the ER and subsequent proteasomal 
degradation (Chang et al., 1999; Roxo-Rosa et al., 2006). CFTR also contains at least one 
di-acidic ER exit motif. Exposure of the exit motif recruits COP-II vesicle machinery, allowing 
export to the Golgi (Wang et al., 2004). Exposure of multiple ER retention signals, and 
concealment of an export motif, contributes to ER retention of ΔF508-CFTR.  
ΔF508-CFTR retained at the ER displays altered interactions with chaperones, such as 
Hsp90 (Coppinger et al., 2012) and CHIP (Meacham et al., 2001), which increase 
ubiquitination and subsequent degradation. Similar mechanisms target peripheral ΔF508-
CFTR, favouring lysosomal degradation and reducing membrane half-life (Okiyoneda et al., 
2010). 
1.5.1 Correction of ΔF508-CFTR 
Correction of ΔF508-CFTR folding defect can be achieved by low temperature incubation, 
revertant mutations, or small molecule correctors. 
1.5.1.1 Low temperature incubation 
Although not clinically relevant, low temperature incubation is often used in the laboratory as 
a tool for studying ΔF508-CFTR ion channel function. Incubation at 30°C for 24 h increases 
mature CFTR (compared to total CFTR) to ~25% that of WT-CFTR, allowing the study of the 
mutant channel at the membrane (Denning et al., 1992). Temperature rescued ΔF508-CFTR 
acquires complex glycosylation, but membrane half-life is still reduced compared to WT-
CFTR (Heda et al., 2001; Sharma et al., 2001). Therefore, whilst capable of promoting 
maturation, low temperature incubation does not appear to induce native folding of ΔF508-
CFTR, which is still targeted by peripheral quality control.  
The existence of cell-type specific effects of temperature correction led to the hypothesis that 
other biological components, such as chaperones, are involved in the mechanism of 
temperature correction (Wang et al., 2008).  
1.5.1.2 Revertant mutations 
Revertant mutations capable of promoting folding and trafficking of ΔF508-CFTR have been 
identified throughout the CFTR protein. By introducing a mutation in cis, revertants repair a 
specific aspect of the folding defect. Mutations include those that stabilise NBD1, and those 
that repair the NBD1:ICL4 interface. ΔF508-NBD1 thermodynamic and kinetic instability can 
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be partially repaired by mutations such as G550E, R553Q and R555K (Roxo-Rosa et al., 
2006; Rabeh et al., 2012). As mentioned, R1070W is a revertant mutation located in ICL4 
which promotes trafficking of ΔF508-CFTR (Thibodeau et al., 2010; Okiyoneda et al., 2013).  
Again, although not clinically relevant, revertant mutations allow study of the ΔF508-CFTR 
ion channel function by promoting plasma membrane localisation. Identifying revertant 
mutations also allows us to better understand the trafficking defect caused by ΔF508. For 
example, the trafficking improvement caused by R1070W confirmed that the NBD1:ICL4 
interface, originally identified in homology models (Serohijos et al., 2008), plays a role in 
ΔF508-CFTR misfolding. This interface is now also a well-established target for corrector 
compounds.  
Using revertant mutations alongside corrector compounds can help elucidate the mechanism 
of correctors. The extent to which a compound can synergise with specific revertants 
indicates the likely mechanism. Compounds which have a small effect alongside R1070W, 
but a large effect alongside NBD1 stabilising mutations, most likely share a mechanism of 
action with R1070W. Okiyoneda et al. (2013) recently employed this tactic to demonstrate 
that most corrector compounds identified to date target the NBD1:ICL4 interface. 
1.5.1.3 ΔF508-CFTR corrector compounds 
ΔF508-CFTR trafficking can be improved by pharmacological chaperones, which bind to 
CFTR to stabilise domain or interdomain interactions and to promote folding; or by 
proteostasis regulators, which target other molecules to promote folding or reduce 
proteasomal degradation. This project will focus on corrector mechanisms that directly target 
the folding of CFTR by binding to the mutant protein. In the search for ΔF508-CFTR 
treatments, compounds that directly target the CFTR are less likely to display off-target 
effects. Additionally, these compounds can help better understand the folding of ΔF508-
CFTR, and be used as tools   to further study this defect and the structure of CFTR.  
VX-809, the corrector compound used alongside VX-770 in the recently approved 
combination treatment Orkambi, was used as a positive control throughout this project. 
Using the revertant mutation synergy assay described above, the mechanism of correction 
by VX-809 was identified as a stabilisation of the NBD1:ICL4 interface. Alongside NBD1 
stabilising mutations, VX-809 restores membrane density to ~100% of WT-CFTR, whereas 
the correction alongside R1070W is modest (Farinha et al., 2013b; Okiyoneda et al., 2013). 
VX-809 binds directly to the ΔF508-CFTR protein (Eckford et al., 2014), to improve 
membrane density ~2-fold (He et al., 2013; Okiyoneda et al., 2013). In silico docking studies 
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suggest a number of putative binding sites at interdomain interfaces (Farinha et al., 2013b; 
He et al., 2013; Okiyoneda et al., 2013), which have yet to be further investigated.  
1.6 ΔF508-CFTR destabilisation by chronic potentiator treatment 
Orkambi (VX-770/VX-809 combination treatment) was recently approved for the treatment of 
ΔF508-CF homozygous patients. A Phase III study revealed a mean absolute improvement 
in lung function (FEV1) of 2.6% – 4% (Wainwright et al., 2015). Compared to in vitro results 
using acute VX-770 treatment alongside VX-809-mediated correction (conductance up to 
30% of WT-CFTR; Van Goor et al., 2011), this was a relatively small improvement. 
A possible explanation for the disappointing clinical results came with the publication of two 
papers in July 2014. Two groups independently reported a decrease in ΔF508-CFTR 
membrane stability following chronic treatment with VX-770, which was unrelated to channel 
function (Cholon et al., 2014; Veit et al., 2014). During drug development, it is likely this 
effect was missed because potentiators were only tested acutely for ability to improve CFTR 
function. Due to the absence of validated CF animal models available at the time, and a lack 
of VX-770 activity on murine CFTR (Van Goor et al., 2009), animal tests, which could have 
identified issues with chronic dosing, were carried out for toxicology and distribution 
purposes only. 
Chronic treatment of ΔF508-CFTR bronchial cells with 100 nM VX-770 destabilised CFTR at 
the membrane, decreasing mature ΔF508-CFTR by up to 40%, regardless of the method of 
rescue. This decrease appears to be caused by reduced biogenesis or increased 
cotranslational degradation, increased degradation of mature CFTR, reduced recycling and 
a small decrease in folding efficiency from immature to mature ΔF508-CFTR. A decrease in 
membrane-localised CFTR was reflected in functional studies using primary cell monolayers 
(Cholon et al., 2014; Veit et al., 2014).  
Promoting ΔF508-NBD1/2 dimer stability by reducing ATPase activity (using mutation 
E1371S), protected ΔF508-CFTR from the negative effects of VX-770. Docking studies 
suggested a number of putative VX-770 binding sites accessible in the partially unfolded 
ΔF508-NBD1/2 dimer, which are not accessible in WT-CFTR, and presumably would not be 
accessible in ΔF508/E1371S-CFTR (Veit et al., 2014). Therefore, VX-770 could be binding 
to the partially unfolded state, accessible due to the folding defect, to stabilise a structure 
with greater propensity for recognition by quality control mechanisms. This could explain the 
variety of changes to the fate of the protein, from increased cotranslational degradation, to 
reduced recycling. 
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It has been disputed whether this would really occur in vivo. Five day VX-770 treatment with 
450 mg resulted in a plasma concentration of 14 µM. Due to high levels of binding in plasma, 
the concentration of free VX-770 following patient treatment could be as low as 8 nM 
(Matthes et al., 2015). When tested in 100% human serum, the IC50 for the negative effects 
caused by VX-770 was 23 nM (Veit et al., 2014). Allowing for accumulation of VX-770 in cell 
membranes during chronic treatment, which does appear to take place (Cholon et al., 2014), 
the potency of VX-770, to induce negative effects on CFTR stability, does seem clinically 
relevant. 
Veit et al. (2014) went on to show a reduction of ΔF508-CFTR plasma membrane density 
with every tested potentiator, except one: P5 (Yang et al., 2003). A library of P5 analogues 
has since been screened and shown a number of compounds which also lack destabilisation 
effects (Phuan et al., 2015). This suggests a different binding site for P5, with molecular 
dynamics and evidence from docking studies supporting different binding sites which do not 
overlap with putative VX-770 binding sites (Veit et al., 2014). The fact that almost all tested 
potentiators have a negative effect on stability of ΔF508-CFTR highlights the importance of 
screening for this characteristic when identifying novel ΔF508-CFTR potentiators. Missing 
the effect of chronic treatment will lead to disappointments in clinical trials. 
1.7 Current screening methods for measuring CFTR function 
Over the last 15 years, high-throughput screening has transformed the study of CFTR 
potentiators. Identification of VX-770 was made possible by industry screening efforts, and 
many other compounds have been identified in academia.  
1.7.1 Cytosolic halide sensitive yellow fluorescent protein (YFP) expression  
Most of the CFTR screening work in academia has come from the Verkman lab, following 
their development of a halide sensitive yellow fluorescent protein (YFP (H148Q/I152L); 
Galietta et al. 2001a, 2001b). The YFP assay is discussed in detail in Chapter 3. Briefly, 
stable cell lines co-express halide sensitive YFP in the cytosol, and CFTR. YFP has a higher 
affinity for iodide (Iˉ) than Clˉ, allowing the function of CFTR to be measured by the influx of 
Iˉ. In the presence of an extracellular Iˉ buffer, if CFTR is expressed at the membrane and 
gating, Iˉ enters the cell and quenches YFP fluorescence. In the case that CFTR is either not 
membrane-localised, or not gating, Iˉ has no route into the cell and YFP fluorescence 
remains high. 
The screen for potentiators involves 24 h low temperature incubation of ΔF508-CFTR to 
increase membrane expression (Denning et al., 1992), and addition of a test compound in 
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the presence of forskolin. Forskolin activates adenylate cyclase, causing an accumulation of 
cyclic adenosine monophosphate (cAMP), which activates PKA, which in turn 
phosphorylates CFTR. For ΔF508-CFTR, only slow quenching occurs, due to the gating 
defect. In the presence of a test compound, increased quenching rate indicates CFTR 
potentiation. 
1.7.2 Membrane potential  
During drug discovery efforts, which eventually led to identification of VX-770, Vertex 
employed a fluorescence resonance energy transfer (FRET) assay. A pair of membrane-
soluble dyes, one of which partitions into the outer membrane leaflet and acts as a fixed 
FRET donor, are used to measure changes in membrane potential of cells expressing 
ΔF508-CFTR, following addition of test compounds with forskolin (Van Goor et al., 2006). 
The FRET acceptor dye is negatively charged, and also partitioned into the membrane outer 
leaflet at resting membrane potential. Upon membrane depolarisation, the acceptor flips to 
the inner leaflet of the membrane, reducing the FRET signal (González et al., 1999).  
1.7.3 Functional screens as an indirect measure of membrane density 
The YFP and membrane potential functional screens have also been utilised to indirectly 
measure CFTR membrane-localisation in screens for ΔF508-CFTR corrector compounds. 
Screening for correctors requires 24 h incubation with the test compound, followed by 
addition of forskolin and a potentiator to induce CFTR activation. Increased quenching rate 
or membrane potential change compared to buffer-incubated ΔF508-CFTR is used as an 
indicator of successful correction of CFTR trafficking. These assays have identified a 
number of active compounds, which are now used in the clinic and as tools to study CFTR.  
Neither the FRET screen, nor the cytosolic YFP assay, has the ability to quantify CFTR 
membrane expression independently of function, which is critical when screening corrector 
compounds on the severe gating mutant ΔF508-CFTR. Using function as an indirect 
measure of membrane density, compounds with unusual or complex mechanisms may be 
missed. For example, correctors which stabilise a conformation capable of trafficking, but 
which cannot be gated by the activating compounds used in the assay, or indeed 
compounds that inhibit the channel function, will not be detected.  
1.8 Current methods for measuring CFTR membrane density 
CFTR maturation is most often studied using visualisation on an immunoblot, using standard 
Western blot techniques. Band B is used to quantify immature, ER-associated CFTR, with 
band C reflecting membrane-localised, mature CFTR. CFTR membrane-localisation is often 
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quantified using the ratio of mature/total CFTR. Whilst this is an important measure of CFTR 
trafficking, it is not the only parameter of interest. For example, an increase in total CFTR 
which does not affect the ratio of mature/total would still be a viab le ΔF508-CFTR treatment 
option. This technique is laborious, time consuming and difficult to quantify. Recently, a 
number of high-throughput assays capable of measuring CFTR localisation have been 
developed. 
1.8.1 Haemagglutinin-epitope  
Carlile et al. (2007) developed a CFTR membrane density assay which involved the use of a 
haemagglutinin epitope (HA)-tagged CFTR. An extracellular HA tag at position 901, which is 
known to be a permissive site for insertion in CFTR, allows fluorescent antibody labelling of 
CFTR expressed at the membrane (Carlile et al., 2007; Robert et al., 2008). Whilst this 
assay was the first published assay capable of screening with respect to membrane-
localised CFTR, it does require antibody incubation, and it is not capable of measuring 
internal CFTR. 
1.8.2 Horseradish Peroxidise  
In a recent screen for CFTR correctors showing synergistic activity with VX-809, a 
Horseradish Peroxidise (HRP)-tag was introduced at position 901 (Phuan et al., 2014). This 
allows quantification of CFTR membrane density by addition of an HRP substrate, which 
luminesces when oxidised by HRP. Again, this assay is only capable of measuring 
membrane-localised CFTR. 
1.8.3 Fluorogen activating protein  
Fluorogen activating proteins (FAPs) are single chain antibody fragments which bind to 
greatly enhance the fluorescence of fluorogens (Holleran et al., 2012; Larsen et al., 2015). 
Using an extra TM added to the N-terminal of CFTR, Larsen et al. (2015) tagged CFTR with 
an extracellular FAP. Extracellular, impermeant, malachite green (MG) binds the FAP and 
fluoresces brightly to quantify membrane-localised CFTR. Total cellular distribution can be 
measured using a cell permeable MG-ester, which is then cleaved and trapped inside the 
cell. However, the two measurements cannot be made on the same sample.  
1.8.4 mCherry/FLAG  
The most recently reported high throughput CFTR trafficking assay was a double-tagged 
mCherry/FLAG CFTR. This screen involves total CFTR detection via fluorescence intensity 
reflecting an N-terminal mCherry tag, and membrane CFTR detection via a FLAG epitope 
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inserted at position 901 (Botelho et al., 2015). This assay is therefore capable of measuring 
both total CFTR (via mCherry) and membrane CFTR (via FLAG). However, quantification of 
membrane CFTR still relies on antibody staining, with the associated incubations and 
washes. Additionally, this assay, as with the other fluorescence and luminescence assays to 
measure CFTR membrane density, critically depends on a low variability in the levels of 
expression of the probe.  
1.9 Other clinical implications of the study of CFTR 
The study of CFTR pharmacology could have an impact outside CF. The prevalence of 
CFTR mutation carriers has been attributed to a partial protection, in the heterozygote state, 
against secretory diarrhoeas. Such diseases are caused by bacteria similar to Vibrio 
cholerae, which produce toxins that activate CFTR in the intestine, causing water loss 
through diarrhoea. Cholera is responsible for approximately 50,000 deaths per year in the 
developing world (Lozano et al., 2012). Animal models of diarrhoea have demonstrated that 
CFTR inhibitors can block fluid secretion (Ma et al., 2002). CFTR inhibitors, therefore, have 
clinical implications in the treatment of secretory diarrhoea.  
Chronic obstructive pulmonary disorder (COPD) is an air pollution and smoke-induced lung 
disease, with some pathological traits similar to CF, including mucus stasis and 
accumulation. Exposing cultured epithelial cells to smoke in the laboratory causes a 
decrease in CFTR-dependent anion transport, due to reduced CFTR mRNA and protein 
expression (Cantin et al., 2006). CFTR potentiators with activity on WT-CFTR have been 
tested in vitro, with some success, for the treatment of COPD (Sloane et al., 2012). 
1.10 Aims of this research 
The study of CFTR pharmacology is paramount in the quest to treat the debilitating disease 
of CF. Furthermore, understanding the trafficking and function of this ion channel has far 
reaching implications, such as in the treatment of COPD, which affects millions of people 
worldwide. The aim of this research was to develop tools to better enable the study of CFTR 
pharmacology, initially in the setting of ΔF508-CFTR. 
Targeting ΔF508-CF will likely require combination therapy with a trafficking corrector and a 
gating potentiator. Furthermore, the potentiator must not have a negative effect on 
biosynthesis and stability, unlike most potentiators identified to date. Identification of such 
compounds will require high-content screening tools, capable of quantifying function and 
membrane density of ΔF508-CFTR. 
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The specific aims of this project were to: 
 Optimise YFP-CFTR assay for screening ΔF508-CFTR potentiators 
 Design an optical assay for measuring localisation of CFTR 
 Screen compound libraries to identify ΔF508-CFTR potentiator compounds 
 Use fluorescence assays to probe VX-770 mechanism of action 
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Chapter 2 
Methods 
 
2.1 Molecular biology (Construction of YFP-CFTR and CFTR-pHTomato fusion 
proteins) 
2.1.1 Overview of YFP-CFTR fusion protein construction 
Green fluorescent protein (GFP)-CFTR, in which enhanced GFP (eGFP) is tagged to the N-
terminal of CFTR via a 23 amino acid linker, was provided by Bruce Stanton (Geisel School 
of Medicine, NH, USA) in pcDNA3.1 plasmid. YFP (H148Q/I152L) in pcDNA3, and WT-
CFTR in pcDNA3.1, were provided by Luis Galietta (Istituto Giannina Gaslini, Genova).  
     
In order to produce YFP-CFTR, eight mutations were introduced in GFP-CFTR. This was 
done using site-directed mutagenesis (SDM). Each SDM reaction was used to transform 
chemically competent E. Coli cells, amplified by culturing the bacteria, from which the DNA 
was purified using midi prep protocols. The success of each SDM reaction was checked by 
sequencing the mutated segment, while the whole coding region was sequenced after the 
final mutagenesis. The steps involved in this process are detailed below. 
2.1.2 Site-directed mutagenesis 
SDM uses polymerase chain reaction (PCR) and mutagenic primers to introduce mutations 
into a plasmid at a designated point. The protocol we used is essentially identical to the 
Quikchange protocol marketed by Stratagene, but individual components were obtained 
from various suppliers. Sequence alignment of YFP (H148Q/I152L) with GFP-CFTR 
Figure 2.1 Plasmid map of 
pcDNA3.1-YFP-CFTR. YFP-
CFTR is under the control of a 
cytomegalovirus immediate-
early promoter (PCMV). The 
plasmid contains coding 
sequences for ampicillin 
resistance (AmpR) for bacterial 
selection and neomycin 
resistance (NeoR) for 
mammalian cell selection. The 
YFP tag is shown at the N-
terminal. 
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identified eight amino acid differences: F46L, L64F, S65G, V68L, S72A, H148Q, I152L and 
T203Y. Forward and reverse complementary primers containing each desired mutation were 
made to order (Eurofins MWG Operon, Germany). Each primer contained the mutation, 
flanked by approximately ten complementary bases to allow annealing to the correct location 
on the plasmid.  
The SDM reaction contained 100 ng template DNA, into which the mutation was to be 
introduced, 20 µl Phusion high fidelity buffer (New England Biolabs (UK) Ltd., Hitchin, UK), 
0.5 µM forward and reverse primers, 80 µM (each) deoxynucleotide triphosphates (dNTPs, 
New England Biolabs), and 2 units Phusion polymerase enzyme (New England Biolabs), 
mixed in a 0.2 ml thin-walled PCR tube (Starlab (UK) Ltd., Milton Keynes, UK). The mixture 
was made up to 95 µl in distilled water (dH2O), and 5 µl of DMSO was added to minimise 
formation of secondary structures. The following SDM cycle was run in a Thermal Cycler 
PCR machine (Applied Biosystems, UK): 
Temp Time Cycle step 
98°C 30 s Initialisation 
98°C 
53°C 
72°C 
10 s 
30 s 
5 min 
Denaturation 
Annealing 
Elongation 
72°C 10 min Final elongation 
38°C Finish Storage hold 
 
Following thermal cycling, 2 h incubation at 37°C with 40 units Dpn I (New England Biolabs) 
destroyed the template, methylated DNA, leaving only nicked plasmids containing the 
mutation. For Dpn I treatment, samples were moved to 1.5 ml microcentrifuge tubes 
(Sarstedt Ltd., Leicester, UK). 
Following Dpn I treatment the DNA was precipitated by addition of 250 µl 100% ethanol and 
10 µl 3 M sodium acetate (NaOAc), and incubated at -20°C for 20 min. The DNA was 
pelleted by a 20 min, 16,100 g spin at 4°C in a microcentrifuge (5415R Eppendorf centrifuge, 
Eppendorf UK Ltd, UK). The pellet was washed with 400 µl 70% ethanol, spun as above and 
resuspended in 10 µl 10 mM tris pH 8. 
The SDM reaction was used to transform chemically competent E. Coli for amplification of 
the plasmid. 
2.1.3 Transformation of chemically competent E. Coli 
3 μl of SDM reaction was chilled on ice in a 13 ml culture tube (Sarstedt). 50 μl of chemically 
competent E. Coli (Life Technologies, Paisley, UK) was added to the plasmid, and incubated 
18 cycles 
Table 2.1 SDM PCR cycle. 
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on ice for 30 min. The mixture was heat shocked at 42°C for 45 s, returned to ice for 2 min, 
and mixed with 950 μl Super Optimal broth with catabolite repression (SOC, Life 
Technologies). The E. Coli suspension was incubated at 37°C in a swirling incubator, for 1 h.  
Agar plates containing antibiotics were used to select for successfully transformed E. Coli 
cells. Molten Luria Bertani broth (LB broth, Sigma-Aldrich Company Ltd., Dorset, UK) 
supplemented with 1.5% (w/w) agar, containing 100 µg/ml ampicillin or 50 µg/ml kanamycin, 
was poured into 100 mm dishes (BD Biosciences, Oxford, UK) and allowed to set.  
Following the 1 h 37°C incubation, 50 μl of E. Coli in SOC medium was pipetted onto an 
agar plate and spread using an ethanol-sterilised glass spreader. Plates were incubated at 
37°C overnight. Following successful transformation, only bacteria containing the antibiotic 
resistance encoded by the transforming plasmid were able to grow and form colonies on 
antibiotic-containing agar plates.  
2.1.4 Midi prep to purify the plasmid 
For every midi prep sample, a single E. Coli colony was used to inoculate 50 ml LB broth in 
a conical flask, using a flame sterilised inoculating loop. The E. Coli culture was grown 
overnight (~17 h for ampicillin resistant bacteria) in a 37°C swirling incubator (250 rpm). The 
culture was spun at 1,811 g for 20 min in a centrifuge (5810R Eppendorf centrifuge) to pellet 
the bacteria. The supernatant was discarded and the midi prep carried out using a Qiagen 
midi prep kit, according to manufacturer’s instructions (Qiagen Ltd., Manchester, UK). This 
protocol exploits an alkaline lysis procedure, followed by purification on an anion exchange 
column. 
The plasmid in the 5 ml of eluate was precipitated by addition of 3.5 ml isopropanol, and 
pelleted by a 24,500 g, 30 min spin at 4°C, in a Beckman J2-M1 centrifuge (Beckman 
Coulter (UK) Ltd., High Wycombe, UK). The supernatant was discarded and the pellet 
washed with 2 ml 70% ethanol, spun as above for 10 min, the ethanol discarded and the air-
dried pellet resuspended in 100 µl 10 mM tris pH8. The expected yield from the Qiagen midi 
prep kit is approximately 1 µg/µl. This was checked using gel electrophoresis. 
2.1.5 Gel electrophoresis  
Each midi prep sample was visualised using gel electrophoresis, to determine the 
approximate length of the DNA fragment in base pairs, and the plasmid concentration. A 
0.8% solution was prepared by dissolving 0.32 g agarose (Starlab) in 40 ml 1X TAE buffer 
(Life Technologies), followed by 1 min heating in a standard microwave oven (1 min, 800 W). 
1 µl of 10 mg/ml ethidium bromide solution (Sigma-Aldrich) was added to the agar solution, 
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which was poured into a plastic mould to set. 260 ml 1X TAE buffer was used to submerge 
the gel. 
2 µl of 6X cyan-yellow Track-It dye (Life Technologies) was added to 10 µl of plasmid 
sample, which was loaded into the wells at the top of the gel. A potential difference of 100 V 
attracted the negatively charged DNA to the positive end of the chamber, in order to 
separate by size. The faster the sample travelled, the smaller the DNA in base pairs. Each 
gel was run for 40 min. 
DNA on a gel is visualised under UV light, as ethidium bromide increases in fluorescence 
when intercalated with nucleic acid. A 1kb ladder was run alongside each set of samples 
(Life Technologies). This ladder is composed of many fragments of known size. Therefore, 
the size of each fragment can be estimated by comparing how far the band has travelled in 
relation to the known fragments on the ladder. 
As well as estimating sample size in base pairs, gel electrophoresis was used to estimate 
plasmid concentration. To estimate midi prep concentration, a 10-fold sample dilution was 
run alongside the concentrated midi prep sample, to enable more accurate comparison with 
the 1 kb ladder. Within the ladder is a 1.6 kb sample of known concentration (5 ng/µl). 
Comparison of the midi prep 10-fold dilution with this fragment on the ladder allowed 
estimation of the concentration of DNA in the sample. 
2.1.6 Sequencing 
The success of each SDM reaction was checked using sequencing. This method required 
the design of location-specific primers (Eurofins), approximately 20 bases long, which 
annealed at least 100 bases upstream of the region to be sequenced.  
Big dye 1.1 (Life Technologies) provided a mix including polymerase, dNTPS for strand 
elongation, and fluorescently labelled dideoxynucleotides (ddNTPs), which terminated strand 
elongation when incorporated. Each ddNTP base type in the mixture (A, T, G and C) was 
linked to a different fluorescent molecule. Due to the mixture of dNTPs and ddNTPs, strands 
were terminated at different lengths, giving a mixture of strands from one base long to 
approximately 700 bases. Using a 3100-Avant Genetic Analyzer (Applied Biosystems), the 
mixture of strands was drawn up a fine glass capillary into a gel matrix, which separated the 
fragments by size. Reading fluorescence after separation of fragments by capillary 
electrophoresis, produced a chromatogram trace, read to give the sequence.  
2 µl of Big Dye 1.1, 0.3 µM primer, and ~100 ng of sample were mixed in a 0.2 ml PCR tube 
and made up to 10 µl using dH2O. The following protocol was run on a PCR machine:  
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The mixture was precipitated by adding 10 µl dH2O, 50 µl 100% ethanol and 2 µl 3M NaOAc, 
chilled on ice for 10 min and spun at 16,100 g for 15 min at 4°C. The supernatant was 
removed, the pellet washed with 100 µl 70% ethanol, and the spin repeated as above. 
Following removal of the supernatant the pellet was left to air dry for 2 h before sending for 
capillary electrophoresis and reading of the sequence (UCL Sequencing, Gower Street, 
London, UK). 
2.1.7 Overview of CFTR-pHTomato fusion construction 
pHTomato in pRham plasmid was provided by Dr Li (Peking University) and Prof. Richard 
Tsien (NYU School of Medicine, NY). Restriction enzyme sites were introduced into CFTR in 
pcDNA3.1 to allow insertion of pHTomato into the fourth extracellular loop (ECL4).  
For reasons discussed in Chapter 4, CFTR-pHTomato was later subcloned into a pIRES2-
eGFP plasmid (Figure 2.2), which contains an internal ribosome entry site (IRES). This 
plasmid directs transcription of one strand of mRNA, containing coding sequences for both 
CFTR-pHTomato and eGFP, but translation of two separate proteins (CFTR-pHTomato and 
eGFP). CFTR in pIRES2-eGFP was provided by Prof. David Gadsby (Rockefeller University, 
New York, USA).  
 
 
 
 
 
 
 
 
 
Temp Time Cycle step 
94°C 30 s Initialisation 
94°C 
50°C 
60°C 
10 s 
30 s 
5 min 
Denaturation 
Annealing 
Elongation 
4°C Finish Storage hold 
25 cycles 
Figure 2.2 Plasmid map of 
pIRES2-eGFP-CFTR-
pHTomato. CFTR-
pHTomato is expressed in 
pIRES2, under control of 
PCMV. The plasmid contains 
kanamycin  resistance (KanR) 
for bacterial selection and 
neomycin resistance (NeoR) 
for mammalian cell selection. 
Between the CFTR-
pHTomato coding region and 
eGFP coding region is an 
IRES. 
 
Table 2.2 Sequencing PCR cycle. 
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2.1.8 Introduction of restriction enzyme sites and pHTomato in ECL4 
In order to insert pHTomato at ECL4 of CFTR in pcDNA3.1, Age I and Bmt I restriction 
enzyme sites were introduced on either side of the insertion site using an overlap extension 
strategy. The same sites were introduced as non-annealing tags on primers, then used for 
PCR amplification of the pHTomato coding sequence, resulting in a PCR product in which 
Age I and Bmt I sites flanked pHTomato. This work was carried out by an undergraduate 
student during a summer project (Stefan Constantinou, supported by a UCL Dean’s summer 
studentship). Restriction enzyme digest with Age I and Bmt I, of both CFTR in pcDNA3.1 
and pHTomato in the PCR product, followed by ligation, resulted in the insertion of 
pHTomato in ECL4 of CFTR. The latter steps were carried out by undergraduate student 
Mahesh Pillai, supported by a CF Trust summer studentship. 
2.1.9 Subcloning CFTR-pHTomato into pIRES2-eGFP plasmid 
To transfer CFTR-pHTomato from pcDNA3.1 to pIRES2, a 4.4 kb region of CFTR including 
pHTomato was subcloned within the WT-CFTR coding sequence on the pIRES2 plasmid, 
using Sal I and BspE I restrictions sites, present in WT-CFTR. Digests of both vector (WT-
CFTR-pIRES2) and insert (CFTR-pHTomato) were carried out at 37°C for 3 h, then run on a 
preparative 0.8% agarose gel to separate the fragments. The fragments were purified using 
Wizard® SV Gel and PCR Clean-up System, according to manufacturer’s instructions 
(Promega UK Ltd., Southampton, UK).  
For ligation, a 1:1 molar ratio of vector:insert was mixed in ATP-containing ligation buffer and 
T4 ligase enzyme (New England Biolabs) was added, before incubation at 16°C overnight. 
The reaction was then used to transform E. Coli as described above, and plated on agar 
plates containing 50 µg/ml kanamycin. Colonies were inoculated in 50 ml LB broth with 50 
µg/ml kanamycin, grown overnight and plasmid preparations were purified by midi prep. 
2.1.10 Introducing CFTR mutations 
This project involved the study of many CFTR mutations, each of which was introduced 
separately into the YFP-CFTR and CFTR-pHTomato plasmids as required, using SDM.  
2.2 HEK293 cell culture and transfections 
2.2.1 HEK293 cell culture 
HEK293 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 2 mM L-glutamine, 100 U/ml penicillin and streptomycin, and 10% foetal 
bovine serum (FBS, all Life Technologies). Cells were cultured in tissue culture treated T25 
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flasks (Nunc, Fisher Scientific Ltd., Leicestershire, UK) in a 37°C incubator supplied with 5% 
CO2. Confluent flasks were passaged every 2-3 days. Medium was discarded and cells were 
rinsed with 5 ml Hank’s Buffered Salt Solution (HBSS, Life Technologies). 1 ml 0.05% 
trypsin (Life Technologies) was added to the flask and left to detach the cells for 3 min. 9 ml 
medium was added to deactivate the trypsin, and the solution was transferred to a 15 ml 
plastic tube (Falcon, Fisher Scientific). The 10 ml cell suspension was spun at 180 g for 2 
min. The supernatant was removed and the pellet resuspended in 10 ml medium. For 
passage of the cells, 2 ml of this cell suspension was added to 8 ml medium in a T25 flask, 
for a 1:4 dilution.  
2.2.2 Plating HEK293 cells for imaging 
For fluorescence imaging cells were seeded in poly-D-lysine (PDL)-coated black walled 96-
well plates (Costar, Fisher Scientific). Flasks of confluent cells were detached as above, 
pelleted, diluted 1:3 (cell suspension:medium), and plated at 100 µl per well the day before 
transfection.  
2.2.3 Lipofectamine transient transfection 
Lipofectamine transfection was used for all imaging experiments. Cells plated in 96-well 
plates as described above were transiently transfected with the required plasmid using 
Lipofectamine 2000 (Life Technologies), according to manufacturer’s instructions. Following 
transfection, cell plates were returned to the 37°C incubator for 24 h. 
2.2.4 Plating HEK293 cells for patching 
Following detachment using trypsin, as described above, cells were pelleted, resuspended in 
10 ml media and diluted 1:9 (cell suspension:medium). Cells were plated in 35 mm plastic 
petri dishes (Nunc, Fisher Scientific) at 2 ml per dish. Cells were transfected using the 
calcium phosphate technique approximately 6 h after plating. 
2.2.5 Calcium phosphate transient transfection 
Lipofectamine transfection reduced seal stability when cells were used in excised patch 
experiments. A calcium phosphate transfection protocol, thought to damage membrane 
structure less, was therefore used to transfect HEK293 cells intended for use in excised 
patch experiments (Groot-Kormelink et al., 2002).  
8.9 µl 2 M CaCl2 solution was added to 1.4 µg CFTR plasmid, together with 40 ng GFP 
plasmid, and made up to 73 µl with dH20. This mixture was added slowly to 73 µl HBS 
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solution (274 mM NaCl, 1.5 mM Na2HPO4, 54.55 mM HEPES, pH 7), then added dropwise 
to the cells. Cell dishes were incubated for 16-24 h before patching. 
2.3 Fluorescence imaging plate reader (FLIPR) 
2.3.1 FLIPR overview 
The fluorescence imaging plate reader (FLIPR Tetra, Molecular Devices, Wokingham, UK) is 
an automated 96-well plate reader with fluidics component. The overhead pipettor enabled 
compound addition from drug plates to the cell plate, whilst fluorescence readings were 
taken simultaneously from each well over a period of time. Light from LEDs passed through 
an excitation filter to illuminate the bottom of the plate, and emitted light passed through an 
emission filter for detection by a CCD camera. 
Two 96-well drug plates enabled two different solutions to be added to each well in the cell 
plate. Following a protocol created using the equipment software, the FLIPR took readings at 
multiple time points, and added the required volumes from the drug plates at programmed 
time points.  
2.3.2 Acquiring YFP readings in FLIPR 
24 h after transfection, medium was removed from all wells using a multichannel pipette. 
Each well was washed twice with 100 µl standard buffer (140 mM NaCl, 4.7 mM KCl, 1.2 
mM MgCl2, 5 mM HEPES, 2.5 mM CaCl2, 11 mM Glucose, pH 7.4).  
Each cell plate required the use of two drugs plates (Falcon, Fisher Scientific), labelled drug 
plate 1 and drug plate 2, for the 1st and 2nd fluid additions in the protocol. The treatments in 
the drug plates exactly replicated the designated treatment of the cell plate, so the cells in 
B1 would receive fluid additions from B1 in drug plate 1 and from B1 in drug plate 2. 
FLIPR Protocol:  
Cell plate contained 100 µl standard buffer 
 Acquire image every second for 10 s 
 Add 50 µl from drug plate 1  
 Acquire image every second for 10 s 
 Acquire image every 15 s for 45 s 
 Acquire image every second for 10 s 
 Add 50 µl from drug plate 2 
 Acquire image every second for 190 s 
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Drug plate 1 contained Iˉ buffer (as standard buffer above, with 140 mM NaCl replaced with 
300 mM NaI), designed to create an extracellular [Iˉ] of 100 mM. Iˉ was diluted 1:2 in the 
original buffer when added to the cell plate (300 mM NaI for a final concentration of 100 
mM). Drug plate 2 contained the specific well treatment (for example, forskolin), made in 100 
mM Iˉ buffer so as to preserve the extracellular Iˉ concentration. Plates were kept at 37°C 
throughout recordings. The excitation/emission filters used for FLIPR readings of YFP were 
470/495 nm and 515/575 nm respectively. The exposure time was 0.8 s. 
2.3.3 Analysis of FLIPR data 
The output from FLIPR recordings is the average fluorescence in each well, at every time 
point, which is exported to a Microsoft Excel worksheet. Fluorescence was normalised to the 
fluorescence at 85 s, a time point after the second addition, when any fluid addition artefact 
was complete (for more information on the artefact see Chapter 3). 
To quantify CFTR activation, the gradient of the fluorescence reading was calculated at 
every time point, to find the maximal quenching rate per second.  
2.4 High-content fluorescence imaging (ImageXpress) 
2.4.1 ImageXpress overview 
ImageXpress (ImageXpress Micro XLS, Molecular Devices) is a widefield inverted 
fluorescent microscope with CMOS camera, and robotics which add compounds to cell 
plates whilst imaging a region of the well. Illumination, fluid additions and image acquisition 
occur at a single well at a time, not simultaneously at all wells as in the FLIPR system. Laser 
autofocus uses the manually entered position of the plate to rapidly focus on fluorescent 
cells. A xenon lamp light source illuminates the well through an excitation filter. Emitted light 
passes through an emission filter for detection by the camera. Each filter cube contains 
excitation and emission filters, and a dichroic mirror.  
The cell plate was loaded above the optics in a temperature controlled chamber. Above the 
imaged well is a small retractable window, which opens at the time of fluid addition to allow 
access to the pipette tip. The drug plates were located to the side of the optics, in a separate 
chamber with environmental control. Alongside the drug plates were located two pipette tip 
racks. Instructed by a fluid addition protocol created using the dedicated software 
(MetaXpress, Molecular Devices), the fluidics component collects a clean tip, draws 50 µl of 
solution from the drug plate, moves to the cell plate, where the retractable window opens, 
and dispenses 50 µl of solution. 
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ImageXpress was used for both YFP-CFTR and CFTR-pHTomato imaging.  
2.4.2 YFP-CFTR image acquisition and analysis 
Cell plates were prepared as for FLIPR and loaded into the ImageXpress chamber. YFP-
CFTR quenching experiments required two drug plates, labelled drug plate 1 and drug plate 
2 for the 1st and 2nd additions. As for FLIPR, drug plates were organised with respect to the 
cell plates.  
Two protocols were in use in YFP-CFTR imaging. These protocols are referred as Iˉ first 
addition and Iˉ second addition, and are described in Chapter 3 and Chapter 6, respectively. 
Iˉ first addition protocol: 
Cell plate contained 100 µl standard buffer 
 Acquire image every 2 s for 20 s  
 Add 50 µl from drug plate 1 
 Acquire image every 2 s for 40 s  
 Add 50 µl from drug plate 2 
 Acquire image every 2 s for 90 s  
 
Drug plate 1 contained 300 mM Iˉ buffer (final extracellular concentration 100 mM). Drug 
plate 2 contained the well treatment made in 100 mM Iˉ to preserve the extracellular Iˉ 
concentration. 
Iˉ second addition protocol: 
Cell plate contained 100 µl standard buffer 
 Acquire image every 2 s for 20 s  
 Add 50 µl from drug plate 1 
 Acquire image every 2 s for 90 s  
 Add 50 µl from drug plate 2 
 Acquire image every 2 s for 40 s  
 
Drug plate 1 did not contain Iˉ, only the well treatment. The second addition contained 400 
mM Iˉ buffer (final concentration 100 mM) with the treatment concentration maintained.  
YFP-CFTR was imaged using a 20X objective, and excitation/emission filters 472 ± 30 nm 
and 520 ± 35 nm (Figure 2.3). Although the filters were not optimised for YFP imaging, 
excitation was sufficient to allow visualisation of YFP-CFTR. For all plates, the laser intensity 
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and exposure were changed to achieve the highest possible fluorescence whilst avoiding 
both photo-bleaching and saturation. For most plates, this meant an illumination intensity of 
100/225 c.d., and exposure time 0.15 s. However, these settings were tested and optimised 
at the start of each experiment. The parameter used to guide this selection was the pixel 
intensities of cells compared to background regions. Ideal cell fluorescence was > 1000 grey 
units higher than background. To reduce the storage size required for the images, and 
increase the speed of image analysis, a camera binning of 5x5 pixels was used when 
recording YFP-CFTR. This reduced image resolution, but did not have a negative impact on 
accuracy of quenching measurements.  
 
Acquired 16-bit images were analysed using ImageJ (http://rsbweb.nih.gov/ij/). Each well 
was exported as a stack, with each time point represented by an image in the stack. Using 
the image obtained at the time point immediately before Iˉ addition, fluorescent cells were 
selected using an appropriate threshold (Figure 2.4 A and B). The threshold was selected 
manually for each plate, and maintained throughout the plate. The aim of the threshold was 
to select as many cells as possible, whilst excluding background regions. 
Each region was expanded by seven pixels in every direction (Figure 2.4C) to define areas 
of the image to be analysed as ‘cells’. As the fluidics component is mounted directly onto the 
microscope, movement which occurs in picking up a tip, injecting solution and dispensing the 
tip can, on rare occasions, move the cell plate and therefore the field of view by a small 
amount. If the regions had not been expanded, this movement would cause an artefact: a 
sharp decrease in ‘cell’ fluorescence and corresponding increase of ‘background’ reading. 
By expanding the regions, small movements of the cell plate in any direction did not alter the 
fluorescence reading. This expansion did result in a slight underestimate of fluorescence 
Figure 2.3 YFP 
excitation/emission spectrum 
with ImageXpress filters. 
Modified from Galietta, Haggie, & 
Verkman, 2001. YFP excitation 
and emission peaks are seen at 
513 nm and 525 nm respectively. 
Green shading highlight the 
bandwidth of the excitation and 
emission filters used in the 
ImageXpress protocol. A dichroic 
mirror allowed transmission > 502 
nm. 
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intensity at each time point. However, our readout (determined by the normalised gradient of 
this reading over time, see Chapter 3), was little affected.  
 
 
 
 
 
The mean fluorescence intensity within the selected cell regions was measured at every time 
point. The selection was then inverted, to obtain a mean fluorescence reading of the 
Figure 2.4 YFP-CFTR image analysis. A) Greyscale YFP-WT-CFTR image at 58 s during 
Iˉ first addition protocol (i.e. immediately before forskolin addition). Scale bar = 100 µm. B) 
Threshold used to select fluorescent cells (areas above threshold are surrounded by yellow 
lines). C) Regions with fluorescence above threshold expanded by seven pixels in every 
direction.  Cells expressing YFP-CFTR are within the yellow line, while areas outside this 
line are analysed as background. D) Image obtained at time point 150 s, after fluorescence 
quenching in response to 30 µM forskolin.  
 
A B 
C D 
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background at every time point. Subtracting the background measurement from the cell 
measurement at each time point gave a trace of YFP fluorescence against time.  
2.4.3 CFTR-pHTomato imaging and image analysis 
CFTR-pHTomato imaging involved reading baseline pHTomato fluorescence in pH 7.4 
standard buffer, decreasing pH using MES buffer (as standard buffer, with HEPES replaced 
with 10 mM MES, pH 5.5), increasing pH using Tris buffer (as standard buffer, with HEPES 
replaced with 100 mM tris, pH 9.5), and finally neutralising lumen pH of internal vesicles 
using 40 mM NH4Cl. eGFP fluorescence reading and Hoechst nuclear stain were also 
acquired, and used for analysis. 
CFTR-pHTomato protocol: 
Cell plate contained 100 µl standard buffer 
 Acquire image every 2 s for 4 s 
 Add 50 µl MES buffer 
 Acquire image every 2 s for 4 s 
 Add 50 µl Tris buffer 
 Acquire image every 2 s for 4 s 
 Add 50 µl NH4Cl buffer 
 Acquire image every 2 s for 4 s 
 
 Excitation Emission Dichroic mirror 
Hoechst 377 ± 25 nm 447 ± 30 nm 
327-404 nm (R) 
415-950 nm (T) 
eGFP 472 ± 30 nm 520 ± 35 nm 
350-488 nm (R) 
502-950 nm (T) 
pHTomato 531 ± 20 nm 593 ± 20 nm 
350-555 nm (R) 
569-950 nm (T) 
 
 
50 µl 1 µg/ml Hoechst (Sigma-Aldrich) was added to each well in cell medium, and 
incubated for 20 min. Cells in cell plates were washed as for YFP-CFTR imaging and plates 
loaded into the ImageXpress chamber. Wells were subject to individual chronic treatment, 
but during imaging all wells received identical fluid additions, with no requirement for well-
specific treatments. Therefore, drug plates of specific treatments were not necessary.  
Table 2.3 Hoechst, eGFP and pHTomato ImageXpress filter cubes. Excitation and 
emission filters, and dichroic mirror. R = reflected, T = transmitted.  
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Images were taken every 2 s. At the first time point, images were acquired sequentially using 
all three filter cubes (Table 2.3). At subsequent time points, only pHTomato images were 
acquired. CFTR-pHTomato imaging was done with a 20X objective. 
Figure 2.5 shows that imaging the three fluorescent probes in parallel did not cause cross-
talk between spectra.  
 
As for YFP-CFTR analysis, acquired 16-bit images were analysed using ImageJ. For 
pHTomato images, each well was exported as a stack, with each time point represented by 
an image in the stack. Hoechst and eGFP images, as there was only one time point per well, 
were exported as single 16-bit images.  
Cells were selected based on eGFP fluorescence (Figure 2.6A), using a manually selected 
threshold which identified the maximal number of cells, without selecting background 
regions. Each region was expanded by seven pixels, to avoid fluid addition artefacts as for 
YFP-CFTR imaging. The mean eGFP fluorescence of each region was measured.  
On the pHTomato image, the eGFP region locations were loaded and the mean pHTomato 
fluorescence of each region was measured at all time points (Figure 2.6B). This allowed the 
fluorescence of each region in the pHTomato image to be normalised to the respective 
region in the eGFP image, to allow for differences in total protein expression.  
Each region was then weighted for the cell count (Figure 2.6C), estimated from the fraction 
of the area which was stained with Hoechst. In one case where Hoechst staining was not 
possible, the area of the GFP regions was used to estimate cell count. Regions containing 
saturated pixels were removed from the analysis.  
Figure 2.5 Hoechst, 
eGFP and pHTomato 
spectra, shown with 
ImageXpress filters. 
Modified from Li and 
Tsien (2012). Blue 
(Hoechst), green (eGFP) 
and red (pHTomato) 
lines and shading 
highlight the respective 
spectrum and excitation/ 
emission filters used in 
the ImageXpress 
protocol.  
 
 Methods 46 
 
    
 
 
 
 
2.4.4 Low temperature and chronic exposure incubation 
Different experimental pre-incubation conditions were added to these protocols in order to 
study mutations or drug effects. Temperature correction of ΔF508-CFTR involved 
transfection of HEK293 cells with ΔF508-CFTR, incubation at 37°C for 24 h, followed by 
incubation at 30°C for 24 h before imaging. Chronic compound treatment (24 h) was tested 
by beginning incubation with the compound 24 h after transfection. 
 
B 
Figure 2.6 CFTR-pHTomato image analysis. A) Regions selected using eGFP 
fluorescence threshold, shown by yellow outline. Regions were expanded by seven pixels in 
every direction. Scale bar = 100 µm. B) pHTomato in acidic buffer (left), basic buffer 
(middle) and after addition of 40 mM NH4Cl (right). Lower panels show small expanded 
region in corresponding conditions. C) Hoechst nuclear stain used to weight fluorescence 
based on cell number. 
C A 
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2.5 High-throughput confocal imaging  
Cells were prepared as for ImageXpress YFP-CFTR imaging, including a Hoechst nuclear 
stain. The plates were loaded into the Opera High Content Screening System (PerkinElmer 
Life and Analytical Sciences, Bucks, UK). Cells were imaged with a 40X objective at 37°C. 
The Opera uses a triple bandpass filter (488/561/640 nm) for excitation of YFP, and a triple 
excitation dichroic mirror. UV light was used to excite Hoechst and a 425 nm dichroic 
longpass mirror with UV bandpass filter 450 ± 25 nm used to detect Hoechst emission. 
Images were analysed using ImageJ. For membrane density analysis, a line was drawn 
across a cell in both the YFP and Hoechst image, and fluorescence along the line was 
plotted as a function of distance along the line.  
2.6 Single channel patch clamp technique  
2.6.1 Excised patch technique 
HEK293 cells in 35 mm dishes, expressing the channel of interest (WT-CFTR or YFP-WT-
CFTR), along with GFP as a marker of transfection, were used for voltage-clamp recording, 
in the excised inside-out patch configuration. Excised patch recordings were made using an 
EPC9 amplifier and Pulse acquisition software (HEKA Instruments Inc., MA, US). Cells were 
mounted in 35 mm dishes above an inverted fluorescence microscope (Nikon Eclipse 
TE200), with mercury light source and GFP filters (excitation/emission 450-500 nm/510-560 
nm, dichroic mirror transmitted > 505 nm). The microscope was placed on an air table, and 
enclosed in a Faraday cage. The pipette was controlled via a micromanipulator (Narishige 
MHW-3, Digitimer Ltd., Hertfordshire, UK). The bath electrode consisted of a silver chloride 
bead immersed in the bath. All metal components were grounded. 
Cells were perfused with bath solution (134 mM NMDG, 134 mM HCl, 2 mM MgCl2, 5 mM 
HEPES, 0.5 mM EGTA, pH 7.1). Pipette solution contained 136 mM NMDG, 136 mM HCl, 2 
mM MgCl2 and 5 mM HEPES (pH 7.4). Pipettes were pulled from borosilicate glass 
capillaries of outer diameter 1.5 mm and inner diameter 0.86 mm (Harvard Apparatus Ltd., 
Cambridge, UK) using a vertical pipette puller (Narishige PP-830, Digitimer Ltd.). Pipettes 
were coated with Sylgard (Sigma-Aldrich) to reduce pipette capacitance, and fire polished 
using a microforge (Narishige MF-830, Digitimer). Pipettes, filled with pipette solution and 
measured in bath solution, typically had a resistance of ~12 MΩ. 
To obtain a seal, a micromanipulator was used to move the pipette towards the cell surface. 
An increase in resistance indicated the pipette was nearing the cell surface. At this point, a 
small amount of suction was applied to the pipette. Upon establishing a seal, the 
 Methods 48 
micromanipulator was used to quickly and sharply pull the pipette upwards, excising the 
patch in the inside-out configuration.  
To apply treatments, a microperfusion system was made using glass capillaries (Harvard 
Apparatus) gravity fed from 25 ml syringes connected by flexible silastic tubing (Harvard 
Apparatus). Treatments made in bath solution were applied to the cytosolic face of the patch 
by moving the pipette within the perfusion system, into the appropriate stream. Continuous 
recordings were made at room temperature with the pipette potential held at + 60 mV (- 60 
mV membrane potential). 
2.6.2 Analysis of patch data 
Records were exported to ClampFit (Molecular Devices), and filtered digitally at 50 Hz. 
Programs developed and provided by László Csanády (Semmelweis University, Hungary) 
were used to analyse traces. A detailed description of multichannel dwell-time distribution 
analysis is published (Csanády, 2000). Briefly, baseline correction removed drift in the trace 
to more clearly show changes in conductance caused by channel opening. An events list 
was produced, by applying half-amplitude threshold crossing on the baseline corrected 
trace, which records the conductance level (i.e. closed, one open channel, two open 
channels) and the length of each event. The events list was used to produce dwell time 
histograms, which showed the number of events observed at each conductance level, 
binned according to the length of dwell-times. The time axis was logarithmic and contained 
six bins per e-fold (Figure 2.7, yellow histograms).  
The distribution of dwell times was fit to a three-state gating model (C1 ↔ O ↔ C2), in which 
C1 ↔ O represents a simplified opening and closing (entry and exit from bursts), and O ↔ C2 
represents ATP-independent fast, flickery closures. Parameters were obtained by Maximum 
Likelihood fitting of dwell-time histograms at all conductance levels to identify the most likely 
opening rate (rCO), closing rate (rOC) and rates of entry (rOF) and exit (rFO) from brief flickery 
closures for the channel, and thus the most likely interburst duration (Tib = 1/rCO), and open 
burst duration (Tb =(1/rOC)*(1+rOF/rFO)). 
Both rCO and rOC can be reliably estimated when the number of channels in the patch is 
known. To calculate the probability of there being another, unseen, channel in the patch, the 
same events list was fit to the model assuming n + 1 channels (with n being the maximum 
number of simultaneously open channels observed). For example, in the data in Figure 2.7, 
rCO would be estimated assuming that this distribution was obtained from three channels 
rather than from two. Given the cumulative length of time the channel spends in the top 
conductance state, the probability of missing the (n+1)th channel was calculated.  In cases 
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where the probability of not seeing this putative additional channel was < 0.05, the number 
of channels in the patch was assumed to be known. These records were fit to obtain Po, rCO 
and  rOC. 
 
 
 
However, in most CFTR recordings the number of channels in the patch could not reliably be 
estimated (probability of missing the (n+1)th channel > 0.05). In these circumstances, noise 
analysis was used to estimate Po, using the relationship between mean and variance for 
binomially distributed samples: 
              
    [Equation 2.1] 
Where σ2(I) is the variance of the current samples, I is the mean of the current samples (pA), 
and i is the single channel current (pA). The gradient of a line between the origin and σ2/i 
against I gives (1 - Po). In these cases, Tb can still be estimated from dwell time distributions, 
as it is not steeply dependent on the number of channels. Therefore, when the number of 
channels in a patch could not be determined, Po was obtained from noise analysis, Tb from 
Maximum Likelihood fitting of dwell-time histograms, and Tib from Equation 2.2. 
      
        
  
                    [Equation 2.2] 
2.7 Figures and statistics 
All average plots including error bars in this thesis represent mean ± SEM. In cases where 
two groups were compared using statistics, this was carried out using paired or unpaired t-
tests, as appropriate. When more than two groups were compared, this was done using a 
Figure 2.7 Dwell time distribution of WT-CFTR. The patch, containing two gating 
channels, was activated with 300 nM PKA + 2 mM ATP. Yellow histograms show the 
number of events at each dwell time (in six bins for each ln unit). Red lines represent the 
expected distribution following fitting to the three state model: C1 ↔ O ↔ C2. 
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one way analysis of variance (ANOVA), followed by a post-hoc Tukey’s test (for all pairwise 
comparisons) or a Dunnett’s test (for comparisons vs. a control). In cases where plots or 
statistics differ from what is described here, for example if a data set failed the normality test 
and was subsequently compared using a non-parametric test, this is stated in the figure 
legend. 
All statistics were carried out using SigmaPlot.  
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Chapter 3 
YFP-CFTR: Gating sensitive fluorescent probe 
 
3.1 Introduction 
Halide sensitive YFP (H148Q/I152L) has been in use in CFTR research for a number of 
years (see Galietta et al., 2001a, 2001c; Muanprasat et al., 2004; Pedemonte et al., 2005a), 
following optimisation by the Verkman lab (Galietta et al., 2001b). This chapter introduces 
the properties of YFP (H148Q/I152L), before describing the utilisation of the fluorescent 
protein in our project. 
3.1.1 GFP 
YFP (H148Q/I152L) is a modified form of GFP, a naturally occurring 238 amino-acid protein 
from the Aequorea victoria jellyfish. GFP is an 11 strand β-barrel formed around a central 
helix, within which the chromophore, generated by an autocatalytic reaction involving 
residues 65 to 67, is located (Heim et al., 1994). Fluorescence occurs when absorption of a 
photon causes excitation of an electron in the chromophore, which, when relaxing back to 
the ground state, releases energy as light of longer wavelength.  
The original GFP has two excitation peaks, at 395 nm and 475 nm, and an emission peak at 
509 nm (Chalfie et al., 1994; Heim et al., 1994). The GFP chromophore can be ionised at the 
phenol group derived from tyrosine residue 66, with the protonated and deprotonated states 
responsible for the two peaks on the GFP excitation spectrum (Heim et al., 1994). Mutations 
to enhance fluorescence following excitation at 475 nm, and increase the rate of post-
translational modification (Heim et al., 1995; Cormack et al., 1996), produced eGFP, the 
form of GFP currently used by most labs. 
3.1.2 Halide sensitive YFP  
Publication of the crystal structure of GFP allowed rational design of mutations, such as 
those which alter excitation and emission spectra to obtain different coloured fluorescent 
proteins. Introducing an aromatic ring at position 203 (T203Y), close to the chromophore, 
caused a red shift in the spectrum, producing the first YFP. Mutations S65G, V68L and S72A 
enhanced the brightness of YFP in living cells (Ormo et al., 1996).  
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Like GFP, YFP (T203Y/S65G/V68L/S72A, hereafter referred to as YFP) exists in protonated 
and deprotonated states (excitation peaks at 416 nm and 514 nm, respectively). Introduction 
of the H148Q mutation increased the pKa of protonation to ~7.1 (Jayaraman et al., 2000; 
Wachter et al., 2000). The two protonation states are the basis of YFP halide sensitivity.  
Binding of Clˉ to the protein destabilises the deprotonated state, causing a decrease in 
absorbance at 514 nm (Figure 3.1A). This causes a shift in the pKa, as the protonated form 
remains favourable in increasingly alkaline conditions (Figure 3.1B).  
  
 
 
 
 
Figure 3.1 YFP (H148Q) absorbance and Clˉ sensing properties. Modified from 
Jayaraman et al. 2000. A) Absorbance spectrum in the presence of increasing [Clˉ], 
measured at pH 6.4. Absorbance at peak 514 nm falls as [Clˉ] increases. This occurs 
alongside an increase in absorbance at peak 416 nm, which is not excited during YFP 
imaging. B) pH titration in the presence of increasing [Clˉ]. Fluorescence emission measured 
following excitation at 514 nm. At physiological pH 7.4 the relative fluorescence units (RFU) 
decrease in increasing [Clˉ]. Note the YFP variant used in this figure (YFP (H148Q)) is 
different to that which is used in subsequent work (YFP (H148Q/I152L)). Introduction of 
I152L did not appreciably alter pH dependence (Galietta et al., 2001b).  
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Structures of crystals obtained in the presence of 100 mM Iˉ showed the halide bound in 
close proximity to the chromophore (Wachter et al., 2000). The negative charge on the 
chromophore shifts the equilibrium of protonation away from the deprotonated state. 
3.1.3 YFP (H148Q/I152L) in CFTR research 
In order to utilise YFP (H148Q) in CFTR research, it was necessary to increase the affinity 
for Iˉ compared to Clˉ. Intracellular [Clˉ] ([Clˉ]i) is approximately 20 mM (Bregestovski et al., 
2009). YFP variants with high Clˉ affinity would be largely quenched at physiological levels of 
[Clˉ]i, regardless of CFTR activity. However, physiological levels of Iˉ are extremely low (i.e. 
[Iˉ]i is close to zero). Clˉ/Iˉ exchange protocols offered a possibility for the study of CFTR 
function, taking advantage of the relatively high permeability of CFTR to Iˉ (Anderson et al., 
1991; Linsdell et al., 1997).  
In order to improve affinity for Iˉ, mutations were made to the halide binding site, with I152L 
producing the lowest KI (2 mM) compared to KCl (85 mM) (Galietta et al., 2001b). This 
property is exploited to assess CFTR channel function because, when co-expressed with 
CFTR in the presence of an extracellular Iˉ buffer, YFP (H148Q/I152L) fluorescence will only 
be quenched if CFTR is open, allowing Iˉ to enter the cell (Figure 3.2).  
 
 
 
 
 
 
 
 
This assay has been used to screen for ΔF508-CFTR potentiators, as described earlier 
(Introduction). In this chapter, some initial control experiments were done using YFP 
expressed in the cytosol, co-expressed with CFTR. Cytosolic YFP quenching was measured 
using a plate reader (FLIPR). Subsequent work describes the optimisation of a YFP-CFTR 
fusion protein, in which YFP is fused to the N-terminal of CFTR. In most cases, YFP-CFTR 
was monitored using an automated fluorescence image acquisition system, exploiting a 
Figure 3.2 Clˉ/Iˉ exchange protocol to study CFTR activity. Left: CFTR is not gating, Iˉ 
cannot enter the cell and YFP (H148Q/I152L) fluorescence remains bright. Right: CFTR is 
gating, and the driving force for Iˉ entry allows large influx. Iˉ binds YFP (H148Q/I152L), and 
fluorescence decreases. 
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wide-field microscope (ImageXpress). Throughout this thesis, YFP (H148Q/I152L) is referred 
to as YFP. 
3.1.4 YFP-CFTR fusion protein 
YFP-CFTR was obtained by mutating GFP-CFTR (Moyer et al., 1998), already in use in 
other labs (donated by Bruce Stanton, Geisel School of Medicine, NH, USA). GFP-CFTR 
was originally designed to study the role of cAMP in targeting of CFTR to the membrane. 
GFP-WT-CFTR colocalises with antibody-stained WT-CFTR (Moyer et al., 1998), as well as 
with a membrane stain (Ban et al., 2007), which suggests that trafficking is not affected by 
the tag. Whole cell and single channel patch clamping show unchanged channel 
conductance, selectivity and blocker sensitivity in GFP-tagged CFTR (Moyer et al., 1998; 
Vais et al., 2004).  
The N-terminal is known to be involved in both gating and trafficking of CFTR, raising 
concerns that the tag would affect one, or both, of these processes. Expressing CFTR 
lacking the N-terminal (Δ2-72) produced only core-glycosylated, immature CFTR with no 
membrane expression (Prince, 1999). Mutations which inhibit interactions between the N-
terminal and other CFTR domains, cause reduced Po, characterised by decreased burst 
duration (Naren et al., 1999). Similar effects are seen for D58N, an N-terminal mutation 
associated with a mild form of CF (Fu et al., 2001). An N-terminal FLAG epitope also 
reduces Po, but in this case opening rate is most affected (Chan et al., 2000).  
Based on these observations, we gave some thought to inserting the YFP tag elsewhere in 
the CFTR protein. Owing to the lack of a CFTR full-length crystal structure, rational design of 
insertional fusions is difficult. Due to the important roles of the NBDs, the R-domain, and the 
ICLs in gating and trafficking, an intracellular tag would most likely need to be fused via the 
internal end of a TM. However, the location and length of the TMs are not entirely known. 
For this reason, a random insertion protocol was used to create a library of insertional 
fusions. However, comparison of the random insertion YFP-CFTR fusions, with the N-
terminal YFP-CFTR fusion, showed that the latter had preferable characteristics. 
Experiments described in this chapter led us to conclude that the function and trafficking of 
the YFP-CFTR N-terminal fusion protein were sufficiently similar to those of the WT-CFTR 
protein. Therefore, work on insertional fusions was discontinued.  
3.2 The HEK293 cellular environment 
When planning experiments involving expression of a genetically encoded probe, the cell 
line in which the protein of interest will be expressed is an important choice, as cell 
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background can affect protein function. When selecting the cell line, three main questions 
were considered: (i) are all proteins essential for processing and function of CFTR present? 
(ii) Will endogenous CFTR and other anion pathways affect the assay? (iii) Will transfected 
CFTR be phosphorylated by endogenous PKA under basal, unstimulated conditions? 
Human embryonic kidney (HEK293) cells are a commonly used cell line, often selected for 
their rapid growth rate and ease of transfection. Results in this chapter, and obtained 
previously by others, suggest that WT-CFTR is successfully trafficked to the membrane of 
HEK293 cells, whilst ΔF508-CFTR is retained at the ER, as expected (Domingue et al., 
2014). Whilst it is unlikely that trafficking of CFTR in HEK293 cells is identical to that 
occurring in native epithelial cells in vivo, it appears that the cellular machinery for function 
and essential processing of CFTR is available, to a suitable degree. 
The work presented in this thesis involved the expression of many different CFTR mutations, 
testing of which would have been affected by the presence of endogenous WT-CFTR. 
Domingue et al. (2014) found no detectable CFTR mRNA or protein in untransfected 
HEK293 cells. To confirm the absence of CFTR in HEK293 cells, cells transfected only with 
YFP (CFTR-null cells, YFP expressed in the cytosol) were treated with 200 nM or 5 µM 
forskolin. 200 nM forskolin has a small effect on CFTR, whilst 5 µM induces near maximal 
WT-CFTR activation (see page 62). CFTR-null cells treated with 200 nM or 5 µM forskolin 
had similar quenching rates (Figure 3.3, p = 0.5). This suggested that there was no 
detectable endogenous CFTR in untransfected HEK293 cells.  
Many endogenous ion channels and G-protein coupled receptors (GPCRs) are expressed in 
HEK293 cells (Dautzenberg et al., 2000; Shaw et al., 2002). CFTR is phosphorylated by 
PKA, a kinase downstream of cAMP, the levels of which would be affected by both GαS- and 
GαI-coupled GPCRs. CFTR-positive cell quenching rate in the absence of forskolin was not 
significantly different to that of CFTR-null cells (Figure 3.3, p = 0.439). This suggested that 
transfected CFTR was not phosphorylated by endogenous PKA in unstimulated HEK293 
cells.  CFTR-positive cells were activated by 200 nM or 5 µM forskolin to demonstrate rates 
achieved by CFTR activation (Figure 3.3). 
Other groups have detected GABAA (Shaw et al., 2002), TMEM16A and ClC2 (Domingue et 
al., 2014) mRNA in HEK293 cells, all of which would provide alternative anion pathways in 
the assay. The slow quenching rates observed in CFTR-null and untreated CFTR-positive 
cells were most likely caused by Iˉ entry via these anion pathways (Figure 3.3), and were 
considered sufficiently low as to not affect assay readout to a significant degree. 
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Galietta et al. (2001) reported that endogenous anion flux was low in Chinese hamster ovary 
(CHO) cells compared to other cell lines. However, in our assay, the anion permeability of 
CFTR-null CHO cells was higher than CFTR-null HEK293 cells (9 ± 0.7 10-3 RFU s-1 vs. 4 ± 
0.2 10-3 RFU s-1). Additionally, the expression of YFP by CHO cells was lower, seen as ~2-
Figure 3.3 Quenching of cytosolic YFP in CFTR-null and CFTR-positive cells. A) YFP 
quenching in response to forskolin in HEK293 cells transfected with cytosolic YFP ± WT-
CFTR. Forskolin is added to each well in the presence of 100 mM Iˉ. Trace colours 
correspond to bar colours in B. B) Quenching quantified by maximal rate per s (RFU s-1), as 
in papers by Galietta et al. (2001c). * indicates p < 0.05 vs. untreated CFTR-positive cells.  n 
= 12 for CFTR-null cells, n = 6 for untreated CFTR-positive cells, and n = 18 for forskolin-
treated CFTR-positive cells.  
 YFP-CFTR: Gating sensitive fluorescent probe 57 
fold decrease in average fluorescence, compared to HEK293 cells. Therefore, for the 
remainder of this work, CFTR was expressed in HEK293 cells by transient transfection.  
3.3 YFP-CFTR fusion assayed using FLIPR  
The function of YFP-CFTR as an anion channel was initially assessed using FLIPR. 
Comparison of 0 µM and 5 µM forskolin treated YFP-WT-CFTR showed that the YFP-CFTR 
fusion protein functioned as an anion channel when activated by forskolin (Figure 3.4). 
Figure 3.4A shows large artefacts, which occur upon fluid addition to the wells. Due to the 
low signal (approximately 10% of that obtained with cytosolic YFP) the artefact affected 
readout more in YFP-CFTR than in separately expressed YFP and CFTR. Figure 3.4B 
shows the traces from immediately after the second addition artefact, with the fluorescence 
axis expanded so quenching can be seen more clearly. 
 
 
        
 
 
These results demonstrated that the N-terminal tag did not render the CFTR non-functional, 
or entirely prevent trafficking to the membrane. However, Figure 3.4 shows a noisy signal 
with large addition artefacts and high fluorescent background which remained following 
quenching of YFP (91% of fluorescence remained). These factors had the potential to limit 
the sensitivity of the assay.  
 
Figure 3.4 YFP-WT-CFTR function measured in FLIPR. A) Quenching traces of HEK293 
cells expressing YFP-WT-CFTR in response to 0 µM or 5 µM forskolin. B) Traces shown 
from after second addition artefact (notice change in y-axis scale). Signal was normalised to 
a point immediately after second addition artefact in both A and B. n = 8. 
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3.4 YFP-CFTR fusion assayed using ImageXpress 
ImageXpress is a high-content, automated wide-field fluorescence microscope with 96-well 
plate holder and fluidics capabilities. Cells expressing YFP-WT-CFTR were imaged in the 
absence and presence of 5 µM forskolin. Comparison of Figure 3.5 with Figure 3.4 shows 
that ImageXpress recordings resulted in a dramatic improvement of the signal-to-noise ratio, 
smaller addition artefacts, and lower background signal (approximately 40% YFP 
fluorescence remained after quenching). All following fluorescence imaging experiments 
were therefore conducted using ImageXpress acquisition and image analysis. 
  
 
 
3.5 Quantification of quenching as a measure of CFTR ion channel function  
In order to further understand the relationship between YFP-CFTR quenching and [Iˉ] at the 
chromophore, we measured fluorescence after equilibrating the cells with different [Iˉ]e.  
YFP-WT-CFTR was activated by maximal (20 µM) forskolin, in the presence of different [Iˉ]e. 
After a short delay, the fluorescence signal decayed exponentially to reach a steady state 
level (Figure 3.6). This quenching reflects Iˉ entry into the cytosol (until [Iˉ]i is at equilibrium 
with [Iˉ]e), and binding of Iˉ to YFP. Fluorescence was normalised to the time point 
immediately before addition of extracellular Iˉ. At this time point, there was no Iˉ at the YFP 
chromophore, and fluorescence was maximal. Figure 3.6A shows quenching in the presence 
of [Iˉ]e ≤ 100 mM. For [Iˉ]e > 100 mM, the concentration was changed after maximal 
activation of CFTR in the presence of 100 mM Iˉ (Figure 3.6B). Experiments of both kinds 
were used to generate Figure 3.6C: fluorescence as a function of [Iˉ]e. These data points are 
well described by a single site binding equation (Equation 3.1). 
Figure 3.5 YFP-WT-CFTR function measured in ImageXpress. ImageXpress quenching 
traces of YFP-WT-CFTR in response to 0 µM or 5 µM forskolin. Signal was normalised to 
the point immediately after addition of forskolin. n = 7. 
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           [Equation 3.1] 
Where F is normalised fluorescence, Bmax is the maximal proportion of fluorescence 
quenched at saturating [Iˉ]e and K0.5 is the [Iˉ]e giving half maximal binding. Best fit parameter 
estimates obtained were: K0.5 = 39.3 mM ± 3 mM and Bmax = 0.98 ± 0.02. The K0.5 obtained 
from Equation 3.1 represents the [Iˉ]e which, at equilibrium, resulted in an [Iˉ] at the 
chromophore equivalent to the YFP binding affinity for Iˉ. A Bmax of ~1 indicated that when 
the Iˉ site was occupied, YFP fluorescence was entirely quenched (FUNBOUND = 1; FBOUND = 0).  
In addition, the good fit suggested that varying [Iˉ]e did not lead to major changes in steady 
state membrane potential (VM), and that the YFP expressed in HEK293 cells, fused to 
CFTR, has very similar characteristics to those of the purified protein (Galietta et al., 2001b). 
By rewriting the equation for unbound receptors (normalised fluorescence as a function of [Iˉ] 
at the chromophore: Equation 3.2), we can express [Iˉ] at the chromophore as a function of 
measured fluorescence (Equation 3.3). 
     
    
     
  
       [Equation 3.2] 
           
     
 
    [Equation 3.3] 
Where F is fluorescence and KI is the published binding affinity (Galietta et al., 2001b).  
Using Equation 3.3, fluorescence values (Figure 3.7A) were converted to [Iˉ] at the 
chromophore (Figure 3.7B). Differentiation of the [Iˉ] curve in Figure 3.7B gave the rate of Iˉ 
entry (Figure 3.7C). CFTR activation was quantified using the maximal observed rate of Iˉ 
entry (d[Iˉ]/dt in mM s-1). This method of quantification was used to construct a 
concentration-response curve to forskolin (Figure 3.7D). The rate of Iˉ entry is related to 
channel Po, the proportion of YFP-CFTR proteins located at the membrane, and the driving 
force for Iˉ entry.  
In published literature on halide sensitive cytosolic YFP, the quenching protocol is run in one 
of two ways. Either, it is run in a similar manner to that which has been described here (i.e. Iˉ 
as a first addition, for example see Galietta et al., 2001c), or, by activating CFTR in the 
absence of Iˉ, followed by addition of extracellular Iˉ (i.e. Iˉ as a second addition, for example 
see Pedemonte et al. 2005). The majority of the work in this thesis was carried out using the 
Iˉ first addition protocol, as in Figure 3.5.  
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Figure 3.6 YFP-WT-CFTR 
quenching in the presence 
of increasing [Iˉ]e. A) 20 µM 
forskolin-induced quenching 
in the presence of low [Iˉ]e. 
Arrows indicate the fraction 
quenched (1 - fluorescence) 
in (i) 20 mM and (ii) 50 mM 
[Iˉ]e as examples. B) [Iˉ]e was 
increased further following 
CFTR activation in the 
presence of 100 mM Iˉ. 
Arrow indicates the fraction 
quenched in (iii) 200 mM Iˉ 
as an example. C) Single 
site binding kinetics of Iˉ 
binding following maximal 
activation of CFTR. (i), (ii) 
and (iii) are indicated on the 
curve. n = 3. Solid line is 
best fit to Equation 3.1 with 
K0.5 = 39.3 mM ± 3 mM and 
Bmax = 0.98 ± 0.02 
 
C 
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This protocol was chosen to allow observation of the time course of CFTR activation. This 
protocol also minimised the consequences of fluid addition artefacts (seen in Figure 3.5). 
These are small, largely unavoidable changes in fluorescence associated with fluid 
additions. Due to the short delay after forskolin addition, before CFTR opening and therefore 
quenching begins, the time points of interest do not occur immediately after any fluid addition 
(for example see Figure 3.7A-C). Therefore, the artefacts have little effect on the final 
readout.  
The alternative protocol, in which CFTR is activated in the absence of Iˉ, and quenching time 
course is followed immediately after Iˉ addition, can also be useful. For these experiments, 
CFTR is activated for 90 s, at which point steady state activation is assumed to have been 
Figure 3.7 Quantification of CFTR ion channel function using YFP-WT-CFTR 
quenching. A) Normalised fluorescence quenching in response to 10 µM forskolin. B) [Iˉ] at 
the chromophore increases in response to 10 µM forskolin. C) The gradient of the trace in B) 
show the rate of Iˉ entry in response to 10 µM forskolin at each time point. D) Forskolin 
concentration-response curve using fastest observed Iˉ entry rate (d[Iˉ]/dt mM s-1) to quantify 
CFTR activation. EC50 = 2.2 µM ± 0.3 µM. n = 3.  
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achieved. Iˉ is then introduced, causing immediate quenching. This, the Iˉ second addition 
protocol, is described in detail in Chapter 6. This protocol is useful when steady state 
conditions are the focus of investigation.    
3.6 YFP-WT-CFTR vs. untagged WT-CFTR ion channel function 
Although the literature reported little effect of the N-terminal GFP tag on CFTR channel 
function, due to the importance of the N-terminal in function and trafficking, and the 
differences in experimental set-up, YFP-WT-CFTR function as an anion channel was 
compared with untagged WT-CFTR in HEK293 cells. 
  
 
 
The forskolin EC50 obtained for YFP-WT-CFTR (2.2 µM ± 0.3 µM, Figure 3.7D) was similar 
to that obtained for WT-CFTR (EC50 = 0.97 µM ± 0.1 µM,  Figure 3.8) and to that of WT-
CFTR obtained in a mouse mammary epithelial cell line (500 nM; Haws et al., 1996). The 
similar forskolin EC50 of tagged and untagged CFTR confirmed that the N-terminal tag did 
not severely affect gating or sensitivity to PKA-mediated phosphorylation.  
To further compare the gating kinetics of YFP-WT-CFTR and WT-CFTR, both were 
expressed in HEK293 cells for single channel analysis using patch-clamping. Excised inside-
out patches were activated with 300 nM PKA and 2 mM ATP for approximately 3 min. Once 
steady state activation was reached, 300 nM PKA was removed leaving only 2 mM ATP. No 
significant differences were seen in any parameter when comparing gating in the presence 
Figure 3.8 Untagged WT-CFTR forskolin concentration-response curve. CFTR 
activation quantified using maximal rate of Iˉ entry, as Figure 3.7. EC50 = 0.97 µM (± 0.1 µM, 
6 ≤ n ≤ 18). Data points obtained using FLIPR, and co-expressing CFTR and cytosolic YFP, 
as in Figure 3.3. 
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of 300 nM PKA + 2 mM ATP with that following PKA washout, in the presence of 2 mM ATP 
only (p > 0.23 for Tb, Tib and Po for both WT-CFTR and YFP-WT-CFTR). Data, therefore, 
was pooled from the two groups.  
 
 
 
YFP-WT-CFTR had a significantly lower Po compared with untagged WT-CFTR (0.39 and 
0.62 respectively, Figure 3.9). This indicated that the YFP tag did interfere with normal 
gating to some degree. However, this analysis did not allow us to determine which gating 
steps were affected. 
Opening and closing rates (rCO and rOC) were estimated using programs developed and 
provided by László Csanády (Semmelweis University, Hungary; Csanády 2000). Using these 
programs, the distributions of dwell times at multiple conductance levels were jointly fit to a 
three state gating model (C1 ↔ O ↔ C2). 
Figure 3.9 Noise analysis of WT-
CFTR and YFP-WT-CFTR patches. 
A) Each point is a different record, 
obtained in the presence of either 
300 nM PKA + 2 mM ATP or 2 mM 
ATP only. The gradient between 
each point and the origin is a 
measure of (1 - Po) for that particular 
record. The average Po, from all 
data points, is stated on the graph. 
The plotted line has a slope equal to 
the mean (1 - Po). B) Po (n = 12 and 
n = 15 for WT-CFTR and YFP-WT-
CFTR, respectively). * p = 0.003, 
from Mann-Whitney U test.  
A 
B 
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Figure 3.10 Dwell time distribution analysis of WT-CFTR and YFP-WT-CFTR. A) 
Average interburst duration derived from dwell time distribution if channel number is known, 
or calculated using Equation 3.1, with Po from noise analysis and burst duration from dwell 
time distribution analysis (p = 0.043, from Mann-Whitney U test). B) Average burst duration 
derived from dwell time distribution analysis (p = 0.177, from Mann-Whitney U test). For A 
and B, n = 11 and 15 for tagged and untagged, respectively. C) Example traces of WT-
CFTR and YFP-WT-CFTR containing two gating channels in the presence of 2 mM ATP, 
following exposure to 300 nM PKA. C = closed state, O = open state conductance of one 
channel. 
B A 
C 
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CFTR gating can be seen as occurring in “bursts”: sojourns in a relatively long-lived closed 
state (interburst closure, C1) are terminated by periods in which the channel toggles between 
short-lived closed states (flickery closures, C2) and the full conductance open state (O). 
Evidence suggests that C1 ↔ O reflects channel opening and closing involving ATP-binding 
and ATP-hydrolysis respectively (Vergani et al., 2005; Csanády et al., 2010), and O ↔ C2 
represents short-lived closures, possibly caused by pore block (Zhou et al., 2001).  
Maximum likelihood fitting allows estimation of the four rates in the three state gating model, 
and thus the most likely interburst and burst duration. 
The decrease in Po seen for YFP-WT-CFTR compared to WT-CFTR was mainly due to an 
increase in interburst duration (Figure 3.10A). The YFP tag thus appears to slow opening in 
a manner similar to that seen with an N-terminal FLAG tag (Chan et al., 2000). Although 
average burst duration appeared to be slightly longer for untagged WT-CFTR, the difference 
was not significant (Figure 3.10B). Example traces of WT-CFTR and YFP-WT-CFTR in the 
presence of 2 mM ATP are shown in Figure 3.10C.  
In summary, our characterisation of the effects of the N-terminal YFP tag on CFTR gating 
suggested that the functional disruption was relatively small. Forskolin concentration 
dependence (Figures 3.7D) and burst duration (Figure 3.10B) were unchanged, and there 
was a relatively minor reduction in Po (Figure 3.9B) reflecting slowed opening (Figure 3.10A). 
We thus concluded that the YFP-CFTR ion channel function was sufficiently similar to that of 
WT-CFTR for the continuation of this work. 
3.7 YFP-CFTR basal phosphorylation levels 
As seen in Figure 3.3, HEK293 cells do display some anion permeability, not dependent on 
CFTR expression or forskolin stimulation. Our study of untagged WT-CFTR concluded that 
this was not due to activation of CFTR by low, basal PKA activity (Figure 3.3), but rather due 
to alternative, endogenous, anion pathways present in HEK293 cells. YFP-CFTR activity 
preceding forskolin stimulation was studied to confirm the same was true when expressing 
the tagged channel. 
As seen in Figure 3.5, upon addition of 100 mM Iˉ, some YFP-CFTR quenching occurs. This 
quenching represents either basal anion permeability of HEK293 cells, or activation of YFP-
CFTR by resting levels of cAMP. To quantify the contribution of CFTR activation to basal 
anion permeability, YFP-WT-CFTR and YFP-G551D-CFTR quenching in the absence of 
forskolin was compared. G551D is a gating mutation which reduces CFTR Po to close to 
zero (Bompadre et al., 2007) without affecting cellular localisation (Gregory et al., 1991). 
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Therefore, it was hypothesised that if CFTR was phosphorylated by resting levels of PKA 
activity, the basal quenching rate would be higher for YFP-WT-CFTR than for YFP-G551D-
CFTR.  
Maximal rate of Iˉ entry in the presence of 100 mM Iˉ only (i.e. basal anion permeability) in 
HEK293 cells transfected with YFP-WT-CFTR or YFP-G551D-CFTR was similar (p = 0.7) 
(Figure 3.11).  
 
  
 
 
However, the traces in Figure 3.11 show a slight difference in late stage quenching kinetics, 
suggesting that YFP-G551D-CFTR reaches a steady state faster than YFP-WT-CFTR. This 
is consistent with there being a small amount of YFP-WT-CFTR activity in the absence of 
exogenous phosphorylation. This activity is not great enough to increase the maximal rate at 
which Iˉ enters the cells, but seems to result in a decrease in the [Iˉ]i reached at equilibrium 
in the case of YFP-G551D-CFTR. This possibly reflects a different steady state VM. Note that 
the basal overall quenching rates are roughly one tenth of those seen after CFTR activation 
(e.g. Figure 3.7D for YFP-WT-CFTR). 
The similarity between YFP-WT-CFTR and YFP-G551D-CFTR basal maximal quenching 
rates indicated that, although HEK293 cells transfected with YFP-CFTR display anion 
permeability, it occurs mainly via channels and pathways other than CFTR, with only a 
minimal contribution from basal CFTR activation. Figure 3.3, Chapter 6 (Figure 6.10), and 
Domingue et al. (2014) support lack of a large contribution from basal CFTR activation in 
HEK293 cells. 
Figure 3.11 Anion permeability in the absence of PKA stimulation. Left: Fluorescence 
quenching traces shown from addition of extracellular Iˉ. Right: Quantified anion permeability 
(p = 0.7, from Mann-Whitney U test, WT n = 6, G551D n = 7).  
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3.8 Temperature correction of YFP-ΔF508-CFTR 
In order to screen compounds for ΔF508-CFTR potentiator activity, low temperature 
incubation must be used to promote plasma membrane-localisation. ΔF508-CFTR rescue by 
low temperature incubation has been shown in HEK293 cells (Wang et al., 2008), and was 
confirmed using YFP-ΔF508-CFTR. 
Fluorescence of YFP-ΔF508-CFTR incubated at 37°C was not quenched, not even in the 
presence of 50 µM forskolin + 10 µM VX-770 (Figure 3.12, no significant difference between 
any treatment at 37°C, p = 0.434). However, low temperature rescued ΔF508-CFTR was 
successfully activated by 50 µM forskolin + 10 µM VX-770 (Figure 3.12). Notice that, even 
after temperature correction, forskolin alone was still insufficient to activate ΔF508-CFTR, 
due to the severe gating defect caused by this mutation.  
Figure 3.12 Temperature correction of ΔF508-CFTR. A) HEK293 cells expressing YFP-
ΔF508-CFTR, incubated at 37°C or 30°C. Traces shown from treatment addition. B) 
Summary of YFP-ΔF508-CFTR activity. * = p < 0.05 Kruskal-Wallis one-way ANOVA on 
ranks and post-hoc Dunn’s test. Treatments compared within temperature groups. Untreated 
n = 5, forskolin treated n = 6, forskolin + VX-770 treated n = 8. 
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3.9 Assay validation using known potentiators 
In order to validate the assay, concentration-response curves to known potentiators were 
constructed using YFP-ΔF508-CFTR (Figure 3.13). P2 and P5 show similar potency to that 
which is published (Yang et al., 2003; Pedemonte et al., 2005b). However, the VX-770 EC50 
is higher than published data (441 nM vs. 25 nM; Van Goor et al., 2009, and 12.8 nM; Veit et 
al., 2014). This could be caused by cell-specific differences in expression of CFTR-
interacting proteins, as the publications mentioned employ epithelial cell lines (fisher rat 
thyroid and a CF bronchial epithelial cell line; CFBE41o-). Alternatively, the YFP tag could 
alter the conformation to which VX-770 binds, reducing the apparent affinity.  
Despite the increase in VX-770 EC50 with respect to native, Figure 3.13 confirms that the 
YFP-ΔF508-CFTR assay is suitable for detecting potentiation in the presence of forskolin. 
 
3.10 Using YFP-CFTR to measure membrane localisation  
As discussed in the Introduction, as well as a severe gating defect, ΔF508-CFTR is largely 
degraded following translation at the ER, causing a reduction in trafficking to the plasma 
Figure 3.13 YFP-ΔF508-CFTR assay 
validation using known potentiators. 
All curves in the presence of 50 µM 
forskolin. YFP-ΔF508-CFTR rescued 
using 30°C incubation for 24 h. A) VX-
770, EC50 = 441 nM ± 144 nM, nH = 0.82 
± 0.2. B) P2, EC50 = 0.93 µM ± 0.22 µM, 
nH = 0.99 ± 0.2. C) P5, EC50 = 1.1 µM ± 
0.4 µM, nH = 1.1 ± 0.4. P2 and P5 
provided by the Cystic Fibrosis 
Foundation Therapeutics (CFFT). 3 ≤ n ≤ 
6. 
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membrane. Therefore, a single tool capable of measuring both membrane density and 
gating would be highly valuable in the search for pharmacological agents to treat ΔF508-CF.  
Methods currently employed to measure maturation and membrane density of ΔF508-CFTR 
are time consuming, often depend on antibody incubations, and can be difficult to quantify.  
Cellular expression patterns of proteins are often studied using fluorescent tags, leading us 
to investigate whether YFP-CFTR could also be used for this purpose.  
The aim was to design an assay in which HEK293 cells expressing YFP-CFTR could be 
imaged at high magnification, in a high-throughput system, to screen compounds for their 
effect on CFTR membrane density. This would require reliable quantification of the cellular 
localisation of CFTR, using confocal fluorescence images. These same cells would then be 
used in parallel to quantify CFTR activity using the YFP-CFTR functional assay. To achieve 
this, we employed a high-throughput confocal microscope (Opera, PerkinElmer).  
     
 
Figure 3.14 shows example images of YFP-WT-CFTR, YFP-ΔF508-CFTR and YFP-ΔF508-
CFTR corrected using corrector compound VX-809 (10 µM for 24 h). The YFP-WT-CFTR 
image clearly shows membrane expression (white arrows), as well as some YFP-CFTR 
present in perinuclear locations, likely corresponding to ER vesicles, inside the cells (green 
arrows). YFP-ΔF508-CFTR images show probable ER retention as bright regions adjacent 
Figure 3.14 HEK293 cells expressing 
YFP-CFTR. Blue = Hoechst nuclear 
stain, yellow = YFP-CFTR. Scale bar = 
10 µm. Membrane expressed YFP-
CFTR indicated by white arrows, 
internal retention of YFP-CFTR by 
green arrows. Top left: YFP-WT-CFTR. 
Top right: YFP-ΔF508-CFTR. Bottom 
left: YFP-ΔF508-CFTR + 10 µM VX-
809.  
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to the Hoechst-stained nucleus. Due to increased degradation rate of ΔF508-CFTR, the 
overall fluorescence signal was significantly lower, so image brightness was increased. This 
resulted in the visibly higher background fluorescence seen in ΔF508-CFTR images (Figure 
3.14). 
Line analysis is a technique used to quantify membrane expression of fluorescent proteins. It 
involves drawing a line across the cell, and plotting the fluorescence intensity as a function 
of distance along the line. Membrane expression is characterised by the presence of two 
‘membrane expression’ peaks, surrounding a low ‘internal expression’ fluorescence trough, 
which represents background fluorescence inside the cell. Examples of this can be seen in 
Figure 3.15A (Lines 1 and 2). However, the heterogeneity of the population is demonstrated 
by Line 3. A YFP peak next to a Hoechst peak suggests some degree of internal retention 
even of YFP-WT-CFTR. 
Figure 3.15B demonstrates some cells with internal retention of YFP-ΔF508-CFTR (Lines 1 
and 3). Line 2 shows how in cells expressing YFP-ΔF508-CFTR the low YFP signal can 
largely disappear in the background noise, giving no information on cellular localisation. The 
exposure used in these images was already extremely high, so any increase would have the 
potential to damage cells and cause photobleaching. 
Using this method, membrane expression could theoretically be quantified using the ratio of 
‘membrane expression’ peaks to ‘internal expression’ troughs. However, as Figure 3.15 
shows, positioning of lines is highly subjective, and the low signal-to-noise ratio made this 
analysis insufficiently discriminating. 
The expected ΔF508-CFTR correction caused by incubation with 10 µM VX-809 illustrates 
this point. The correction is only ~2-fold (He et al., 2013; Okiyoneda et al., 2013) and was 
not obviously visible in Figure 3.14. It was clearly not possible to quantify membrane density 
using line analysis of these images with enough robustness to reliably detect such small 
increases caused by ΔF508-CFTR correctors.  
3.11 Discussion 
This chapter described the characterisation of the YFP-CFTR fusion protein, and 
optimisation of an assay for the study of CFTR function. We carried out experiments to 
determine influence of expression cell line, to compare different imaging techniques, and to 
confirm relatively unchanged gating kinetics and ion channel function for the fusion protein. 
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Figure 3.15 YFP-CFTR confocal images and corresponding line analyses. A) YFP-WT-
CFTR and B) YFP-ΔF508-CFTR. Traces show fluorescence intensity along the line for 
Hoechst nuclear staining (blue) and YFP-CFTR (yellow). Scale bar = 10 µm. 
A 
ΔF508  
B ΔF508 
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3.11.1 Optimising the imaging technique 
Initial fluorescence quenching traces obtained using FLIPR show a noisy signal with a high 
intensity fluorescence background and large addition artefacts (Figure 3.4).  Clear 
improvement was obtained by changing the acquisition system from a fluorescence plate 
reader to an automated wide-field fluorescence microscope (Figure 3.5). Improvement was 
in part due to the analysis technique, in which image regions (containing cells) are selected 
and followed over time, with a concurrent background measurement, which is subtracted. 
This allows monitoring and removal of a well-specific background signal, which is not 
available when using a plate reader such as FLIPR. Image analysis thus allowed us to focus 
on image regions corresponding to cells expressing YFP, resulting in sensitive monitoring of 
small, localised fluorescence changes. 
Another advantage of the fluorescence microscope is the ability to obtain information on the 
health of cells. Occasionally, during fluid addition, cells detach from the plate. This can be a 
sign of ill health, or poor PDL-coating of the plate. Detachment of cells is easily seen in the 
images when using ImageXpress, and wells with a high percentage of detached cells, or 
image regions containing several detached cells, can be discarded. This would not be seen 
using FLIPR, so recordings could be unknowingly taken from unhealthy or badly adhered 
cells. 
In ImageXpress readings, due to smaller addition artefacts, the low rate of basal quenching 
seen upon addition of 100 mM Iˉ became measurable (Figure 3.5). This forskolin-
independent anion permeability readout can provide additional information on the cells’ 
anion permeabilities. This was particularly valuable in later experiments, where a change in 
the basal permeability of the cells highlighted an interesting aspect of the mechanism of 
potentiator VX-770 (Chapter 6). Large addition artefacts obscured this quenching in FLIPR 
(Figure 3.4). Basal quenching was also not visible when using separately expressed YFP 
and CFTR in FLIPR (Figure 3.3A). 
ImageXpress acquisition provides higher information content than FLIPR acquisition. 
However, this comes at the cost of a considerably longer length of time taken to read each 
plate. ImageXpress acquires images from individual wells, one well is read before moving to 
the next. Each well is monitored for 150 s, which, once fluid addition time is added, means 
~3 min of imaging per well (compared to FLIPR, in which fluorescence measurements are 
done simultaneously in all wells such that the whole protocol is run on a full plate in around 5 
min). ImageXpress is entirely automated, so the time taken for imaging a plate is not labour 
intensive. 
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The absolute value of the fluorescence signal obtained with the YFP-CFTR probe is much 
smaller than that obtained with co-expression of cytosolic YFP and CFTR. Indeed YFP-
CFTR could not have been used for screening ΔF508-CFTR potentiators had the only 
available fluorescence acquisition system been FLIPR. The quenching signal of YFP-ΔF508-
CFTR is even lower than that that of YFP-WT-CFTR (Figure 3.4), and small potentiation by 
compounds in the screen would not have been detected. Pairing YFP-CFTR and 
ImageXpress fluorescence acquisition, however, we have developed a tool that can be 
valuable to tackle projects in which a relatively small number of conditions needs to be 
tested but high sensitivity is required, such that small differences in the CFTR-dependent 
response can be detected. 
3.11.2 YFP-CFTR normalises for different CFTR expression levels 
We believe YFP-CFTR has further advantages over cytosolic YFP. In the fusion protein, the 
YFP signal is proportional to the amount of CFTR expressed in the cell. Therefore, in 
normalising to the initial YFP signal, before exposure to Iˉ, variability in CFTR expression 
between plates or wells is accounted for. The probe is therefore very flexible, easily adjusted 
for use in a number of different cells and screening conditions. This is not possible using 
cytosolic YFP, as fluorescence is unrelated to CFTR expression. CFTR expression levels 
would have to be tightly controlled, i.e. carefully selected cell lines need to be engineered, 
when using cytosolic YFP.  
In this assay, the rate of Iˉ entry into the cell is a function of Po, the proportion of membrane-
localised CFTR, and the driving force for Iˉ entry. This assay uses acute addition of 
compounds to measure the immediate effect on CFTR function. Acute treatment, which 
remains on the cells for only a few minutes, will is not likely to have an effect on the 
proportion of CFTR at the membrane. However, it is possible that changes affecting the 
membrane potential would cause a change in the electrochemical potential gradient for Iˉ 
entry and therefore appear to affect quenching rate (e.g. Figure 3.11). Therefore, changes in 
quenching rate can be interpreted mainly by changes in Po, with possible impact from 
changes in driving force. 
3.11.3 YFP-CFTR has function comparable to untagged CFTR 
Published studies suggested that a GFP tag on the N-terminal of CFTR was not detrimental 
to either trafficking or function of the channel (Moyer et al., 1998; Vais et al., 2004; Ban et 
al., 2007).   
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Four critical acidic residues have been identified in the N-tail of CFTR. Mutation of each of 
these residues individually reduced CFTR currents, and combining the mutations further 
hindered CFTR gating (Naren et al., 1999). All four residues are expected to lie on the same 
surface of an α-helix, and play a positive regulatory role in CFTR gating, possibly by 
interacting with the R-domain. Mutating three or four of these residues decreased the Po to 
approximately 0.15 (from 0.5 for WT-CFTR), by reducing the burst duration (Naren et al., 
1999; Fu et al., 2001).  
To confirm that the N-terminal YFP tag did not have a similar effect, single channel patch-
clamp analysis was used to compare gating kinetics of YFP-tagged and untagged WT-
CFTR. Po is reduced by the tag to 64% that of WT-CFTR (Figure 3.9). The effect is not as 
large as that which is caused by the N-tail mutations, and the main cause is an increase in 
interburst duration (Figure 3.10). This suggests that whilst gating is slightly altered by the N-
terminal tag, some, if not all, of the four critical residues are accessible. Similarly small basal 
phosphorylation (Figures 3.11 vs. 3.3), as well as similar forskolin concentration-dependence 
(Figures 3.7D and 3.8), suggests that control of gating of YFP-WT-CFTR is sufficiently 
similar to that of WT-CFTR to allow study of CFTR function using this fusion protein. 
Accurate quantification of YFP-WT-CFTR localisation could not be achieved using the YFP 
signal. Work done by others suggested that trafficking of GFP-CFTR was normal (Moyer et 
al., 1998; Ban et al., 2007). Confocal images show mainly membrane expression of YFP-
WT-CFTR and internal, ER-like retention of YFP-ΔF508-CFTR (Figures 3.14 and 3.15). 
YFP-CFTR fluorescence quenching experiments, (e.g. robust quenching in YFP-WT-CFTR-
expressing cells; quenching dependence on incubation temperature for YFP-ΔF508-CFTR 
expressing cells etc.) also qualitatively confirm that the YFP tag has no dramatic effect on 
trafficking. 
3.11.4 pH sensitivity of YFP-CFTR 
As well as depending on halide concentration, YFP fluorescence is also sensitive to changes 
in pH, due to the interaction between protonation and anion binding. Using published 
information, and that shown in this chapter, the impact of pH sensitivity on YFP quenching in 
this assay has been estimated. 
Figure 3.6C shows a K0.5 of 39.3 mM, suggesting that when [Iˉ]e is 39.3 mM, [Iˉ]i is 1.9 mM 
(published KI; Galietta et al., 2001b). This allows us to estimate VM at equilibrium, using the 
Nernst equation: 
   
  
  
  
     
     
    [Equation 3.4] 
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Where R is the gas constant (8.214 J molˉ1 K-1), T is the temperature (310.15 K), F is 
Faraday’s constant (96485 C mol-1), and z is -1, the valency of Iˉ. At 37°C, when [Iˉ]e = 39.3 
mM and [Iˉ]i = 1.9 mM, VM = -81 mV. 
The good fit in Figure 3.6C to a simple hyperbolic binding equation suggests that the change 
in VM is not dramatic as [Iˉ]e is changed. This allows us to estimate [Iˉ]i in the presence of 100 
mM [Iˉ]e, by rearranging the Nernst equation: 
        
    
    
     [Equation 3.5] 
Using Equation 3.5, in the presence of 100 mM [Iˉ]e, at equilibrium, we expect the [Iˉ]i in our 
assay to be ~5 mM. Using Equation 3.6 we estimate occupancy of the anion binding site in 5 
mM Iˉ to be 71%. 
                    
     
        
  [Equation 3.6] 
In the presence of 150 mM Clˉ, YFP has a pKa of 7.89 and receptor occupancy of 64% 
(Galietta et al., 2001b). Therefore, anion site occupancy is similar in 5 mM Iˉ and in 150 mM 
Clˉ, and we can assume a similar pKa. Galietta et al. (2001a) measured the intracellular pH 
change that occurred upon full activation of CFTR as a decrease from 7.35 to 7.2. Using the 
Hill equation, we can estimate the fluorescence at pH 7.35 and pH 7.2 (Equation 3.7). 
   
 
   
   
  
 
      [Equation 3.7] 
Where F = fluorescence, pKa = 7.89 and nH = 1. At pH 7.35, F = 0.482 and at pH 7.2, F = 
0.477. Therefore, pH change accounts for only ~0.5% of the quenching seen upon maximal 
CFTR activation. A dramatic change in pH, such as a decrease to pH 6, still only induces 
~5% quenching. Quenching seen upon activation of CFTR in this assay is, therefore, not 
strongly affected by changes in intracellular pH. 
3.11.5 YFP-CFTR cannot be used for membrane density assay 
Often in screening for ΔF508-CFTR corrector compounds, function of CFTR is used as an 
indicator of correction (for example see Pedemonte et al. 2005). Chronic treatment with 
potential corrector compounds is followed by a functional measure, an increase in which is 
assumed to indicate an increase in membrane density.  
Due to the severe gating defect caused by ΔF508, this method also requires acute addition 
of a potentiator in order to see measurable channel activity. This further complicates the 
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assay and introduces possible drug:drug interactions, among other problems. For example, 
true correctors which stabilise a conformation to promote trafficking, but which cannot be 
potentiated by the compound in use, would not be detected. 
A screen for CFTR correctors that does not rely on ion channel function quantification would 
be highly valuable in the field of CF pharmacology. To this end, we attempted to quantify 
membrane density using the YFP-CFTR signal. Section 3.10 demonstrates the problems 
encountered in using YFP-CFTR to measure membrane density. Although qualitative 
differences between WT-CFTR and ΔF508-CFTR distribution can be seen in the images, 
automating line analysis for the reliable, high-throughput quantitative analysis required for 
this screen proved problematic. 
The cells represent a highly heterogenous population, and localisation of the signal is not 
only at the plasma membrane but also, to some extent, in biosynthetic vesicles in variable 
locations within the cells. Carrying out line analysis of enough cells to achieve a robust 
measure of membrane expression, avoiding any user-bias when selecting cells, would be 
extremely time consuming and thus could not achieve any degree of “high-throughput”. 
Additionally, due to the low signal associated with YFP-ΔF508-CFTR, caused by increased 
rate of degradation of the channel, the signal-to-noise ratio is so poor as to make much of 
the analysis unusable (Figure 3.15B).  
A different type of image analysis was also attempted, by a collaborator at UCL (Janos 
Kriston-Vizi, MRC Laboratory for Molecular Cell Biology). He used a fluorescence threshold 
to select YFP-CFTR expressing cells, and then segmented each cell into an outer ring 
(representing membrane localisation) and an inner ring (representing fluorescence in the 
cytosol, just inside the membrane). The ratio of mean outer ring fluorescence/mean inner 
ring fluorescence was used to quantify membrane localisation. However, the low signal-to-
noise ratio and lack of any fluorescence at the membrane with which to identify the correct 
location for the ‘outer ring’, made this analysis ineffective. For example, controls used for a 
pilot screen gave an average ratio of 0.86 for YFP-WT-CFTR, and a greater ratio of 1.1 for 
YFP-ΔF508-CFTR. 
This hurdle in measuring membrane density led us to design the CFTR-pHTomato assay, 
discussed in the next chapter. 
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Chapter 4 
CFTR-pHTomato: A novel CFTR localisation assay 
 
4.1 Introduction 
In recent years, a number of CFTR localisation assays have been developed, utilising 
fluorescence to improve the ease with which CFTR trafficking can be quantified (see 
Introduction). These assays have been used to identify ΔF508-CFTR correctors from 
compound libraries (Phuan et al., 2014; Robert et al., 2008). Fluorescence assays are an 
improvement on the slow, laborious immunoblot technique. However, these assays do suffer 
from a number of drawbacks. Some are only capable of measuring membrane-localised 
CFTR, such as HA-tagged and HRP-tagged CFTR. Others depend on antibody staining, 
which involves multiple washes and incubations. To enable rapid quantification of membrane 
density and total CFTR expression, we developed a fluorescence assay capable of reporting 
on both in live cells. 
4.1.1 pHTomato 
Our CFTR localisation assay utilises fluorescence of pHTomato; a pH sensitive, red 
derivative of GFP. The excitation/emission spectrum of pHTomato is strongly pH-dependent 
with a pKa of ~7.8 (Figure 4.1).  
 
 
 
Figure 4.1 pHTomato pH-sensing properties (Modified from Li & Tsien, 2012).  A) Upon 
protonation (in acidic pH), the intensity of the excitation/emission spectrum decreases. 
Maximal fluorescence occurs at ~pH 10. Excitation/emission peaks are at 550 nm and 580 
nm, respectively. B) pH dependence of emission intensity. pKa is approximately 7.8. 
 CFTR-pHTomato: A novel CFTR localisation assay 78 
The fluorescence intensity of protonated pHTomato is low. As pH increases, less pHTomato 
exists in the protonated form, and fluorescence increases (Figure 4.1). pH-sensing by 
pHTomato is not dependent on a shift in the excitation/emission spectrum, but rather a 
decrease in fluorescence intensity, accompanying protonation (Li and Tsien, 2012). 
4.1.2 The fourth extracellular loop 
The CFTR-pHTomato assay required CFTR to be inserted into an extracellular domain, for 
which we chose a site following position 901 in ECL4. This is known to be a permissive site 
for tag insertion to CFTR.  
ECL4 is the largest extracellularly exposed loop in CFTR. Position 901 was originally chosen 
by other groups as a potentially permissive site because dogfish and Xenopus CFTR contain 
additional amino acids at this point. An M2 tag (eight amino acids) or 3HA tag (27 amino 
acids), introduced after position 901, allowed expression of functional CFTR, which could be 
labelled at the membrane using an antibody stain (Howard et al., 1995; Sharma et al., 2001).  
Although not critical for the CFTR-pHTomato assay, it has been shown that CFTR tagged at 
this position is regulated by phosphorylation, undergoes ATP-induced gating, and has similar 
conductance to WT-CFTR (Schultz et al., 1997). Due to the close proximity to the 
glycosylated residue 900, tags on ECL4 interfered with glycosylation. However, the amount 
of immature and mature tagged-CFTR was similar to untagged, suggesting this interruption 
made little difference to CFTR expression patterns (Howard et al., 1995; Hildebrandt et al., 
2015). Finally, insertion of a large tag, HRP (308 amino acids), at this position in ΔF508-
CFTR did not alter drug response or revertant sensitivity of cellular localisation patterns 
(Phuan et al., 2014; Veit et al., 2014). 
Therefore, CFTR with a tag at position 901 is expressed at the membrane, and is functional. 
This has also been confirmed in HEK293 cells (Hildebrandt et al., 2015). Results discussed 
in this chapter suggest that WT-CFTR-pHTomato is expressed at the membrane, ΔF508-
CFTR-pHTomato is retained inside the cell, and the latter can be corrected using known 
corrector compounds, suggesting that a pHTomato insertion (273 amino acids), like the HRP 
tag, does not alter CFTR biogenesis. 
Successful ΔF508-CF treatment will require identification of corrector compounds, capable 
of increasing ΔF508-CFTR membrane density. Drug discovery projects will likely now also 
be required to test the effect of chronic potentiator treatment on membrane density of 
ΔF508-CFTR (Cholon et al., 2014; Veit et al., 2014). This chapter describes the optimisation 
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and validation of the CFTR-pHTomato assay, capable of achieving these drug discovery 
aims. 
4.2 The CFTR-pHTomato assay 
pHTomato was inserted into ECL4 of CFTR by subcloning (molecular biology carried out 
with the help of undergraduate students Stefan Constantinou and Mahesh Pillai, supported 
by UCL Dean’s Summer Student Scholarship and CF Trust Studentship, respectively, see 
Methods). The fusion protein was expressed in HEK293 cells for fluorescence imaging 
(assay described in Figure 4.2).  
The fluorescence imaging begins in pH 7.4 buffer (i). Fluorescence from internal CFTR-
pHTomato is very low, as the pH of internal vesicles is low (varies from neutral to pH 5; Wu 
et al., 2001). The fluorescence of membrane-localised CFTR-pHTomato, exposed to pH 7.4, 
is ~40%.  
The extracellular buffer is then changed to pH 6. Only CFTR-pHTomato located at the 
plasma membrane is exposed to the acidic environment (ii). Therefore, the fluorescence of 
any pHTomato exposed to the extracellular buffer (i.e. membrane-localised CFTR) will 
decrease, but the fluorescence of internal CFTR-pHTomato will be unchanged.  
The second fluid addition raises extracellular pH to pH 9, which increases the fluorescence 
of any membrane exposed pHTomato, whilst internal pHTomato fluorescence is, again, 
unchanged (iii).  
The final step introduces 40 mM NH4Cl (iv). NH3 permeates membranes and alkalises 
internal vesicles, increasing fluorescence of internal CFTR (Li and Tsien, 2012; Xu et al., 
2014). The extracellular pH is maintained at pH 9, so the fluorescence of membrane-
exposed pHTomato will not change. 
The change in fluorescence seen upon extracellular pH change from pH 6 - pH 9 represents 
membrane-localised CFTR (ΔF membrane). The fluorescence change induced by 40 mM 
NH4Cl reflects internal CFTR (ΔF internal).  
Example fluorescence traces of WT-CFTR-pHTomato and ΔF508-CFTR-pHTomato are 
shown in Figure 4.3A. ΔF values were used to quantify the membrane density and internal 
expression of WT-CFTR and ΔF508-CFTR (Figure 4.3B). 
Note that in order to compare raw CFTR quantification values (ΔF membrane and ΔF 
internal), data must come from within one plate. Exposure time and laser intensity are 
optimised for reading of each plate, so raw fluorescence values between plates cannot be 
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compared. Most comparisons in this chapter show raw fluorescence ΔF values of two 
conditions within one plate, compared using paired t-tests. Each plot in these figures is the 
mean ± SEM of within-plate replicates (n = 3 or 4). In some cases, to allow pooling of data 
obtained from different plates, membrane density and internal CFTR values are expressed 
as -fold changes compared to within-plate negative controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 The CFTR-pHTomato assay. Left: Imaging begins in standard buffer, pH 7.4 (i). 
Extracellular buffer is changed to pH 6, which reduces fluorescence of membrane-exposed 
pHTomato (ii). Extracellular buffer is then changed to pH 9, which increases fluorescence of 
membrane-exposed pHTomato (iii). Addition of 40 mM NH4Cl (at pH 9) increases 
fluorescence of internal CFTR (iv). Right: Images of HEK293 cells expressing WT-CFTR-
pHTomato, obtained at the four stages described on the left. Blue fluorescence = Hoechst 
nuclear stain, red fluorescence = WT-CFTR-pHTomato.  
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4.3 pIRES2-eGFP-CFTR-pHTomato 
During the design of this assay, we aimed to avoid quantifying membrane CFTR as a 
percent of total CFTR, or as a ratio with internal CFTR. These are often used as measures 
of CFTR membrane expression (for examples see Van Goor et al., 2011 and Cholon et al., 
2014). However, these ratios are not the most informative quantification. Should a ΔF508-
Figure 4.3 WT-CFTR-pHTomato and ΔF508-CFTR-pHTomato cellular localisation 
quantification. A) Fluorescence traces of WT-CFTR-pHTomato and ΔF508-CFTR-
pHTomato. Fluorescence change when extracellular pH is increased from pH 6 to pH 9 
represents membrane CFTR (ΔF membrane). Fluorescence change upon addition of 40 mM 
NH4Cl represents internal CFTR (ΔF internal). n = 3. Four images were taken in each 
condition. Following optimisation, this was reduced to two images per condition. (i) to (iv) 
indicate the stages in Figure 4.2. B) Membrane and internal CFTR quantified using ΔF 
membrane and ΔF internal. No significant difference in internal CFTR (p = 0.66). WT-CFTR n 
= 6, ΔF508-CFTR n = 5. * p = 0.004, from Mann-Whitney U test. 
 
A 
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CFTR corrector compound increase total CFTR at the same rate as membrane CFTR, the 
ratio of the two would remain unchanged.  
Independent quantification of membrane and internal CFTR could be achieved using raw ΔF 
values. However, raw fluorescence values depend on the amount of protein present in the 
cells, which in turn depends on the transfection efficiency. A low CFTR-pHTomato signal 
could be caused by increased CFTR degradation, but it could also be caused by low 
transfection efficiency. Therefore, we required expression of an independent protein, the 
amount of which could be used to normalise CFTR expression. For this, we used the eGFP 
signal, resulting from translation of eGFP in the pIRES2-eGFP-CFTR-pHTomato plasmid.  
The CFTR-pHTomato coding sequence was subcloned into an internal ribosome entry site 
(IRES) plasmid (pIRES2-eGFP). pIRES2-eGFP contains an IRES between the eGFP coding 
sequence, and the coding sequence for the protein of interest (CFTR-pHTomato). One 
strand of mRNA is transcribed from the plasmid, but two separate proteins are translated, as 
the ribosome initiates translation at the start of the bicistronic mRNA, as well as at the IRES. 
Therefore, CFTR-pHTomato expression is directly proportional to eGFP expression (ρ = 
0.71, in our system, Figure 4.4A). This can also be seen in the fluorescence values of 
individual cells (Figure 4.4B). Although the mean eGFP and pHTomato fluorescence 
changes, the ratio of the two remains unchanged. Critically, the excitation and emission 
peaks of pHTomato (550 nm and 580 nm) are distinct from those of eGFP (488 nm and 509 
nm), so the two proteins can be imaged simultaneously (Li and Tsien, 2012). Normalising 
the CFTR-pHTomato signal to the eGFP signal normalised for differences in total protein. 
Any decrease or increase in the ratio between CFTR-pHTomato and eGFP signals was, 
therefore, due to changes in biosynthetic and/or degradation rates of the CFTR-pHTomato 
protein. 
An eGFP image was taken at time point 1, and pHTomato images were taken at each 
successive time point. A Hoechst nuclear stain was used to enable cell counting. Analysis 
involved selecting regions of the image containing transfected cells, by applying a 
fluorescence threshold on the eGFP image. Mean fluorescence of each region was 
measured in the GFP channel (FGFP) and pHTomato channel (FPHTOMATO). FPHTOMATO was 
normalised to the FGFP signal, and each region was weighted for cell count. The sum of all 
regions was then divided by the sum of the cell count (Equation 4.1, excluding any regions 
that reached fluorescence saturation). 
   
  
         
    
             
             
       [Equation 4.1] 
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This resulted in a weighted average fluorescence ratio, which was used to quantify ΔF 
membrane and ΔF internal (see Methods). 
 
 
 
 
 
4.4 Validation of CFTR-pHTomato 
4.4.1 Correction of ΔF508-CFTR-pHTomato by VX-809 
One of the potential applications of this assay is to screen corrector compounds to identify 
those which increase membrane density of ΔF508-CFTR. Known corrector, VX-809, was 
used to confirm that ΔF508-CFTR-pHTomato was capable of measuring such correction. 
VX-809 is the corrector component of Orkambi, the corrector/potentiator combination 
Figure 4.4 Correlation of eGFP and WT-CFTR-pHTomato, coded in a pIRES2-eGFP 
plasmid. A) Cell regions were identified using a fluorescence threshold on the eGFP image. 
The same regions were used to measure FGFP and FPHTOMATO. Due to high cell density, only a 
small proportion of regions showing fluorescence above threshold included only a single 
nucleus. Therefore, each point represents a region including more than one cell (n = 4 
images). Pearson product-moment correlation coefficient (ρ) = 0.71 (p = 1.2-21). B) HEK293 
cells expressing WT-CFTR-pHTomato in pIRES2-eGFP, and corresponding mean 
fluorescence values.  
 
A 
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recently approved for the treatment of ΔF508-CF. This corrector stabilises the NBD1:ICL4 
interaction to promote native folding and thus improve trafficking of ΔF508-CFTR to the 
membrane (Van Goor et al., 2011; Farinha et al., 2013a; Okiyoneda et al., 2013).  
 
 
 
 
 
At physiological temperature, 24 h incubation with 10 µM VX-809 improved internal ΔF508-
CFTR ~1.5-fold, compared to vehicle treated controls. A similar, but not significant, effect 
was seen on membrane-localised ΔF508-CFTR (Figure 4.5A). At 30°C, treatment with the 
Figure 4.5 Correction of ΔF508-CFTR-pHTomato by VX-809. A) 24 h incubation with 10 
µM VX-809 at physiological temperature (membrane ΔF508-CFTR p = 0.17, internal ΔF508-
CFTR p = 0.018). B) As A, but alongside low temperature incubation (p = 0.003 and 0.019 
for membrane and internal CFTR, respectively).  
A 
B 
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corrector compound induced a ~4-fold increase in membrane density, and a ~1.5-fold 
increase in internal ΔF508-CFTR (Figure 4.5B). This is similar to the level of correction 
observed in other experimental systems (He et al., 2013; Phuan et al., 2014). Temperature 
correction is known to increase the efficacy of VX-809, as thermal stability is conveyed to 
NBD1 (Farinha et al., 2013a; He et al., 2013; Okiyoneda et al., 2013).  
These results confirm that ΔF508-CFTR-pHTomato can be used to detect correction by VX-
809. However, the low levels of ΔF508-CFTR-pHTomato present at 37°C (especially 
membrane levels) make it difficult to obtain meaningful quantification. Therefore, all 
remaining ΔF508-CFTR work was carried out at 30°C, to enhance the ΔF508-CFTR-
pHTomato signal. 
 
 
 
 
 
Figure 4.6 ΔF508-CFTR-pHTomato concentration-response curves to known 
correctors. A) 24 h incubation with VX-809 at 30°C increased both membrane and internal 
ΔF508-CFTR in a concentration-dependent manner (3 ≤ n ≤ 6). B) 24 h incubation with Corr-
4a increased membrane CFTR but changes in internal CFTR were not dose-dependent (1 ≤ 
n ≤ 3). Values expressed as fold increase compared to vehicle controls. EC50 values, where 
obtained, are stated on the graphs. 
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4.4.2 Concentration-response curves using known correctors 
By way of further validation, concentration-response curves were constructed to two known 
correctors: VX-809 and Corr-4a.  
Both correctors increased membrane CFTR in a concentration-dependent manner (Figure 
4.6). The EC50 values for both compounds were similar to those that have been published 
previously (259 nM ± 97 nM and 2.9 µM ± 1.3 µM for VX-809 and Corr-4a, respectively) 
(Pedemonte et al., 2005a; Van Goor et al., 2011).  Correction by VX-809 was ~2-fold greater 
than that which was achieved by Corr-4a, which also confirms published results (Farinha et 
al., 2013a; He et al., 2013; Okiyoneda et al., 2013). 
The similarity of these concentration-response curves to published data further confirmed 
that ΔF508-CFTR-pHTomato was capable of measuring correction by known corrector 
compounds, and that the pHTomato tag did not alter cellular trafficking in the presence of 
correctors to a great extent. Corr-4a did not induce a dose-dependent correction of internal 
CFTR, unlike VX-809 (Figure 4.6B).  
4.5 ΔF508-CFTR destabilisation by chronic VX-770 treatment 
Recently published studies have shown that chronic potentiator treatment reduces 
biosynthesis and decreases membrane stability of rescued ΔF508-CFTR (Cholon et al., 
2014; Veit et al., 2014). Irrespective of the mechanism of rescue, chronic treatment with the 
majority of potentiators caused a concentration-dependent decrease in membrane-localised 
and internal ΔF508-CFTR. This recently discovered phenomenon is the most likely cause of 
relatively disappointing clinical effects of combination treatments (Wainwright et al., 2015).  
CFTR-pHTomato was used to measure membrane density of ΔF508-CFTR following chronic 
treatment with VX-770. As shown in Figure 4.5, correction induced by VX-809 at 37°C is low. 
Therefore, the signal change caused by VX-770-induced destabilisation would be small, and 
difficult to detect. For this reason, chronic potentiator treatment was carried out at 30°C, and 
in the presence of 10 µM VX-809. Membrane ΔF508-CFTR decreased by approximately 
20% following 24 h incubation with 10 µM VX-770 (Figure 4.7). This decrease is slightly 
smaller than that seen by others (~40%; Veit et al., 2014; Bali et al., 2016, or greater; Cholon 
et al., 2014), which could be caused by over-expression in the HEK293 cell system, or 
inclusion of low temperature incubation. There was no significant change in internal ΔF508-
CFTR.  
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4.6 Destabilisation of WT-CFTR by chronic VX-770 treatment 
There is some evidence that smoke exposure decreases WT-CFTR mediated anion 
transport in epithelial cells, leading to symptoms of COPD (Sloane et al., 2012). Therefore, 
CFTR potentiator treatment has been suggested as a treatment for COPD (Cantin et al., 
2006; Sloane et al., 2012). 
Work published to date is inconsistent on whether chronic VX-770 destabilises WT-CFTR. 
Veit et al. (2014) see no effect on WT-CFTR, whilst Cholon et al. (2014) see ~50% reduction 
in mature WT-CFTR expression and function. If VX-770 does destabilise WT-CFTR, this 
would reduce the suitability for treatment of COPD patients.  
In our assay, WT-CFTR expression is not decreased by 24 h incubation with 1 µM VX-770 
(Figure 4.8). This supports data published by Veit et al. (2014), and studies carried out by 
Sloane et al. (2012), which demonstrate effective potentiation of the anion current in non-CF 
epithelial cells, treated with chronic VX-770. 
4.7 Discussion 
This chapter detailed the generation and validation of a novel optical assay, capable of 
reporting on membrane and internal CFTR in live cells. A rapid and cost-effective measure 
of CFTR localisation could be instrumental for efficient identification of ΔF508-CFTR 
corrector compounds. Additionally, it is now apparent that testing for negative biosynthetic 
Figure 4.7 VX-770 chronic treatment on ΔF508-CFTR.  Membrane and internal ΔF508-
CFTR following low temperature and VX-809 rescue, ± 10 µM VX-770 (p = 0.02 and p = 
0.56, respectively).  
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effects of chronic potentiator treatment will be important for avoiding clinical trials with high 
risk of failure.  
Recently published fluorescence assays have overcome the immediate need for techniques 
to quantify ΔF508-CFTR localisation without relying on channel function (Carlile et al., 2007; 
Phuan et al., 2014; Larsen et al., 2015). This chapter details efforts towards optimising a 
particularly simple and inexpensive localisation assay, to be used for medium/high 
throughput screens. As will become evident in Chapter 5, we were only partially successful 
in this aim.  
 
  
 
 
4.7.1 Normalising for differences in transfection efficiency 
One of the strengths of the CFTR-pHTomato assay is that it does not require membrane 
CFTR to be expressed as a percent of total CFTR, which inevitably results in a loss of 
information regarding overall expression levels. To avoid normalising the membrane density 
signal to total CFTR, raw fluorescence values were used. Transient transfection of cells has 
variable efficiency, with protein expression of individual cells dependent on the number of 
plasmids taken up during transfection. Should a cell take up many plasmids, the raw 
fluorescence change representing membrane CFTR would be larger than the corresponding 
change in a cell that took up very few plasmids.  
To normalise for this, we expressed CFTR-pHTomato in a pIRES2-eGFP plasmid. The 
fluorescence intensity obtained on the GFP channel quantifies the amount of total protein 
transcribed from the plasmids present in each cell. It is this reading that is used to normalise 
Figure 4.8 VX-770 chronic treatment on WT-CFTR. Membrane and internal WT-CFTR 
following chronic treatment with 1 µM VX-770 (p = 0.14 and p = 0.35, respectively).  
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the pHTomato fluorescence, so CFTR levels are given as pHTomato/GFP fluorescence 
ratios. Figure 4.4 shows correlation of the eGFP and pHTomato signal, which confirms that 
eGFP can be used to normalise for transfection efficiency. As far as we are aware, no other 
CFTR localisation assay controls for transfection efficiency.  
 
 
 
 
Using the eGFP signal to normalise for transfection efficiency of individual regions also 
dramatically reduced the standard error (average error 9% vs. 27%, Figure 4.9). This shows 
that variability in transfection efficiency was one large source of error in this assay, which we 
were able to reduce. 
4.7.2 Independent quantification of membrane and internal CFTR 
Maturation is often expressed using mature CFTR (band C) as a percent of total CFTR, or 
the ratio of mature CFTR to immature. Both of these are a complex function of many rates, 
such as the rate of synthesis at the ER, of ER-associated CFTR degradation, of mature 
CFTR degradation, of ER to Golgi and Golgi to membrane trafficking etc. These ratios are, 
therefore, not always an effective quantification of CFTR maturation.  
Figure 4.10 illustrates that these ratios do not always accurately represent correction of 
CFTR. Using membrane and total ΔF508-CFTR following treatment with VX-809 or Corr-4a, 
the trafficking efficiency (membrane CFTR as a percent of total) was calculated. According 
to the trafficking efficiency, Corr-4a is as efficacious as VX-809 (Figure 4.10, 10 µM VX-809 
vs. 10 µM Corr-4a). However, Figure 4.6 shows that less ΔF508-CFTR reaches the 
membrane following correction with Corr-4a, than following correction with VX-809. Figures 
Figure 4.9 Reduced variability following normalisation to eGFP signal. ΔF508-CFTR 
correction by VX-809 and low temperature incubation. Data points collected from one 
experiment, and displayed using two analysis techniques. Left: pHTomato signal of each 
region in the image was normalised to the eGFP signal, to account for differences in 
transfection efficiency. Right: eGFP signal was not used. 
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4.6 and 4.10 demonstrate that the absolute level of membrane CFTR is not necessarily 
proportional to trafficking efficiency, and highlights the importance of independent 
quantification of membrane-localised CFTR. 
 
 
 
 
Whilst it is possible to measure changes to internal CFTR (Figures 4.5 and 4.6), high error 
makes the sensitivity of this assay insufficient to measure small changes in internal CFTR 
expression.  
It is likely that this method of internal CFTR quantification does not only measure CFTR 
retained at the ER. NH3 permeates all internal vesicles, such that CFTR in the recycling 
pathway, undergoing degradation, and held at the ER will be included. The only requirement 
being that the pHTomato tag is intact and inside a vesicle. Thus, an increase in ΔF internal 
does not necessarily indicate an increase in immature, ER-associated CFTR. 
4.7.3 Compound mechanism of action studies 
4.7.3.1 Corrector compounds 
The mechanisms by which corrector compounds work to increase membrane density of 
ΔF508-CFTR are beginning to be understood. It is thought that VX-809 stabilises the 
NBD1:ICL1 or NBD1:ICL4 interface, whilst Corr-4a stabilises NBD2 or NBD2 interfaces 
(Okiyoneda et al., 2013). 
Figure 4.10 ΔF508-CFTR trafficking efficiency in the presence of known correctors. 
ΔF508-CFTR expressing cells incubated at 30°C + 10 µM of the indicated corrector (or 
vehicle control). * = p < 0.05, from Kruskal-Wallis one way ANOVA on ranks and post-hoc 
Dunn’s test. Vehicle control n = 19, VX-809 n = 12, Corr-4a n = 3. 
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A recent publication suggests that Corr-4a and VX-809 act at different stages of maturation 
to increase ΔF508-CFTR membrane density. VX-809 induces an accumulation of immature 
CFTR. The turnover of immature ΔF508-CFTR is decreased, and the processing efficiency 
to mature ΔF508-CFTR is increased, which together results in increased ΔF508-CFTR 
membrane density (Farinha et al., 2015). An increase in immature CFTR can be indicative of 
a compound which acts early in biosynthesis, before the protein achieves membrane-
localisation. Corr-4a appears to stabilise only ΔF508-CFTR which reaches maturity (Farinha 
et al., 2015, but see Bali et al., 2016). 
These different mechanisms are consistent with results in Figure 4.6. Whilst both membrane 
and internal CFTR increase in a dose-dependent manner when treated with VX-809, only 
membrane CFTR is increased by Corr-4a.  
This highlights a potential use of the CFTR-pHTomato assay: to rapidly indicate levels of 
biogenesis intermediates, as well as mature CFTR. This is a first step in understanding the 
potential mechanisms by which corrector compounds promote membrane ΔF508-CFTR. 
However, the relatively high variability, especially of the internal readout, means that only 
very strong effects will be reliably detected. 
4.7.3.2 Quantification of membrane half-life 
Quantification of membrane half-life can give important information on compound 
mechanism. Pulse-chase experiments are usually used to estimate CFTR protein half-life. 
This involves preventing the synthesis of new protein, using cycloheximide, and quantifying 
the remaining CFTR at multiple time points thereafter. Using a similar experimental 
procedure, it should be possible to measure membrane half-life using CFTR-pHTomato. 
Preliminary results are shown in Figure 4.11. Cells were transfected with ΔF508-CFTR, left 
to express the protein for 24 h, then treated with 100 µg/ml of cycloheximide, to prevent 
synthesis of new protein. CFTR-pHTomato assays were taken at multiple time points 
following initiation of cycloheximide treatment. 
Figure 4.11 shows how membrane ΔF508-CFTR varied over time in the presence of 
cycloheximide. The data is noisy and cannot be fit for a time constant. Repeat experiments 
showed no significant decrease in ΔF508-CFTR membrane density, suggesting that 
cycloheximide treatment did not successfully prevent synthesis of new protein. A possible 
cause of this is over-expression of CFTR in the HEK293 cell system. Should ΔF508-CFTR 
be over-expressed, the protein could be overwhelming even this high concentration of 
cycloheximide. In future efforts, less plasmid could be used for transfection, or ΔF508-CFTR 
could be expressed in a different cell system, i.e. one less prone to over-expression. 
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If membrane half-life measurements could be achieved using CFTR-pHTomato, compound 
mechanism studies would be easier and faster to acquire than techniques currently in use. 
4.7.4 Expression in CF bronchial epithelial cells (CFBEs) 
One of the weaknesses of the CFTR-pHTomato assay is the cell line in which the protein is 
expressed. CFTR folding and trafficking are complex processes, dependent on many 
accessory proteins, some of which are likely to be cell-specific. Indeed, corrector 
mechanisms have shown cell specificity. For example, whilst functional in recombinant cells, 
Corr-4a has only modest activity in primary cultures of bronchial cells derived from ΔF508-
CF patients (Farinha et al., 2015). Should this assay be used for screening potential ΔF508-
CFTR correctors, the number of false positives and negatives, and eventually the high 
attrition rate in drug development, will be reduced by a screen that more accurately 
represents the environment in which the drug will be used.  
Some effort was directed at expressing CFTR-pHTomato in a more relevant cell line. 
Collaborators at the Institute of Child Health (Prof. Steve Hart and Dr. Mustafa Munye) have 
developed a semi-immortalised cell line using bronchial epithelial cells from healthy and CF 
donors (purchased from Lonza, Belgium). By knocking out a senescence gene, this group 
have made it possible to passage these cells up to 20 times. In submerged cultures (rather 
than air-liquid interface), these cells do not differentiate into epithelial cells, but are 
representative of an earlier basal airway cell. Using a lipid-peptide transfection technique 
Figure 4.11 ΔF508-CFTR-pHTomato membrane density following treatment with 
cycloheximide. The time axis indicates the length of time in 100 µg/ml cycloheximide 
treatment. ΔF508-CFTR was rescued using 3 µM VX-809 and 30°C incubation. n = 3. 
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optimised by the Hart lab (Munye et al., 2015), we attempted transient transfection of CFBEs 
with CFTR-pHTomato. Unfortunately, transfection efficiency was too low to achieve a 
measurable signal (work carried out with the help of MSci Pharmacology student Pengxiang 
Zhao, supported by a British Pharmacological Society Summer Studentship).  
In the future, it might be desirable to make a stable CFBE cell line expressing ΔF508-CFTR-
pHTomato. However, the level of expression would need to be sufficiently high for reliable 
fluorescence imaging, a result that might not be easy to achieve. 
4.7.5 Assay variability 
The main advantage of the CFTR-pHTomato assay is the ability to measure membrane-
localised CFTR, independent of both total CFTR expression, and function. The data 
presented in this chapter demonstrates this can, to some extent, be achieved. During the 
optimisation of this assay, effort was made to reduce the variability of measurements. As 
mentioned above, normalising the pHTomato signal to the eGFP signal (Figure 4.9) resulted 
in reduced variability. Additionally, acquisition settings were optimised on each plate to 
increase the pHTomato signal, to avoid very low fluorescence signals, too close to the plate 
noise. 
Despite these efforts, as error bars in many figures show, variability remains high, 
particularly for internal CFTR measurements. This variability suggests that an uncontrolled 
factor within the assay is affecting fluorescence change. For example, fluid addition 
artefacts, similar to those discussed in Chapter 3, could impact ΔF readings. Variation in the 
behaviour of individual HEK293 cells, within the culture, could also contribute to 
inconsistency of readings. To improve this, a new clonal cell line could be started for future 
experiments. 
If variability could be reduced, the pHTomato assay could be exploited for other protein 
trafficking diseases, the only requirement being a suitable extracellular domain to which the 
pHTomato can be tagged. One obvious protein, related to CFTR, whose cellular localisation 
is an important determinant of disease severity is ABCA4, an ABC transporter mutated in 
Stargardt disease (Sabirzhanova et al., 2015). 
In this thesis, CFTR-pHTomato is used to support the YFP-CFTR assay in the screening for 
potentiators. It is used as a secondary screen of the hit compounds, by measuring 
membrane density following chronic treatment with potential novel potentiator compounds. 
Recent results (Cholon et al., 2014; Veit et al., 2014) suggest that a sensitive quantification 
of membrane CFTR will be a requirement of any screen targeting CFTR, increasing the 
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chance of early detection of any negative effect a drug candidate might have on biogenesis. 
However, further reductions in variability will be required in order to make the CFTR-
pHTomato really suited for this purpose (see Chapter 5). 
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Chapter 5 
ΔF508-CFTR functional potentiator screen 
 
5.1 Introduction 
This chapter describes two pilot studies, in which compound libraries were screened using 
the YFP-ΔF508-CFTR assay. The first library included 138 compounds. Following the 
successful identification of hit compounds, another library was constructed based on the 
most promising hit compound. A further library included compounds selected directly by 
similarity to VX-770. 
Identification of ΔF508-CFTR potentiator compounds is required for the successful treatment 
of ΔF508-CF patients. The majority of ΔF508-CFTR potentiators identified to date have a 
negative effect on the stability and biosynthesis of ΔF508-CFTR (Cholon et al., 2014; Veit et 
al., 2014). Potentiator/corrector combination treatment of ΔF508-CF resulted in marginal 
improvements in clinical trials (Wainwright et al., 2015), the modest results most likely 
reflecting destabilisation of ΔF508-CFTR by the VX-770 component (Cholon et al., 2014; 
Veit et al., 2014). These studies highlight the requirement for more ΔF508-CFTR 
potentiators, devoid of negative effects on stability and biosynthesis of the rescued protein. 
Effective screening assays, capable of measuring both ΔF508-CFTR function and 
membrane density, are required to meet this need in CFTR pharmacology. 
5.1.1 The ChemiBank Library 
The pilot library of 138 compounds was donated by David Selwood from UCL ChemiBank 
(The Wolfson Institute for Biomedical Research). ChemiBank is a resource of 30,000 diverse 
compounds, available at UCL for identification of small molecule ligands for proteins. The 
pilot library was constructed for a different project (targeting Natriuretic Peptide Receptor C; 
CNP), but compounds bore structural resemblance to VX-770.  
5.1.2 Ligand-based virtual screening 
Novel compound libraries were constructed for this project using ligand-based virtual 
screening (LBVS), in collaboration with researchers at the University of Bern (Professor JL 
Reymond’s group). LBVS is a compound selection method by which ligands from a large 
virtual compound database are identified based on their similarity to a starting ligand.  
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Chemical space is a vast and largely untapped resource, which, thanks to large database 
screening, is becoming accessible to drug discovery researchers. The Reymond lab have 
developed a virtual screening method in which atom pair fingerprints are used to 
characterise the 3D structure of a compound, in a time efficient manner to allow searches 
through millions of compounds to identify structural analogues. They have verified that the 
atom pair fingerprint is capable of matching compounds based on 3D structure (Awale and 
Reymond, 2014). The 3D-fingerprint method distinguishes between different stereoisomers 
of a compound, not possible with 2D-fingerprints (Awale et al., 2015). 
By changing the way compound libraries are selected, they hope to reduce the exceedingly 
high attrition rate suffered by drug discovery efforts.  
For this project, Professor Reymond’s group used the lead hit compound from the pilot 
screen, and VX-770, as query ligands to construct two separate libraries. They searched the 
ZINC database (a virtual screening platform which contains > 10 million commercially 
available compounds; Irwin et al., 2012) to identify compounds similar in 3D structure to 
these starting ligands.  
5.1.3 The YFP-CFTR potentiator screen 
Following temperature rescue, compounds were screened for potentiator activity using the 
YFP-ΔF508-CFTR assay, in the presence of 50 µM forskolin (Figure 5.1). 
Controls were run on every plate to allow within-plate normalisation of the function of test 
compounds. Negative controls contained 50 µM forskolin + DMSO (vehicle), whilst wells 
containing 50 μM forskolin + 10 μM VX-770 were used as positive controls. 
Hit compounds identified in the YFP-CFTR screen were then tested chronically for effects on 
ΔF508-CFTR membrane stability, using the ΔF508-CFTR-pHTomato assay. 
5.2 Screening conditions and positive and negative controls 
The pilot screen consisted of 138 compounds organised over two 96-well plates, with 
column 12 reserved for control wells. Compounds were stored at 10 mM in DMSO, at -20°C.  
Forskolin and the test compounds were both dissolved in DMSO, so cells were exposed to 
0.35% vehicle during the assay. DMSO is a solvent, which can alter responses in cellular 
assays. To measure the effect of the vehicle, quenching caused by 0% and 0.35% DMSO 
was compared (Figure 5.2).  
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The quenching in Figure 5.2A suggests that there is some vehicle effect caused by 0.35% 
DMSO. Upon addition of solution (0% or 0.35% DMSO), there was an initial apparent 
increase in YFP fluorescence (suggesting an efflux of Iˉ), which was larger in the presence 
of DMSO.  This initial change is followed by fluorescence quenching, with DMSO causing a 
decrease in maximal Iˉ entry rate by only ~0.7 µM s-1 (Figure 5.2B). Although this effect 
Figure 5.1 YFP-ΔF508-CFTR potentiator screen protocol. HEK293 cells in 96-well plates 
are transiently transfected with YFP-ΔF508-CFTR. 1) 24 h after transfection, cells are 
transferred to 30°C for 24 h to promote ΔF508-CFTR trafficking to the membrane. 2) During 
the assay, extracellular Iˉ buffer is added to create a large Iˉ gradient. 3) Each test compound 
is added in the presence of 50 µM forskolin. 4) Readout from wells receiving active 
compounds show quenching (left) in response to forskolin addition, whilst inactive 
compounds do not (right). FSK = forskolin.  
30°C 
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seems large in Figure 5.2A, the maximal Iˉ entry rate achieved in the presence of 50 µM 
forskolin + 10 µM VX-770 is ~80 µM s-1. Therefore, the reduction in Iˉ entry rate caused by 
this DMSO effect was < 1% of the maximal quenching rate achieved by potentiators.  
The delayed, relatively low YFP quenching seen in Figure 5.2 confirms that any increase in 
the rate of Iˉ entry during the YFP-ΔF508-CFTR screen is an effect of the test compound, 
and not the vehicle.  
As the potentiator with the highest efficacy, and the only potentiator compound approved for 
treatment, VX-770 was chosen as the positive control. 
 
 
 
 
5.3 Quality control  
An indicator of the quality of a high-throughput screening assay is the ability to distinguish 
between positive and negative controls. Strictly standardised mean difference (SSMD) is a 
quantitative parameter measuring assay quality. Originally developed for use in RNA 
interference (RNAi) screens, SSMD is also suitable for assessing quality of small molecule 
screens (Zhang et al., 2007; Zhang, 2008, 2011). SSMD is defined as a measure of the 
difference between two groups (negative and positive references), penalised by the 
variability of the difference (Equation 5.1).  
     
     
            
        [Equation 5.1] 
Figure 5.2 DMSO tolerability of YFP-ΔF508-CFTR potentiator assay. A) 0% and 0.35% 
DMSO in YFP-ΔF508-CFTR quenching assay. B) Quenching rates quantified using rate of Iˉ 
entry of traces shown in A. No significant difference between treatments (p = 0.68). 
 ΔF508-CFTR functional potentiator screen 99 
Where µP and µN are means of the positive and negative references, and σP and σN are the 
standard deviations of the positive and negative references (Zhang, 2007). 
To reduce the impact of outliers, mean and standard deviation are replaced with median and 
median absolute deviation (MAD), in the calculation of robust SSMD (SSMDR) (Equation 
5.2). 
      
       
             
         [Equation 5.2] 
Where     and     are medians of the positive and negative references, and     and     are 
the MADs of the positive and negative references (Zhang, 2007; Goktug et al., 2013).  
The output of the SSMD calculation is an interpretable number, it is easy to calculate, and is 
not dependent on sample size (Bray and Carpenter, 2013). Zhang et al. (2007) interpret an 
SSMD value > 3 as a 95% chance that a value from the positive control group is greater 
than a value from the negative control group. Using Equation 5.2, SSMDR was calculated for 
each plate used in the pilot screen. The library covered two plates, which were each 
screened three times. Each plate contained three or four negative control wells (50 µM 
forskolin + vehicle) and three or four positive control wells (50 µM forskolin + 10 µM VX-770). 
According to Bray and Carpenter (2013), small molecule screens with only one type of 
positive control should use the criteria in Table 5.1 to interpret SSMD quality control values. 
The SSMDR values in the pilot screen varied from 3.5 to 11.3. Three plates fell into the 
‘good’ category, and three were ‘excellent’. Data from all plates was used, since none fell 
into the ‘poor’ category.  
Quality  
Excellent SSMD ≥ 5 
Good 5 > SSMD ≥ 3 
Inferior 3 > SSMD ≥ 2 
Poor 2 > SSMD 
 
5.4 Hit selection  
High-throughput screening requires prior identification of criteria to be met in order for a 
compound to be considered a hit. SSMD was chosen as the method of hit selection, since it 
Table 5.1 SSMD quality control 
criteria for small molecule screens 
with only 1 type of positive control 
(Modified from Bray & Carpenter, 
2013). 
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is capable of incorporating the variability of test compounds in replicate screens (Zhang et 
al., 2007; Zhang, 2011).  
To calculate SSMD, the measured value of each repeat is compared to the median of a 
negative reference within the plate. The mean and standard deviation of the difference 
between the test and the negative reference is used to calculate one SSMD value, which 
incorporates all replicates (Equation 5.3, SSMDi, where i is n between 1 and 138 in the pilot 
screen).  
When the standard deviation calculation is based on a very small n number (i.e. three 
replicates, as in this screen), variation estimates can become highly variable. Considering 
that most compounds will have the same variation, the standard deviation of all tests can be 
incorporated in order to stabilise the estimate (Zhang, 2011). In Equation 5.3, a combination 
of a common factor (     
 ), and the individual sample variance (     
 ) was used to penalise 
the difference between test and negative control (Zhang, 2011). 
       
   
      
       
 
             [Equation 5.3] 
Where     is the mean of the differences between the test compound and negative reference, 
si is the standard deviation of the same and so
2 is the median of all si
2 (Zhang, 2011).  
A positive SSMDi value indicates that the effect of the test compound is consistently greater 
than the negative control. A negative SSMDi value indicates the effect of the test compound 
is consistently smaller than the negative control. In our screen, we are interested in 
identifying compounds with a positive effect. An SSMDi value > 2 indicates a strong positive 
effect (Zhang, 2011). 
Equation 5.3 was used to calculate an SSMDi value for each compound in the pilot screen. 
Compounds with weak but very consistent effects will also have high SSMDi values. To 
avoid selecting these compounds as hits, data was plotted on a dual-flashlight plot, in which 
SSMDi is plotted against average percentage activation (Figure 5.3). Percentage activation 
is calculated using the within-plate positive controls (i.e. percentage activation compared to 
10 µM VX-770), and averaged over three replicates. This allows compounds with a very high 
SSMDi value, but not a high percentage activation, to be discounted. Selected hits are 
therefore both statistically and biologically favourable (Zhang, 2011).  
The points in Figure 5.3 appear as if they belong to two different populations. The distinct 
groups on the plot do represent the two separate compound plates (i.e. 88 compounds were 
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stored and screened on Plate 1, represented in black, and 50 compounds were stored and 
screened on Plate 2, represented in red). A negative SSMDi value, such as that of most 
compounds on Plate 2, suggests the quenching result is significantly smaller than the 
negative control. There are two explanations for a negative SSMD i value. Either the negative 
control wells do not accurately represent the population, or these compounds are acting as 
inhibitors of ΔF508-CFTR.  
  
 
 
Temperature rescued ΔF508-CFTR is not activated by 50 µM forskolin (Chapter 3, Figure 
3.12). Therefore, it seems unlikely that the compounds on Plate 2 are acting as inhibitors, as 
there is no “control activation” to inhibit. Additionally, the percentage activation of the two 
populations is not different (Figure 5.3: 25.6% (± 5%) and 25.4% (± 4%) median for the two 
populations).  
It seems more likely that the negative control wells in this plate do not accurately represent 
the population. The negative control wells in Plate 1 (population with SSMDi ~ 0.2) have 
18.6% (± 5%) activation compared to within plate positive controls. Plate 2 negative control 
wells have 34.9% (± 3%) activation. This is also reflected in the raw quenching rate data (5.7 
± 0.9 µM s-1 vs. 10.3 ± 0.7 µM s-1 for Plate 1 and Plate 2, respectively). Therefore, it seems 
the negative control wells on Plate 2 are unusually high. This gives a population with 
negative SSMD values, as test compounds have slower quenching rates than the 
abnormally high negative controls, to which they are compared. 
Figure 5.3 Dual-flashlight plot of pilot screen results. SSMDi calculated using Equation 
5.3. Percentage activation calculated using within-plate positive controls (50 µM forskolin + 
10 µM VX-770). The black and red plots represent two separate plates used in the screen 
(Plate 1 and Plate 2, respectively). 
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Differences in controls can occur because control wells are usually located at the edge of the 
plate, which suffers more evaporation during culture, and they are run together, usually at 
the end of the experiment. 
B C 
D 
Figure 5.4 Pilot screen results. A) Dual-flashlight plot. SSMDi calculated using the median 
of test compounds as the negative control. Each cross represents one test compound, 
tested three times. Potentiators with an SSMDi value > 2 and activity > 50% compared to 10 
µM VX-770 were selected as hits, structures shown in B-D. B) MS131A. C) MS134A. D) 
MS131.  
A 
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When only a few hits are expected per plate, the median of the test compounds can be used 
as a negative reference, and often better represents the sample (Goktug et al., 2013). 
Although this plate of compounds had some structural similarity to VX-770, an initial 
assessment of the data showed that not many compounds were active as ΔF508-CFTR 
potentiators (Figure 5.3). Therefore, the median of the test samples was used as the 
negative reference.  
Figure 5.4 shows the dual-flashlight plot constructed when the median of the test 
compounds was used as the negative reference. This plot shows one population of 
compounds, with an average SSMDi of ~0, and ~25% activation compared to within plate 
positive controls. The three compounds with SSMDi > 2 and activation > 50% were chosen 
for further study. One compound (circled in red, Figure 5.4A) showed high activation (mean 
127% of VX-770 control). However, inspection of the images and quenching traces indicated 
this was an artefact, supported by the low SSMDi value. 
Structures of hits from the ChemiBank library are shown in Figures 5.4B to 5.4D. 
Compounds had the expected molecular weights and high purity, confirmed using liquid 
chromatography mass spectrometry (LCMS, carried out by David Selwood, UCL Wolfson 
Institute for Biomedical Research). 
5.5 Confirmation of hit activity 
In order to confirm activity of hit compounds, concentration-response curves were 
constructed using both YFP-ΔF508-CFTR and YFP-G551D-CFTR (Figure 5.5). All solutions 
were prepared freshly from solid stock at 10 mM in DMSO. This was done to confirm that the 
potentiator activity was not caused by a contaminant of the sample. 
MS131A and MS134A activity was confirmed on both mutations (Figures 5.5A and 5.5B). 
MS131 had little efficacy, with what appears to be very low affinity (Figure 5.5C). No further 
work was done with MS131, the least active compound in the screen, as precipitates were 
noted and insolubility became a major obstacle preventing further work. 
Differences in potency and efficacy between ΔF508-CFTR and G551D-CFTR confirm that 
the activation detected in the screen is mediated by potentiation of CFTR, and not an 
alternative anion channel. 
In summary, of the three compounds identified in the pilot screen, two were confirmed as 
ΔF508-CFTR potentiators using fresh compound stocks. This encouraged further 
characterisation of these novel potentiator compounds. 
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Figure 5.5 Activity confirmation of hit compounds on ΔF508-CFTR and G551D-CFTR. 
A) MS131A. B) MS134A. C) MS131. Best fit EC50 values, where obtained, are shown on the 
graphs. 3 ≤ n ≤ 6.  
A 
B 
C 
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5.6 Novel compound effects on ΔF508-CFTR following chronic treatment  
The ΔF508-CFTR-pHTomato assay was used to assess whether the novel potentiators 
identified in the pilot screen had a negative effect on ΔF508-CFTR stability and biosynthesis 
when used chronically.  
Figure 5.6 Cellular levels of ΔF508-CFTR following 24 h incubation with novel 
potentiators. Cells expressing ΔF508-CFTR-pHTomato were treated with 10 µM VX-809 at 
30°C for 24 h, alongside novel potentiators MS131A and MS134A. Pairs (10 µM VX-809 ± 
compound) were compared using Wilcoxon signed rank test, and showed no significant 
differences. 
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ΔF508-CFTR was corrected by 10 µM VX-809, alongside low temperature incubation. 24 h 
incubation with 10 µM MS131A or 10 µM MS134A had no significant effect on membrane 
density of ΔF508-CFTR (Figure 5.6). MS131A was chosen as the lead compound for the 
next step of this drug discovery project, due to a slightly higher efficacy on ΔF508-CFTR, 
compared to MS134A (Figure 5.5A vs. Figure 5.5B). 
To confirm that the lack of destabilisation was not due to a degradation of MS131A occurring 
during chronic incubation, potentiator activity was confirmed following 24 h incubation. 
ΔF508-CFTR has an increased rate of Iˉ entry after activation with forskolin alone, following 
24 h incubation with MS131A, compared to vehicle-treated controls (Figure 5.7). Quenching 
rates are increased vs. Figure 5.5 because a different protocol was in use (Iˉ second addition 
– see Chapter 6). 
 
 
 
 
 
5.7 Ligand-based virtual screening 
Collaborators at the University of Bern selected new compound libraries, using LBVS (based 
on atom pair 3D-fingerprints), to identify compounds close in chemical space to the pilot 
screen hit MS131A, or VX-770 (see section 5.7.2), from the ZINC database of commercially 
available compounds (Irwin et al., 2012). 
Two potentiator libraries were screened using YFP-ΔF508-CFTR: a 61 compound MS131A-
like (MS13AL) library, and an 82 compound VX-770-like (VX-770L) library. Note that due to 
the high number of active compounds in these libraries, median of test compounds was not 
Figure 5.7 MS131A potentiator activity following chronic treatment. HEK293 cells 
expressing ΔF508-CFTR-YFP were treated chronically with 10 µM MS131A or vehicle. Cells 
were washed before imaging, and activated with 50 µM forskolin. Left: YFP quenching trace 
shown from addition of extracellular Iˉ. 50 µM forskolin added 90 s before Iˉ (for protocol 
details see Chapter 6). Right: Quantified maximal quenching rates. * p = 0.01, from Mann-
Whitney U test, n = 9. 
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an acceptable negative reference. The median of within-plate negative control wells (50 µM 
forskolin + vehicle), was used to calculate test compound SSMDi values. Examination of the 
data indicated that the negative control wells better represented the population than in the 
pilot study. Improvements were made before running the LBVS YFP-CFTR assay to 
increase the chance that control wells on the plate would represent the data.  
  
 
 
 
 
Figure 5.8 MS131AL library screen for potentiator activity on YFP-ΔF508-CFTR. A) 
Dual-flashlight plot. Hits selected using criteria of activity > 23% VX-770 and SSMDi > 2. B) 
Structures of hit compounds. Left: Structure common to all hits and MS131A. Right: R 
groups of hit compounds and MS131A for comparison. 
A 
B 
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5.7.1 MS131AL library 
The MS131AL library was tested for ΔF508-CFTR potentiator activity using the YFP-ΔF508-
CFTR assay, in triplicate. Quality control SSMDR values of these plates were 7.2, 16.8 and 
116.8.  
 
 
 
Figure 5.9 MS131AL hits in ΔF508-CFTR-
pHTomato assay. Membrane-localised ΔF508-CFTR 
following chronic treatment with 10 µM VX-809 ± 10 
µM of the indicated compound. Incubation carried out 
at 30°C. Screen data n = 1 (empty symbols). 
Confirmation data n = 3 (filled symbols). All VX-809 
treated controls n = 3. No treatment was found to 
cause a significant difference. Paired t-test 
comparison of 10 µM VX-809 ± 10 µM each 
compound. 
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Although in the pilot screen MS131A had activity > 50% of VX-770, only lower levels of 
activity could be confirmed later. This was caused by an increase in the positive control 
reading for VX-770, following the purchase of new VX-770 stock (30 ± 2 µM s-1 for old stock 
vs. 77 ± 4 µM s-1 for new stock). Using a comparison of freshly prepared 10 µM MS131A and 
newly purchased 10 µM VX-770, i.e. those used at the time of screening LBVS plates, 
MS131A activity was measured as 23.3% ± 1.7% of VX-770 (n = 8). 23.3% of 10 µM VX-770 
activity was therefore used as the cut-off to identify hit compounds in the MS131AL library 
screen.   
The MS131AL library screen identified seven hit compounds with activity > 23.3% of 10 µM 
VX-770 and an SSMDi value > 2 (Figure 5.8A). All identified compounds had very similar 
structure to MS131A (Figure 5.8B).  
Hit compounds were tested for effects on ΔF508-CFTR membrane density. ΔF508-CFTR-
pHTomato was rescued by 10 µM VX-809 and low temperature incubation, and treated 
chronically with each test compound. Test compound treated cells (run in high-throughput 
screen format so n = 1), were compared to VX-809 treated controls (Figure 5.9, empty 
circles). No hit compounds from the MS131AL library appeared to cause a decrease of 
membrane ΔF508-CFTR. Compounds were then tested in triplicate for confirmation (Figure 
5.9, filled circles). 
5.7.2 VX-770L library 
Our collaborators at University of Bern prepared a library of compounds similar in structure 
to VX-770. The VX-770L library was prepared as for the pilot screen, at 10 mM in DMSO. All 
compounds were stored on one plate, which was tested in triplicate. Quality control SSMDR 
values were 2.2, 9 and 105.6. Again, no plates fell into the “poor” category (Table 5.1), so 
data from all plates was analysed to measure the effect of the VX-770L library.  
Five new hits were identified in the VX-770L library (Figure 5.10A). Hit compounds had 
potentiator activity > 50% of VX-770, and SSMDi > 2. Structures of the hit compounds are 
shown in Figure 5.10B, alongside VX-770. V-033, V-034, V-041 and V-042 have a very 
similar chemical scaffold to that of VX-770. Compound V-046 has quite a different structure. 
This confirms that the LBVS method of compound selection can identify structural analogues 
of the query ligand VX-770, sharing some aspects of its biological activity but not necessarily 
possessing the same chemical scaffold. 
To determine the effect of hit compounds on membrane stability, the ΔF508-CFTR-
pHTomato assay was used to measure membrane-localised ΔF508-CFTR following chronic 
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treatment with hit compounds. Overall, VX-770L hit compounds did not appear to destabilise 
membrane ΔF508-CFTR (Figure 5.11). 
 
 
 
 
 
 
B 
A 
Figure 5.10 VX-770L library screen for potentiator activity on YFP-ΔF508-CFTR. A) 
Dual-flashlight plot. Hits selected using criteria of activity > 50% VX-770 and SSMDi > 2. V-
046 is highlighted in red because of an interesting structure (discussed in text). B) Structures 
of hit compounds alongside VX-770 for comparison.  
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5.8 Discussion 
This chapter described pilot screens of compounds with some structural similarity to VX-770, 
to identify those with potentiator activity on ΔF508-CFTR. This study was prompted by the 
recent discovery of the negative effects most potentiators, including VX-770, have on 
ΔF508-CFTR biogenesis. The aim was to identify novel potentiators that do not possess 
such negative effects. 
5.8.1 Pilot screen results 
The initial pilot screen identified three hit compounds, two of which were confirmed using 
new compound stock. MS131A and MS134A showed different efficacy on ΔF508-CFTR 
compared to G551D-CFTR, which confirmed the activity was via potentiation of CFTR, 
rather than another anion pathway.  
Figure 5.11 VX-770L hits in ΔF508-CFTR-pHTomato destabilisation assay. Membrane-
localised ΔF508-CFTR following chronic treatment with 10 µM VX-809 ±10 µM of the 
indicated compound. Incubation carried out at 30°C. Screen data n = 1 (empty symbols). 
Confirmation data n = 3 (filled symbols). All VX-809 treated controls n = 3. No treatment was 
found to cause a significant difference. Paired t-test comparison of 10 µM VX-809 ± 10 µM 
each compound. Compound V-033 ran out so could not be retested. 
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Although lower in efficacy and affinity than VX-770, chronic treatment with MS131A did not 
reduce membrane density of ΔF508-CFTR (Figure 5.6). Unfortunately, this compound does 
not represent a good drug candidate. The two ester groups are likely to be readily 
hydrolysed by esterases present in the plasma, in the intestine and in the liver (Oda et al., 
2015). The lack of effect of MS131A on membrane-localisation, however, is not caused by 
hydrolysis of the compound during chronic treatment. This is shown by Figure 5.7, in which 
MS131A is still functional as a potentiator following 24 h chronic incubation on cells. 
To identify improved starting ligands for future screens, LBVS was used to construct libraries 
based on the structures of VX-770 and MS131A. Both LBVS plates identified a number of hit 
compounds. During the screening of LBVS compounds for membrane destabilisation effects, 
some problems with the CFTR-pHTomato assay were identified. 
5.8.2 ΔF508-CFTR-pHTomato in membrane density screen 
ΔF508-CFTR-pHTomato was used in this chapter to measure destabilisation of ΔF508-
CFTR following chronic treatment with novel potentiators.  
There appears to be some inconsistency in membrane ΔF508-CFTR measurements, 
demonstrated by chronic treatment with VX-770L potentiators (Figure 5.11). Screen test data 
points (empty circles) showed a decrease in membrane ΔF508-CFTR. This suggested that 
potentiator compounds identified in this screen caused similar membrane destabilisation to 
VX-770. However, the confirmation data points (filled circles) show that upon re-testing, in 
triplicate, the destabilisation effect was lost. 
In Chapter 4 we showed that the ΔF508-CFTR-pHTomato assay can be used to construct 
concentration-response curves to known corrector compounds (Figure 4.6). The increase in 
membrane density caused by corrector treatment is sufficiently large to be reliably detected. 
ΔF508-CFTR-pHTomato also successfully identified ~20% destabilisation by VX-770 (Figure 
4.7). In Figure 5.11, membrane density in the presence of novel compounds is compared to 
VX-809 treated controls. Therefore, quantification of the membrane density of VX-809 
treated controls must be extremely reliable, reproducible, and representative of the plate. 
Additionally, depending on only one reading for each test compound means that this 
measurement must also be highly reliable. This is especially important when identifying 
small effects, such as those caused by chronic potentiator treatment. For this small effect to 
be identified during a screen, such as the one described here, readings must be extremely 
sensitive and reproducible. It appears, from Figure 5.11, that this is not the case in the 
ΔF508-CFTR-pHTomato destabilisation screen. 
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This is reflected by the poor quality control SSMDR values of some plates, e.g. 1.6 and 1.7. 
These SSMDR values were calculated using membrane density of 10 µM VX-809-treated 
wells (positive controls) and 10 µM VX-809 + 10 µM VX-770-treated wells (negative 
controls). Low SSMDR values show that the difference between the positive and negative 
controls is not great enough to withstand the variability in the measurements. If we expect a 
similar change in membrane ΔF508-CFTR in the presence of test compounds, then the 
ΔF508-CFTR-pHTomato assay as a screen is not sensitive or reliable enough to make these 
measurements in a high-throughput screen format. 
Therefore, membrane density measurements in this chapter must be interpreted with 
caution. Whilst it would appear that MS131A and MS131AL compounds do not destabilise 
membrane ΔF508-CFTR (Figures 5.6 and 5.9), this should be confirmed by further testing, 
or using an alternative assay. 
5.8.3 LBVS results 
5.8.3.1 MS131AL library 
LBVS was used to construct a new library, with MS131A as a starting ligand. Unfortunately, 
all hit compounds identified by the MS131AL screen had the same ester structure as 
MS131A (Figure 5.8). These are not promising drug leads, as it is likely that all these hit 
compounds will be degraded by esterases before reaching the target CFTR (i.e. in airways).  
Had this library produced a ΔF508-CFTR potentiator with a drug-like structure, alongside no 
negative effects on membrane density, this ligand would have been used for another round 
of virtual screening, to create a new library. However, given the results shown in this 
chapter, none of the identified compounds are suitable for continuation of this aspect of the 
project. 
5.8.3.2 VX-770L library 
Functional screening of the VX-770L library identified an active compound with a different 
structural backbone to VX-770 (V-046, Figure 5.10). As discussed above, is not yet clear 
whether this compound also causes destabilisation of ΔF508-CFTR. Further testing must be 
carried out with ΔF508-CFTR-pHTomato, or another membrane density assay. 
5.8.4 Screening summary 
The YFP-CFTR screen was successfully used in this chapter to achieve one aim of this 
thesis: to identify novel ΔF508-CFTR potentiators. It appears that the hits identified in the 
inital pilot screen, MS131A and MS134A, do not destabilise ΔF508-CFTR (Figure 5.6). 
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However, testing more compounds in a high-throughput screen protocol for effects on 
stability of ΔF508-CFTR was not as successful. 
Chapter 4 described an assay in which membrane-localised ΔF508-CFTR could be 
quantified to measure the effect of corrector compounds and chronic potentiator treatment. 
However, the data discussed in this chapter suggests that this assay is not reliable or 
reproducible enough to detect small changes in a screen dependent upon a single 
measurement for each condition, and is also heavily dependent upon controls which 
represent the sample. 
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Chapter 6 
VX-770 mechanism of action 
 
6.1 Introduction 
Following the publication of the structure of potentiator compound VX-770 in 2009, a handful 
of studies were published on its mechanism of action. Nevertheless, the mechanism is not 
yet fully understood. This chapter describes VX-770 mechanism studies, using the YFP-
CFTR gating probe.  
Two aspects of VX-770 mechanism are investigated: Is phosphorylation of CFTR necessary 
for VX-770 to potentiate gating? Does VX-770 stabilise the post-hydrolytic O2 state in our 
system, as has been proposed? 
6.1.1 Gating of CFTR mutants 
A number of CFTR gating mutants which have been extensively studied in the past were 
used to investigate the mechanism by which VX-770 potentiates gating.  
G551D, the CF-associated mutation for which treatment with VX-770 was approved, is 
located in the signature sequence of NBD1, which contributes to forming one face of the 
catalytic ATP-binding site 2. Due to this mutation, electrostatic repulsion likely destabilises 
the NBD dimer with an ATP molecule bound at site 2 (Lin et al., 2014; Corradi et al., 2015). 
Therefore, ATP-dependent opening is virtually abolished (Drumm et al., 1991; Bompadre et 
al., 2007). Only ATP-independent gating is retained in these channels (also present in WT-
CFTR; Mihalyi et al., 2016), with a Po ~120-fold lower for G551D-CFTR than for WT-CFTR 
(Bompadre et al., 2007). 
As discussed earlier, the vast majority of WT-CFTR opening events are initiated after ATP 
binding at site 2, and terminated by hydrolysis of that ATP, whilst a very small proportion of 
events close via non-hydrolytic closing (Figure 6.1). K464A and D1370N are gating 
mutations that alter the proportion of events closing via the non-hydrolytic pathway (Csanády 
et al., 2010).  
K464 is located in the Walker A motif of NBD1. The alanine replacement reduces the 
turnover rate of ATP hydrolysis ~10-fold, and destabilises the pre-hydrolytic dimer 
(Ramjeesingh et al., 1999; Csanády et al., 2010). Dwell-time distribution analysis suggests 
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that approximately 80% of K464A-CFTR opening events close via non-hydrolytic closing, 
thus reducing the proportion of openings entering the post-hydrolytic O2 state (Figure 6.1). A 
longer interburst duration reduces the Po to ~25% that of WT-CFTR (in Xenopus oocytes) 
(Vergani et al., 2003; Csanády et al., 2010).  
D1370N is located in the Walker B motif of NBD2, at the interface of the catalytic ATP-
binding site 2. The corresponding mutation abolishes ATP-hydrolysis in other ABC 
transporters (Urbatsch et al., 1995; Rai et al., 2006). In CFTR, a prolonged burst duration is 
observed, presumably reflecting impaired hydrolysis. In oocytes, both the interburst duration 
and the burst duration are increased, giving a Po similar to WT-CFTR (Vergani et al., 2003; 
Csanády et al., 2010). Open dwell-time distribution data are consistent with 100% of opening 
events terminating via the non-hydrolytic closing pathway, so D1370N-CFTR would not enter 
the post-hydrolytic O2 state during ATP-dependent gating (Figure 6.1). However, D1370N-
CFTR has a higher rate of spontaneous ATP-independent gating than WT-CFTR (Csanády 
et al., 2010).  
 
 
 
 
 
Figure 6.1 Gating mechanisms of WT-CFTR, K464A-CFTR and D1370N-CFTR. Modified 
from Csanády et al., 2010. The majority of WT-CFTR opening events terminate via 
hydrolysis of ATP (95%). All D1370N-CFTR and 79% of K464A-CFTR opening events 
terminate via non-hydrolytic closing.  
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Very little is known about the structure of the post-hydrolytic O2 state, or the state occupied 
during ATP-independent gating. The fact that ATP inhibits G551D-CFTR gating (Lin et al., 
2014; Corradi et al., 2015), suggests that, during G551D-CFTR opening events, the NBDs 
are tightly dimerised, forming composite ATP binding sites similar to those formed during 
ATP-dependent opening. In G551D-CFTR, electrostatic repulsion occurs between the 
gamma phosphates and the negatively charged aspartic acid in the signature sequence. 
Additionally, a recent study used mutant cycles to show that other mutants undergoing ATP-
independent gating also likely adopt an open channel conformation in which the NBDs are 
tightly dimerised (Mihalyi et al., 2016).  
R352C-CFTR is a mutation in which two distinct open states with different conductance 
levels can be observed. During ATP-dependent gating, the channels follow a preferential C 
→ O1 → O2 → C sequence of transitions, suggesting that the O2 state indeed reflects a post-
hydrolytic conformation. When tested in the absence of ATP, most R352C-CFTR opening 
events followed a C → O2 → C transition, leading to the suggestion that ATP-independent 
events, at least in this mutant, utilise an O2-like state (Jih et al., 2012a). However, the 
difference in conductance results in a minute difference in current between these two states 
(~0.1 pA on a channel with maximal single-channel current of ~0.3 pA; Jih et al., 2012a), 
which makes reliable quantification of these events challenging and prone to error. 
Whilst it is not clear which state is populated during spontaneous ATP-independent gating, 
potentiation of G551D-CFTR does suggest that this state of CFTR is stabilised by VX-770. 
6.1.2 VX-770 mechanism of action 
VX-770 increases the Po of CFTR, via a prolonged mean open time, and an increased 
opening rate, as seen in single channel patching experiments (Van Goor et al., 2009; Yu et 
al., 2012; Jih and Hwang, 2013; Kopeikin et al., 2014). VX-770 is able to potentiate purified 
CFTR in reconstituted liposomes (Eckford et al., 2012), suggesting that the drug binds 
directly to the CFTR protein. The compound itself is incapable of phosphorylating CFTR 
(Pyle et al., 2011) and does not induce an increase in intracellular cAMP (Van Goor et al., 
2009). In the absence of PKA in the reconstituted liposome system, no VX-770 potentiation 
of WT-CFTR was detected (Eckford et al., 2012). This led to the hypothesis that VX-770 can 
act only on phosphorylated CFTR. 
VX-770 is capable of potentiating G551D-CFTR, ΔF508-CFTR and WT-CFTR in vitro (Van 
Goor et al., 2009). Therefore, this compound increases the open time of both WT-CFTR, 
terminated by ATP-hydrolysis (Vergani et al., 2005), and G551D-CFTR, which likely opens 
via a mechanism independent of ATP binding and hydrolysis (Bompadre et al., 2007).  
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It has been hypothesised that VX-770 achieves potentiation via stabilisation of the O2 state 
(Eckford et al., 2012; Jih and Hwang, 2013). However, the evidence supporting this 
conclusion (mostly involving the conductance mutant R352C-CFTR), is not entirely 
convincing (Jih and Hwang, 2013). Furthermore, Kopeikin et al. (2015), demonstrate that 
non-hydrolytic closing is slowed by VX-770. Closure of E1371S-CFTR channels used in 
these experiments does not involve hydrolysis, and so these channels do not enter the post-
hydrolytic O2 state. Therefore, slowing the closure of these events suggests stabilisation of 
O1, rather than O2. 
We used the YFP-CFTR probe to attempt to clarify some aspects of the VX-770 mechanism. 
6.2 VX-770 dependence on phosphorylation 
First, the phosphorylation status of CFTR potentiated by VX-770 was investigated.  
We were initially alerted to this aspect of the VX-770 mechanism whilst studying the effect of 
VX-770 pre-treatment on WT-CFTR. Following 1 h pre-incubation with 5 µM VX-770, WT-
CFTR showed a high degree of forskolin-independent anion permeability. Upon addition of 
extracellular Iˉ, rapid quenching occurred immediately (i.e. before addition of forskolin, 
Figure 6.2A). A simple interpretation consistent with this observation was that potentiation of 
CFTR by VX-770 was independent of exogenous phosphorylation.  
Even without VX-770 pre-incubation, quenching upon acute addition of forskolin + VX-770 
did not follow the same kinetics as activation by forskolin alone (Figure 6.2B). The time delay 
seen upon forskolin addition, before quenching begins, is attributed to the time required for 
accumulation of cAMP, necessary to activate PKA, which phosphorylates CFTR. This 
interpretation is supported by the forskolin concentration-dependence of the time delay 
(Figure 6.3). No time delay was present when WT-CFTR was activated in the presence of 
VX-770 (Figure 6.2B). 
Others have observed a small degree of VX-770 activity in the absence of exogenous 
phosphorylation, but this has been attributed to basal phosphorylation of CFTR in the 
specific material investigated (G551D/ΔF508-CFTR human bronchial epithelial cells, HBE 
cells; Van Goor et al., 2009). That is not likely to be the case in our experiments, as figures 
in Chapter 3 demonstrate that very little basal phosphorylation of CFTR is detected in our 
system.  
The maximal Iˉ entry rate following 1 h pre-incubation with 5 µM VX-770 was 263 µM s-1 ± 25 
µM. It is clear from Figure 6.2A that this rate of Iˉ entry was achieved by VX-770 alone, 
before the addition of 1 µM forskolin. In the absence of VX-770, the maximal quenching rate 
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induced by 1 µM forskolin was 59 µM s-1 ± 4 µM (Figure 6.2A). This indicates that, in these 
conditions, addition of VX-770 in the absence of phosphorylation, resulted in faster anion 
entry than addition of 1 µM forskolin. This could reflect either a higher Po, or a stronger 
driving force for Iˉ entry.  
 
 
 
 
 
The quenching kinetics of the two curves in Figure 6.2B are visibly different. Quenching 
triggered by VX-770 was immediate, whereas that which was brought about by 1 µM 
forskolin followed a delay, during which time slow quenching occurred. In the absence of VX-
770, when forskolin-induced quenching reaches the maximal rate, the driving force for Iˉ 
entry will have fallen, because of previous Iˉ influx into the cytosol. Therefore, no quantitative 
comparison of CFTR Po (induced by VX-770, vs. that induced by forskolin), is possible.  
Figure 6.2 Activation of WT-CFTR by VX-770 occurs independently of exogenous 
phosphorylation. A) HEK293 cells expressing YFP-WT-CFTR were pre-incubated with 
DMSO or 5 µM VX-770 for 1 h, then treated acutely with 1 µM forskolin. B) Cells were not 
pre-treated. CFTR activation was obtained acutely, via addition of 1 µM forskolin with or 
without 5 µM VX-770. n = 6. 
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In order to minimise the effect of different activation kinetics in the study of VX-770 
mechanism, the Iˉ second addition protocol was used. 
 
 
 
 
 
 
 
6.3 Iˉ second addition protocol and quantification 
In the Iˉ second addition protocol, CFTR is activated for 90 s in standard buffer (Figure 6.4). 
During this period, no quenching takes place due to the absence of extracellular Iˉ.  After 90 
s, CFTR is assumed to have reached steady state activation and 100 mM extracellular Iˉ is 
Figure 6.3 Forskolin concentration-dependence of quenching time delay. Top: Time 
delay was estimated by fitting quenching curves to an exponential decay with two 
components: one slow exponential, common to all curves (red solid line), and one faster 
exponential starting after a time delay, specific to the forskolin concentration. Green solid 
lines show representative fits. Bottom: The estimated time delay decreased in the presence 
of increasing forskolin. Only higher forskolin concentration points can be fit using this 
method, as two distinct components cannot be identified in low concentration traces. n = 3.   
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added. At this time point, the rate at which Iˉ can enter the cell is dependent only on the level 
of this activation, and not on the kinetics of activation. Whilst this minimises the effect of 
different activation kinetics, direct conclusions relating to Po must remain cautious, as the 
driving force for Iˉ entry (also a function of VM and the Iˉ concentration gradient), and the 
proportion of YFP-CFTR located at the membrane, might not be identical in all conditions. 
 
 
 
 
This protocol is more susceptible to noise caused by fluid addition artefacts. Any artefact 
caused by addition of extracellular Iˉ will occur at the exact time point used to quantify CFTR 
activity, i.e. the time point following Iˉ addition, at which the Iˉ concentration gradient is 
steepest. A cause of artefact at this time point is the movement of cells upon fluid addition. 
Steps were taken to minimise the effect of this artefact during image analysis (for more 
information see Methods, page 42). The relatively small errors on traces in Figure 6.4 
suggest that fluid addition artefacts did not greatly affect the readout.  
The analysis which was described in Chapter 3 was also applied to this protocol, to construct 
a forskolin concentration-response curve on WT-CFTR (Figure 6.5A), with the response 
quantified in terms of rate of change in [Iˉ]i. The fastest rate of Iˉ entry observed was again 
used to quantify CFTR activation, but in this case the maximal rate was observed 
immediately upon Iˉ addition to the bath. The EC50 for forskolin was similar to that which was 
Figure 6.4 Iˉ second addition protocol. Fluorescence traces of YFP-WT-CFTR obtained 
during the I- second addition protocol, in response to 0 µM (n = 20) or 10 µM forskolin (n = 9).  
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obtained using the Iˉ first addition protocol (2.1 µM ± 0.4 µM vs. 2.2 µM ± 0.3 µM, Figure 
3.7D).  
 
 
 
Figure 6.5 CFTR mutation characterisation. A) YFP-WT-CFTR forskolin concentration-
response curve, quantified using fastest rate of Iˉ entry (EC50 = 2.1 µM ± 0.4, nH = 1.9 ± 
0.5). Temperature rescued ΔF508-CFTR and G551D-CFTR did not respond to forskolin. B) 
K464A EC50 = 0.48 µM ± 0.56 µM. nH constrained to 1 for fitting. D) D1370N-CFTR EC50 = 
0.88 µM ± 0.06 µM, nH = 3.7 ± 1.5. 3 ≤ n ≤ 12. 
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Forskolin-dependence of gating mutants was also characterised using the Iˉ second addition 
protocol. Neither ΔF508-CFTR nor G551D-CFTR responded to forskolin alone, due to 
severe gating defects caused by these mutations (Figure 6.5A). 
Maximal forskolin induced ~10-fold smaller anion permeability in K464A-CFTR, compared to 
WT-CFTR (Figure 6.5B). The published Po of K464A-CFTR, measured using single channel 
patching, is ~4-fold smaller than WT-CFTR (Vergani et al., 2003; Csanády et al., 2010). 
Anion influx in the YFP-CFTR assay is also dependent on the proportion of CFTR that 
reaches the membrane. A low proportion of channels at the membrane is predicted to result 
in a slower maximal rate of Iˉ entry. K464A is also known to cause a trafficking defect 
(Thibodeau et al., 2010), which could explain the greater reduction in K464A-CFTR activity 
vs. WT-CFTR in our system, compared to published gating data.  
D1370N-CFTR had a slightly higher maximal Iˉ entry rate than WT-CFTR (6.2 mM s-1 ± 0.2 
vs. 5.2 mM s-1 ± 0.3; Figure 6.5C). EC50 values, where obtained, were comparable (0.48 µM, 
0.88 µM and 2.1 µM for K464A-CFTR, D3170N-CFTR and WT-CFTR, respectively; Figure 
6.4). 
All remaining work described in this chapter was carried out using the Iˉ second addition 
protocol. 
6.4 Phosphorylation-independent activation of WT-CFTR by VX-770 
Figure 6.2 shows that VX-770 activates WT-CFTR in the absence of exogenous 
phosphorylation. However, due to the differences in quenching kinetics, the extent of WT-
CFTR gating in the presence and absence of phosphorylation could not be quantitatively 
compared. This comparison was achieved using the Iˉ second addition protocol. 
Figure 6.6 compares concentration-response curves to VX-770, in the absence (left) and 
presence (right) of phosphorylation by 1 µM forskolin. The maximal steady state activation 
induced by VX-770 alone was ~15% that which was achieved by VX-770 in the presence of 
1 µM forskolin (Figure 6.6; 0.77 mM s-1 vs. 5.2 mM s-1). In other words, the effect of VX-770 
was enhanced ~7-fold by phosphorylation with 1 µM forskolin. A simple interpretation of 
these results is that VX-770-bound CFTR can gate, albeit at a low Po, in the absence of 
phosphorylation.  
In summary, VX-770 is capable of activating WT-CFTR in the absence of forskolin, in a 
system in which basal phosphorylation of WT-CFTR is minimal (see Chapter 3, Figures 3.3, 
3.11 and Domingue et al., 2014). This has not been seen previously. The anion current 
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carried by VX-770-activated CFTR in the absence of phosphorylation is low, which could 
explain how this effect has so far been missed. 
 
 
 
 
 
6.5 Activation of CFTR gating mutants by VX-770 
The second aim of this chapter was to investigate whether the O2 state is potentiated by VX-
770, as has been proposed. To achieve this, gating mutants which alter the gating cycle 
were utilised. 
Due to severe gating defects, G551D-CFTR and low temperature rescued ΔF508-CFTR did 
not respond to forskolin alone (Figure 6. 5A). However, we know from published work and 
data presented in Chapter 5 that both mutations are potentiated by VX-770 (Van Goor et al., 
2009). 
We measured the response of G551D-CFTR, ΔF508-CFTR and K464A-CFTR to VX-770, in 
the presence and absence of 10 µM forskolin (Figure 6.7). In the case of all three mutants, 
VX-770 increased the response to forskolin ~4-fold. Whilst the potentiation on WT-CFTR 
appears to be lower, the very high quenching rate observed with 10 µM forskolin + 10 µM 
VX-770 on WT-CFTR could be saturating the assay. Therefore, VX-770 potentiation of WT-
CFTR was measured in the presence of a lower concentration of forskolin, to enable 
accurate estimation of the fold increase caused by VX-770. In these conditions, VX-770 
again increased the response to forskolin ~4-fold. In the same conditions, potentiation of 
K464A-CFTR by VX-770 is undetectable (Figure 6.8).   
Figure 6.6 VX-770 concentration response curve, in the absence and presence of 
exogenous phosphorylation. Top: YFP-WT-CFTR treated with VX-770 in the absence of 
forskolin. EC50 = 456 nM ± 215 nM, nH = 1.0 ± 0.4, 3 ≤ n ≤ 11. Bottom: In the presence of 1 
µM forskolin. EC50 = 1.4 µM ± 243 nM, nH = 1.9 ± 0.5, 2 ≤ n ≤ 6. Note the different y-axis 
scale.  
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To avoid saturation of the assay whilst measuring D1370N-CFTR quenching (higher anion 
permeability that WT-CFTR; Figure 6.5), an even lower concentration of forskolin was used 
to measure VX-770 activation of D1370N-CFTR (Figure 6.9). 1 µM VX-770 increased the 
response to 300 nM forskolin ~2.5-fold. Upon lowering the phosphorylation status of WT-
CFTR, the effect of VX-770 was reduced to an undetectable level (Figure 6.9). 
In summary, regardless of the gating mutant in question, 10 µM VX-770 increased the 
response to forskolin ~4-fold, and 1 µM forskolin, induced a 2.5-fold increase in D1370N-
CFTR. Therefore, VX-770 potentiates to a similar degree, whether the channel displays no 
ATP-dependent gating (G551D-CFTR), or reduced time spent in the O2 state (K464A-CFTR 
and D1370N-CFTR).  
 
Figure 6.7 Phosphorylation-dependence activity of VX-770 on WT-CFTR and mutants. 
Cells were treated with 10 µM forskolin, 10 µM VX-770 or 10 µM VX-770 + 10 µM forskolin. * 
= p < 0.05. Conditions compared within a mutation using Kruskal-Wallis one way ANOVA 
and post-hoc Dunn’s test. 3 ≤ n ≤ 29. 
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Figure 6.8 Potentiation of K464A-CFTR by VX-770. WT-CFTR is potentiated by 10 µM 
VX-770 in the presence of 1 µM forskolin, whilst potentiation of K464A-CFTR is 
undetectable. * p < 0.001. WT-CFTR forskolin n = 10, + VX-770 n = 6, K464A-CFTR n = 3.  
Figure 6.9 Potentiation of D1370N-CFTR by VX-770. D1370N-CFTR is potentiated by 1 
µM VX-770 in the presence of 300 nM forskolin. The effect on WT-CFTR is lost at low 
phosphorylation level. WT-CFTR 300 nM forskolin n = 15, + 1 µM VX-770 n = 3. D1370N-
CFTR n = 6. * p < 0.05, from Kruskal-Wallis ANOVA on ranks and post-hoc Dunn’s test. 
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6.6 Discussion 
6.6.1 Phosphorylation is not a pre-requisite for activation by VX-770 
A study published in 2012 showed that VX-770 did not potentiate WT-CFTR which had not 
been pre-phosphorylated prior to reconstitution in liposomes (Eckford et al., 2012). It has 
since been assumed that phosphorylation is a pre-requisite for VX-770 activity. Experiments 
of pre-treatment of WT-CFTR with VX-770 led us to believe that this was not the case 
(Figure 6.2). 
It seems unlikely that the increased quenching seen in the absence of forskolin, following 1 h 
VX-770 pre-incubation, could be entirely via potentiation of basally phosphorylated CFTR, 
since basal phosphorylation of WT-CFTR in HEK293 cells is minimal (WT-CFTR vs. G551D-
CFTR in Chapter 3 and Figure 6.10). In addition it has been shown that VX-770 incubation 
does not increase accumulation of cAMP, or directly induce phosphorylation of CFTR in 
other systems (Van Goor et al., 2009; Pyle et al., 2011). 
Activation in the absence of phosphorylation suggests that phosphorylation is not 
necessarily a pre-requisite for WT-CFTR gating. Phosphorylation of the R-domain is thought 
to relieve an inhibition in the protein, allowing gating when the NBDs dimerise (Csanády et 
al., 2000). However, it has been shown that in some conditions CFTR can be activated 
without pre-phosphorylation. With all phosphorylation sites mutated to alanine, a mutant 
CFTR can be activated to near WT-CFTR levels by using deoxy-ATP as a ligand 
(Aleksandrov et al., 2002). Another small molecule CFTR activator, Cact-A1, activates CFTR 
without the need for exogenous phosphorylation (Namkung et al., 2013). Interestingly, VX-
770 has been shown to potentiate ΔF508-CFTR in the presence of Cact-A1 in fisher rat 
thyroid cells (Namkung et al., 2013). Therefore, it is possible to circumvent the need for 
CFTR phosphorylation, and VX-770 is functional in these circumstances. 
To investigate the phosphorylation dependence of VX-770 activity on gating mutants, 
mutants were treated with the potentiator in the absence of forskolin. G551D-CFTR, ΔF508-
CFTR and K464A-CFTR were not potentiated by VX-770 in the absence of exogenous 
phosphorylation (Figure 6.7, compare white and black bars). It is possible that the low anion 
permeability state achieved by VX-770 in the absence of phosphorylation is not detectable in 
mutants which already have a low Po. 
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We have shown that phosphorylation enhances the effect of VX-770 on WT-CFTR (Figure 
6.6). Figures 6.7 and 6.8 clearly show a synergistic effect of forskolin and VX-770, compared 
to the effects when used separately. This suggests that phosphorylation and VX-770 
increase CFTR Po via different pathways. At low phosphorylation levels (for example K464A-
CFTR in Figure 6.8 and WT-CFTR in Figure 6.9), this synergistic activity is lost. This 
suggests that a certain level of phosphorylation, different depending upon the Po, must be 
achieved in order for synergistic activity of the two to be seen. 
To confirm effectiveness of VX-770 on unphosphorylated WT-CFTR, it would be interesting 
to patch WT-CFTR channels in the absence of PKA phosphorylation, verifying activity by 
applying ATP, without and with VX-770. 
6.6.2 Stabilisation of the O2 state? 
It has been proposed that VX-770 potentiates CFTR via stabilisation of the O2 state  (Jih and 
Hwang, 2013). This is understood to potentiate WT-CFTR during ATP-dependent gating by 
stabilisation of the post-hydrolytic state, and G551D-CFTR during ATP-independent gating. 
However, as discussed above, it is not known which state is occupied during ATP-
independent gating. Additionally, it has been shown that VX-770 slows closure of E1371S-
CFTR channels, presumably by stabilisation of the O1 state during ATP-dependent gating 
Figure 6.10 Iˉ entry rates of CFTR mutations, in the absence of exogenous 
phosphorylation. * p = 0.02, mutations tested for significance vs. WT-CFTR control using 
Kruskal-Wallis one way ANOVA and post-hoc Dunn’s test. 
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(Kopeikin et al., 2014). In order to study this mechanism using YFP-CFTR, CFTR mutations 
which alter the gating cycle were utilised. 
K464A is a mutation which destabilises the pre-hydrolytic NBD dimer to increase the rate of 
non-hydrolytic closing. The proportion of opening events which close via the O2 state is 
approximately 20%. D1370N likely prevents ATP-hydrolysis at the catalytic site, consistent 
with all ATP-dependent opening events closing via non-hydrolytic closing (Figure 6.1) 
(Csanády et al., 2010). Additionally, studies in particular conditions in which differential 
buffer susceptibility resulted in different conductance levels being detected in pre- and post-
hydrolytic open channels, showed that D1370N-CFTR only resides in the O1 state 
(Gunderson and Kopito, 1995).  
It was hypothesised that, should VX-770 stabilise the O2 state, K464A-CFTR would be 
potentiated to a lesser extent than WT-CFTR, simply because fewer opening events would 
reach O2. Similarly, it was expected that the extent of potentiation of D1370N-CFTR would 
be far less than of WT-CFTR, as this channel has been shown to only reside in O1 
(Gunderson and Kopito, 1995; Csanády et al., 2010). Unexpectedly, the fold increase in 
K464A-CFTR gating caused by 10 µM VX-770 was similar to WT-CFTR (~4-fold, Figures 6.7 
and 6.8), and D1370N-CFTR gating was increased ~2.5-fold by the lower concentration of 1 
µM VX-770 (Figure 6.9). 
This data suggests that stabilisation of the O2 state is not the main mechanism by which VX-
770 potentiates gating, as it is difficult to explain this level of potentiation in mutants that 
rarely enter the O2 state. Even if D1370N-CFTR enters the O2 state during ATP-independent 
gating (which occurs more than for WT-CFTR; Csanády et al., 2010), the extent of 
potentiation is too great to be entirely via stabilisation of these events (Figure 6.9). Equally in 
the case of K464A-CFTR – only one fifth of opening events enter O2, yet potentiation is 
similar to that of WT-CFTR, in which 95% of opening events enter O2 (Csanády et al., 2010). 
The simplest explanation of this data is that VX-770 stabilises the O1 state during both ATP-
dependent and ATP-independent gating. This would explain the similar level of potentiation 
of WT-CFTR, G551D-CFTR, which only gates via ATP-independent opening events, and 
D1370N-CFTR and K464A-CFTR, which rarely enter the O2 state.  
 
6.6.3 Mechanism summary 
In summary, combining the YFP-CFTR assay with known gating mutations provides a way of 
testing hypotheses and obtaining an initial assessment of compound mechanism of action. 
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Further mechanistic insights can be gained only by patch clamp. To test our first hypothesis, 
that WT-CFTR does not require phosphorylation for VX-770 to increase anion permeability, 
we would need to patch WT-CFTR in the absence of PKA. Our second hypothesis, that VX-
770 stabilises the O1 state during ATP-dependent and ATP-independent gating, has, to an 
extent, already been tested using E1371S-CFTR patching by Kopeikin et al. (2014), 
although different interpretations of those data were given. Similar experiments, in which the 
closing rate of D1370N-CFTR opened in the presence of ATP, was measured, could provide 
further evidence for stabilisation of the O1 state. 
This chapter describes the investigation of the mechanism by which VX-770 potentiates 
CFTR gating. Using a cell free assay it has been shown that phosphorylation is a pre-
requisite for activation by VX-770 (Eckford et al., 2012). Data presented in this chapter 
shows that this is not necessarily the case, and that phosphorylation and VX-770 potentiate 
gating of CFTR via distinct mechanisms. Other data presented in this chapter suggests that 
the proposed mechanism of action for VX-770, i.e. stabilisation of the O2 state, is unlikely. 
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Chapter 7 
Conclusions 
 
The aims of this research, to optimise two fluorescence assays for use in compound 
screening and mechanism studies, were set out at the start of this thesis. Below, I discuss 
how these aims were met, and summarise future research directions. 
7.1 The search for novel ΔF508-CFTR potentiators 
We have demonstrated the use of the YFP-CFTR functional assay to screen compounds for 
ΔF508-CFTR potentiator activity. The pilot screen identified two novel compounds, with 
activity ~50% of VX-770 positive controls.  
It is likely that destabilisation of membrane ΔF508-CFTR by chronic VX-770 treatment 
contributed to the relatively small improvement in FEV1 seen in clinical trials of Orkambi 
(Cholon et al., 2014; Veit et al., 2014; Wainwright et al., 2015). The pilot screen hit 
compounds, MS131A and MS134A, had no negative effect on ΔF508-CFTR membrane-
localisation or internal expression, measured using ΔF508-CFTR-pHTomato (Figure 5.6).  
Based on these results, we carried out further compound screening, using LBVS for library 
selection. Two libraries were assembled; using either VX-770 or MS131A as starting ligands. 
Both screens identified a number of further potentiators, the majority of which were very 
similar to the starting ligand. However, one compound with a very different structure was 
identified in the VX-770L library: compound V-046.  
The identification of a structurally different compound supports the use of LBVS to identify 
novel potentiators with different scaffolds. The next step in this iterative process will be to 
create a library using V-046 as a starting ligand. It is possible that compounds based on this 
structure could maintain potentiator activity, but lose the negative effects on stability. Once 
more compounds have been tested for both effects it will be possible to draw some 
conclusions on structure-activity relationship. 
7.2 VX-770 potentiator mechanism 
As well as compound screening, YFP-CFTR was used to study the mechanism of action by 
which VX-770 potentiates CFTR.  
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We showed, for the first time, that WT-CFTR does not require phosphorylation in order for 
VX-770 to exert potentiator effects. The anion flux is small in the absence of 
phosphorylation, and was not detectable if basal Po was reduced, as in many gating 
mutants. 
Gating mutants were employed to study whether stabilisation of the post-hydrolytic O2 state 
is a likely mechanism of potentiation by VX-770. Well-studied mutations and dose-response 
curves linking forskolin concentration to Iˉ permeation were used as tools to investigate 
which gating steps might be affected by VX-770 binding. The K464A and D1370N mutations 
reduce the proportion of gating events which terminate via hydrolysis, thus reducing the 
amount of time spent in the O2 state. Unexpectedly, potentiation of K464A-CFTR and 
D1370N-CFTR was not reduced compared to WT-CFTR (Figures 6.7 to 6.9). This work 
suggests that stabilisation of the O2 state is an unlikely mechanism for VX-770. Whilst YFP-
CFTR studies can be used to test an initial hypothesis, patch clamping is required to obtain 
further insight into mechanism.  
7.3 Two CFTR-YFP protocols 
This thesis described the use of two CFTR-YFP protocols: Iˉ first addition (Chapter 3) and Iˉ 
second addition (Chapter 6). The advantages and drawbacks of both protocols are 
summarised here. 
The fastest rate of Iˉ entry into the cells depends on CFTR Po, the proportion of CFTR-YFP 
at the membrane, and the driving force for Iˉ entry. How the driving force affects the readout 
is the main difference between the two assays. In the Iˉ first addition protocol, the driving 
force for Iˉ entry changes during activation of CFTR. A treatment that is slow to reach steady 
state activation will reach such activation only once Iˉ influx into the cytosol has reduced the 
driving force. This can be seen in Figure 6.2. Forskolin-only treated cells activate slower than 
VX-770 treated cells, resulting in a slower maximal Iˉ entry rate.  
This change in driving force over time is overcome using the Iˉ second addition protocol. The 
maximal rate of Iˉ entry occurs upon addition of Iˉ (Figure 6.4A). At this point, the driving 
force for Iˉ entry will be the same, irrespective of the rate of CFTR activation. Two 
assumptions are made in using Iˉ second addition protocol assay readouts to compare 
CFTR activity in two separate wells: the presence of a similar transmembrane 
electrochemical gradient for Iˉ, and that a maximal Po has been reached. In most conditions 
these assumptions are likely to be true.  
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In summary, the assay to use depends on the experiment. The Iˉ first addition protocol is 
less susceptible to noise caused by fluid addition, and gives qualitative information about the 
rate of CFTR activation. However, quantitative comparisons between conditions/mutants can 
be complicated by differences in activation rate. The Iˉ second addition protocol is less 
influenced by CFTR activation rate, so can be used to quantitatively compare situations in 
which the rate of CFTR activation is different. 
7.4 Future work 
7.4.1 CFTR-pHTomato assay for ΔF508-CFTR corrector screens 
This thesis focused on identification of novel ΔF508-CFTR potentiators. However, successful 
treatment of ΔF508-CF will likely also require corrector compounds, like VX-809. Most 
corrector screens in other labs have been carried out using functional assays. Due to the 
severe gating defect associated with ΔF508-CFTR, it would not be possible to detect 
correction in a functional screen without the use of a potentiator. This means compounds 
that stabilise a form of ΔF508-CFTR which cannot be activated by the potentiator in use, will 
not be detected as correctors. In using a functional assay as a corrector screen, it is also 
impossible to distinguish between effects on trafficking and function, resulting in some 
compounds with potential beneficial effects being missed. 
Both the trafficking and gating defects are caused by aberrant folding, so it is possible that a 
corrector compound which promotes native folding would also restore some level of  function 
to ΔF508-CFTR. Searching for compounds with this characteristic would provide information 
on how channel folding is related to function, as well as moving towards monotherapy for 
ΔF508-CF patients.   
Investigating these compound effects using the two assays described will allow us to 
discriminate between effects on ion channel gating and on membrane-localisation, allowing 
us a better understanding of both. 
Figure 7.1A shows how this discrimination is possible. Untreated ΔF508-CFTR has low 
membrane density and low function compared to WT-CFTR. 30°C incubation restores some 
membrane density, but does not increase ΔF508-CFTR function. VX-809 incubation has an 
even greater effect on membrane density, and also restores a small amount of function to 
ΔF508-CFTR. This suggests that VX-809 stabilises a form of ΔF508-CFTR that has some 
rescued function, without the need for potentiators. This effect of VX-809 has also been 
shown by other groups (Eckford et al., 2014).   
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To test this method of discrimination using novel compounds, LBVS was used to construct a 
pilot library of compounds based on VX-809. The functional and membrane density assays 
were both carried out following chronic treatment (24 h), alongside low temperature 
correction (Figure 7.1B). 
 
 
 
 
 
Figure 7.1 Function vs. membrane CFTR in ΔF508-CFTR corrector screens. A) Function 
and membrane CFTR of controls, expressed as a percentage of WT-CFTR. Plots are mean 
± SEM, 3 ≤ n ≤ 6. B) Screening of compound library constructed using LBVS with VX-809 as 
a query ligand. Each point is the mean of an individual compound, tested twice in each 
assay. Dotted lines indicate control values obtained for untreated, temperature rescued 
ΔF508-CFTR. Data points expressed as percentage of ΔF508-CFTR treated with 10 µM VX-
809. Both screens carried out following 24 h low temperature incubation. 
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Unfortunately, all of the VX-809 like (VX-809L) library compounds showed similar, or even 
lower, activity and membrane expression than temperature rescued ΔF508-CFTR (Figure 
7.1B, ΔF508-CFTR indicated by the dotted lines).  
A potential problem with using the CFTR-pHTomato assay to screen compound libraries is 
the strength of the assay for high-throughput screening. As discussed in Chapter 5, SSMDR 
is a measure of the suitability of an assay for high-throughput screening. The SSMDR scores 
for the two VX-809L screen repeats were 1.5 and 6.5. An SSMDR score of 1.5 indicates a 
plate of poor quality (Table 5.1). It is likely that data from this plate would not be used in a 
high-throughput screen. Again, although the effect of corrector compounds on membrane 
density is greater than the effect of potentiator compounds, it seems that the reliability of the 
CFTR-pHTomato assay is insufficient to be used in high-throughput screening. 
SSMDR is calculated using the difference between positive and negative controls, penalised 
by the variability in the difference. Therefore, causes of a low SSMDR are a poor response to 
the positive control, or large variability in the assay. As has already been mentioned, the 
CFTR-pHTomato assay does suffer from high variability, which contributed to the low 
SSMDR score. At this time, there is no better positive control available for corrector screens.  
Ultimately, for the CFTR-pHTomato assay to be used in high-content screening to identify 
small effects of destabilisation or correctors with limited efficacy, reliability of the assay must 
be improved. 
7.4.2 YFP-CFTR for CFTR membrane localisation studies 
Initially, it was thought that YFP-CFTR could be used for localisation studies as well as 
functional tests. However, heterogeneity in the cells, and a low fluorescence signal made 
automated quantification of CFTR localisation impossible (see Section 3.10). For these 
reasons, the CFTR-pHTomato assay was developed. 
The CFTR-pHTomato assay is capable of measuring membrane-localised and internal 
CFTR. For the reasons described above, it is useful to quantify localisation independent of 
function. However, measuring localisation and function in different assays means both YFP-
CFTR and CFTR-pHTomato assays must be run if both parameters are to be quantified (for 
example in Figure 7.1). Measuring both parameters, independently, but on the same cells, 
would save time and resources, as well as give more accurate, informative, readings. 
A future project will be focussed on using YFP-CFTR for a CFTR localisation assay. To 
achieve this, YFP-CFTR will be expressed in a pIRES2-mCherry plasmid. The mCherry 
signal will act as a control for total amount of protein, similar to the function of eGFP in the 
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CFTR-pHTomato assay. mCherry expression in the cytosol will also allow for automated 
algorithms capable of accurately recognising cells, and localising the cell membrane. High 
resolution, high magnification images will allow quantification of membrane and internal 
YFP-CFTR. Presence of the mCherry signal will aid in identifying the cell membrane, which 
was a problem suffered in using the YFP-CFTR signal only (Figure 3.14). The same cell 
samples will also be used in the YFP-CFTR functional screen. By using estimates of the 
number of channels present at the membrane, it will be possible to better infer Po of these 
channels from measurements of YFP quenching rate. 
When optimised, this high-content assay will provide similar information to whole cell 
recordings, but with the added benefit of informing on channel cellular distribution. For 
example, in Chapter 6, the function of K464A-CFTR was deemed to be ~10-fold lower than 
WT-CFTR (Figure 6.5). However, K464A is also known to cause a trafficking defect 
(Thibodeau et al., 2010). A lower proportion of CFTR at the membrane is predicted to 
decrease the maximal quenching rate. Using the proposed YFP-CFTR/mCherry assay, the 
effect of the change in channel distribution could be measured, and accounted for, resulting 
in a more accurate quantification of CFTR activity. 
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Appendix 
 
A.1 LBVS plate data in CFTR-pHTomato screen 
As described in Chapters 4 and 5, the CFTR-pHTomato assay is susceptible to variation. 
Data in Chapter 5 showed that the assay was not reliable enough to measure small changes 
in membrane density, in a high-throughput screen protocol. Here, we show CFTR-pHTomato 
data from the entire LBVS libraries, unlike Chapter 5 in which only hit compounds were 
presented. In examining the full plates, including controls, we have identified a source of 
irregularities in the CFTR-pHTomato screen. 
MS131AL compounds had little effect on membrane-localised or internal ΔF508-CFTR 
(Figure A1.A, all compounds ~100% compared to VX-809 treated controls). However, 
surprisingly, the majority of compounds in the VX-770L library appeared to increase internal 
ΔF508-CFTR (Figure A1.B).  
Other have shown that chronic incubation with VX-770 causes a decrease in immature 
ΔF508-CFTR, by increasing cotranslational degradation or decreasing translation (Cholon et 
al., 2014; Veit et al., 2014). In our assay, we see no significant change in internal ΔF508-
CFTR expression following chronic VX-770 treatment (Chapter 4, Figure 4.7).  
An increase in internal ΔF508-CFTR in our VX-770L screen could suggest an effect on 
biosynthesis, different to that of VX-770. For example, stabilisation of a conformation that is 
unable to be exported from the ER, but which does not undergo faster degradation, causing 
an accumulation of internal ΔF508-CFTR. 
Alternatively, these compounds could be having off-target effects on a chaperone protein, 
preventing export from the ER. Although there is strong evidence that VX-770 binds directly 
to CFTR (Eckford et al., 2012; Jih and Hwang, 2013) and these compounds are based on 
the VX-770 structure, we have no evidence of direct binding of these compounds.  
There is a third, more likely, explanation. All compounds in Figure A1 are normalised to 
within-plate controls (treated with 10 µM VX-809 only), to allow comparison of fluorescence 
values between different plates. Upon inspection of the within-plate controls, both 
membrane-localised and internal measurements appear normal (Figure A2.A and A2.B, left), 
i.e. 10 µM VX-770 decreased membrane-localised ΔF508-CFTR, and had no significant 
effect on internal ΔF508-CFTR.  
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Comparison of membrane-localised ΔF508-CFTR controls with data from the entire plate 
shows the expected pattern, i.e. values of within-plate controls correlate to values in the rest 
of the plate, and are within the same range (Figure A2.A, compare left and right).  
However, comparison of the within-plate internal controls with the full plate data reveals an 
inconsistency. Internal ΔF508-CFTR within-plate controls on VX-770L plates show much 
lower values than the respective plate data (Figure A2.B, compare triangles on left to 
triangles on right). When compound results are normalised to (abnormally low) VX-809-
Figure A1 Internal and membrane ΔF508-CFTR from LBVS plates. A) MS131AL and B) 
VX-770L libraries screened for destabilisation effects using ΔF508-CFTR-pHTomato. 
Membrane-localisation corrected using 24 h 10 µM VX-809 and low temperature incubation. 
Membrane and internal ΔF508-CFTR normalised to VX-809 treated wells (i.e. 100% = no 
change caused by 24 h compound treatment). 
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treated wells, this gives the illusion that all VX-770L compounds have caused an increase in 
internal ΔF508-CFTR. It seems more likely that abnormally low internal ΔF508-CFTR 
readings from VX-809 treated controls is the cause of the results seen in Figure A1.B, rather 
than a genuine ~3-fold increase in internal ΔF508-CFTR. 
 
 
 
 
 
Again, it seems that depending too heavily on controls, which do not necessarily represent 
the sample, leads to irregularities in the destabilisation screen.  
Figure A2 ΔF508-CFTR-pHTomato within-plate controls. A) Membrane-localised ΔF508-
CFTR and B) Internal ΔF508-CFTR, from MS131A and VX-770L libraries, each run twice. 
Left: 10 µM VX-809 treated controls, ± 10 µM VX-770. Right: All compound data from 
corresponding plates. 
A 
B 
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Following the YFP-CFTR pilot ChemiBank screen, steps were taken to improve within-plate 
controls. For example, control wells were run at regular intervals throughout the plate, rather 
than only at the end, and were not placed in wells on the edges of the plate. Whilst these 
steps have improved controls in the YFP-CFTR screen (see section 5.7), the same does not 
appear to be true of CFTR-pHTomato.  
In the YFP-CFTR pilot screen, to circumvent the problem caused by negative controls which 
did not accurately represent the plate data, the median quenching rate of the test 
compounds was instead used as the negative control (see section 5.4). This was possible 
because inspection of quenching traces showed that not many compounds had potentiator 
activity. This cannot be used for CFTR-pHTomato plate data. ΔF values, used to quantify 
CFTR, are not comparable between plates. Therefore, there is no ‘normal’ negative control 
range to which plate data can be compared. If we cannot be confident that only a few 
compounds in the library are having an effect on membrane density, then obviously we 
cannot use the test compounds as the negative control. 
A.2 Imaging movies 
Examples of the images obtained during YFP-CFTR and CFTR-pHTomato imaging are 
stored on a DVD attached to the back cover.  
M1.A and M1.B show YFP-WT-CFTR quenching in the presence and absence, respectively, 
of 10 µM forskolin, using the Iˉ first addition protocol described on page 41 of the thesis. 
M2.A and M2.B show the same, using the Iˉ second addition protocol described on page 41. 
The speed of these movies is increased 20X. 
M3.A shows WT-CFTR-pHTomato imaging described on page 44 of the thesis. The speed of 
this movie is increased 2X. M3.B and M3.C show GFP and Hoechst, respectively, obtained 
during WT-CFTR-pHTomato imaging.  
All images are 717.12 µm x 717.12 µm. 
 
 
 
 
 
 References 141 
References 
 
Aleksandrov, A. a, Aleksandrov, L., and Riordan, J.R. (2002). Nucleoside triphosphate 
pentose ring impact on CFTR gating and hydrolysis. FEBS Lett. 518: 183–8. 
Ameen, N., Silvis, M., and Bradbury, N.A. (2007). Endocytic trafficking of CFTR in health and 
disease. J. Cyst. Fibros. 6: 1–14. 
Anderson, M.P., Gregory, R.J., Thompson, S., Souza, D.W., Paul, S., Mulligan, R.C., et al. 
(1991). Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. 
Science 253: 202–5. 
Awale, M., Jin, X., and Reymond, J.-L. (2015). Stereoselective virtual screening of the ZINC 
database using atom pair 3D-fingerprints. J. Cheminform. 7: 3. 
Awale, M., and Reymond, J.L. (2014). Atom pair 2D-fingerprints perceive 3D-molecular 
shape and pharmacophores for very fast virtual screening of ZINC and GDB-17. J. Chem. 
Inf. Model. 54: 1892–1907. 
Bachhuber, T., König, J., Voelcker, T., Mûrie, B., Schreiber, R., and Kunzelmann, K. (2005). 
Cl- interference with the epithelial Na+ channel ENaC. J. Biol. Chem. 280: 31587–31594. 
Bali, V., Lazrak, A., Guroji, P., Matalon, S., and Bebok, Z. (2016). Mechanistic Approaches 
to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis. 
PLoS One 11: e0155882. 
Ban, H., Inoue, M., Griesenbach, U., Munkonge, F., Chan, M., Iida, A., et al. (2007). 
Expression and maturation of Sendai virus vector-derived CFTR protein : functional and 
biochemical evidence using a GFP-CFTR fusion protein. Gene Ther. 14: 1688–1694. 
Bompadre, S.G., Sohma, Y., Li, M., and Hwang, T.-C. (2007). G551D and G1349D, two CF-
associated mutations in the signature sequences of CFTR, exhibit distinct gating defects. J. 
Gen. Physiol. 129: 285–98. 
Botelho, H.M., Uliyakina, I., Awatade, N.T., Proença, M.C., Tischer, C., Sirianant, L., et al. 
(2015). Protein Traffic Disorders: an Effective High-Throughput Fluorescence Microscopy 
Pipeline for Drug Discovery. Sci. Rep. 5: 9038. 
Boucher, R.C. (2007). Airway surface dehydration in cystic fibrosis: pathogenesis and 
 References 142 
therapy. Annu. Rev. Med. 58: 157–70. 
Boyle, M.P., and Boeck, K. De (2013). A new era in the treatment of cystic fibrosis: 
correction of the underlying CFTR defect. Lancet Respir. Med. 1: 158–163. 
Bozoky, Z., Krzeminski, M., Muhandiram, R., Birtley, J.R., Al-Zahrani, A., Thomas, P.J., et al. 
(2013). Regulatory R region of the CFTR chloride channel is a dynamic integrator of 
phospho-dependent intra- and intermolecular interactions. Proc. Natl. Acad. Sci. U. S. A. 
110: E4427–36. 
Bray, M., and Carpenter, A.E. (2013). Advanced Assay Development Guidelines for Image-
Based High Content Screening and Analysis Assay Guidance Manual. Assay Guid. Man. 
Bregestovski, P., Waseem, T., and Mukhtarov, M. (2009). Genetically encoded optical 
sensors for monitoring of intracellular chloride and chloride-selective channel activity. Front. 
Mol. Neurosci. 2: 15. 
Cantin, A.M., Hanrahan, J.W., Bilodeau, G., Ellis, L., Dupuis, A., Liao, J., et al. (2006). Cystic 
fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. 
Am. J. Respir. Crit. Care Med. 173: 1139–1144. 
Carlile, G.W., Robert, R., Zhang, D., Teske, K. a, Luo, Y., Hanrahan, J.W., et al. (2007). 
Correctors of protein trafficking defects identified by a novel high-throughput screening 
assay. Chembiochem 8: 1012–20. 
Chalfie, M., Tu, Y., Euskirchen, G., Ward, W.W., and Prasher, D.C. (1994). Green 
fluorescent protein as a marker for gene expression. Science 263: 802–805. 
Chan, K.W., Csanády, L., Seto-young, D., Nairn, A.C., and Gadsby, D.C. (2000). Severed 
Molecules Functionally Define the Boundaries of the Cystic Fibrosis Transmembrane 
Conductance Regulator’s NH2 -terminal Nucleotide Binding Domain. J. Gen. Physiol. 116: 
163–180. 
Chang, X.B., Cui, L., Hou, Y.X., Jensen, T.J., Aleksandrov,  a a, Mengos,  a, et al. (1999). 
Removal of multiple arginine-framed trafficking signals overcomes misprocessing of delta 
F508 CFTR present in most patients with cystic fibrosis. Mol. Cell 4: 137–42. 
Chang, X.B., Tabcharani, J. a, Hou, Y.X., Jensen, T.J., Kartner, N., Alon, N., et al. (1993). 
Protein kinase A (PKA) still activates CFTR chloride channel after mutagenesis of all 10 PKA 
consensus phosphorylation sites. J. Biol. Chem. 268: 11304–11. 
Cheng, S.H., Gregory, R.J., Marshall, J., Paul, S., Souza, D.W., White, G. a, et al. (1990). 
 References 143 
Defective intracellular transport and processing of CFTR is the molecular basis of most 
cystic fibrosis. Cell 63: 827–34. 
Cholon, D.M., Quinney, N.L., Fulcher, M.L., Jr, C.R.E., Das, J., Dokholyan, N. V, et al. 
(2014). Potentiator ivacaftor abrogates pharmacological correction of D F508 CFTR in cystic 
fibrosis. Sci. Transl. Med. 6: 1–11. 
Coakley, R.D., Grubb, B.R., Paradiso, A.M., Gatzy, J.T., Johnson, L.G., Kreda, S.M., et al. 
(2003). Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium. 
Proc. Natl. Acad. Sci. U. S. A. 100: 16083–16088. 
Coppinger, J. a, Hutt, D.M., Razvi, A., Koulov, A. V, Pankow, S., Yates, J.R., et al. (2012). A 
chaperone trap contributes to the onset of cystic fibrosis. PLoS One 7: e37682. 
Cormack, B.P., Valdivia, R.H., and Falkow, S. (1996). FACS-optimized mutants of the green 
fluorescent protein (GFP). Gene 173: 33–8. 
Corradi, V., Vergani, P., and Tieleman, D.P. (2015). Cystic fibrosis transmembrane 
conductance regulator (CFTR): closed and open state channel models. J. Biol. Chem. 
jbc.M115.665125. 
Csanády, L. (2000). Rapid kinetic analysis of multichannel records by a simultaneous fit to 
all dwell-time histograms. Biophys. J. 78: 785–99. 
Csanády, L., Chan, K.W., Seto-Young, D., Kopsco, D.C., Nairn,  a C., and Gadsby, D.C. 
(2000). Severed channels probe regulation of gating of cystic fibrosis transmembrane 
conductance regulator by its cytoplasmic domains. J. Gen. Physiol. 116: 477–500. 
Csanády, L., Vergani, P., and Gadsby, D.C. (2010). Strict coupling between CFTR’s catalytic 
cycle and gating of its Cl- ion pore revealed by distributions of open channel burst durations. 
Proc. Natl. Acad. Sci. U. S. A. 107: 1241–6. 
Cui, L., Aleksandrov, L., Chang, X.-B., Hou, Y.-X., He, L., Hegedus, T., et al. (2007). Domain 
interdependence in the biosynthetic assembly of CFTR. J. Mol. Biol. 365: 981–94. 
Cui, L., Aleksandrov, L., Hou, Y.-X., Gentzsch, M., Chen, J.-H., Riordan, J.R., et al. (2006). 
The role of cystic fibrosis transmembrane conductance regulator phenylalanine 508 side 
chain in ion channel gating. J. Physiol. 572: 347–58. 
Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Dott, K., Dreyer, D., et al. (1991). 
Altered chloride ion channel kinetics associated with the deltaF508 cystic fibrosis mutation. 
Nature 354: 526–528. 
 References 144 
Dautzenberg, F.M., Higelin, J., and Teichert, U. (2000). Functional characterization of 
corticotropin-releasing factor type 1 receptor endogenously expressed in human embryonic 
kidney 293 cells. Eur. J. Pharmacol. 390: 51–9. 
Davies, J.C., Wainwright, C.E., Canny, G.J., Chilvers, M.A., Howenstine, M.S., Munck, A., et 
al. (2013). Efficacy and safety of Ivacaftor in patients aged 6 to 11 years with cystic fibrosis 
with a G155D mutation. Am. J. Respir. Crit. Care Med. In press.: 
Denning, G.M., Anderson, M.P., Amara, J.F., Marshall, J., Smith, A.E., and Welsh, M.J. 
(1992). Processing of mutant cystic fibrosis transmembrane conductance regulator is 
temperature-sensitive. Nature 358: 761–764. 
Dodge, J. a, Lewis, P. a, Stanton, M., and Wilsher, J. (2007). Cystic fibrosis mortality and 
survival in the UK: 1947-2003. Eur. Respir. J. 29: 522–6. 
Domingue, J.C., Ao, M., Sarathy, J., George, A., Alrefai, W. a, Nelson, D.J., et al. (2014). 
HEK-293 cells expressing the cystic fibrosis transmembrane conductance regulator (CFTR): 
a model for studying regulation of Cl- transport. Physiol. Rep. 2: 1–16. 
Drumm, M.L., Wilkinson, D.J., Smit, L.S., Worrell, R.T., Strong, T. V, Frizzell, R.A., et al. 
(1991). Chloride Conductance Expressed by delF508 and Other Mutant CFTRs in Xenopus 
Oocytes. Science (80-. ). 254: 1797–1799. 
Du, K., and Lukacs, G.L. (2009). Cooperative Assembly and Misfolding of CFTR Domains In 
Vivo. Mol. Biol. Cell 20: 1903–1915. 
Du, K., Sharma, M., and Lukacs, G.L. (2005). The DeltaF508 cystic fibrosis mutation impairs 
domain-domain interactions and arrests post-translational folding of CFTR. Nat. Struct. Mol. 
Biol. 12: 17–25. 
Eckford, P.D.W., Li, C., Ramjeesingh, M., and Bear, C.E. (2012). Cystic fibrosis 
transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the 
defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-
independent manner. J. Biol. Chem. 287: 36639–49. 
Eckford, P.D.W., Ramjeesingh, M., Molinski, S., Pasyk, S., Dekkers, J.F., Li, C., et al. 
(2014). VX-809 and Related Corrector Compounds Exhibit Secondary Activity Stabilizing 
Active F508del-CFTR after Its Partial Rescue to the Cell Surface. Chem. Biol. 18: 1–13. 
Farinha, C.M., and Amaral, M.D. (2005). Most F508del-CFTR is targeted to degradation at 
an early folding checkpoint and independently of calnexin. Mol. Cell. Biol. 25: 5242–5252. 
 References 145 
Farinha, C.M., King-Underwood, J., Sousa, M., Correia, A.R., Henriques, B.J., Roxo-Rosa, 
M., et al. (2013a). Revertants, low temperature, and correctors reveal the mechanism of 
F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. Chem. Biol. 
20: 943–955. 
Farinha, C.M., King-Underwood, J., Sousa, M., Correia, A.R., Henriques, B.J., Roxo-Rosa, 
M., et al. (2013b). Revertants, Low Temperature, and Correctors Reveal the Mechanism of 
F508del-CFTR Rescue by VX-809 and Suggest Multiple Agents for Full Correction. Chem. 
Biol. 20: 943–55. 
Farinha, C.M., Sousa, M., Canato, S., Schmidt, A., Uliyakina, I., and Amaral, M.D. (2015). 
Increased efficacy of VX-809 in different cellular systems results from an early stabilization 
effect of F508del-CFTR. Pharmacol. Res. Perspect. 3: e00152. 
Flume, P. a, Liou, T.G., Borowitz, D.S., Li, H., Yen, K., Ordoñez, C.L., et al. (2012). Ivacaftor 
in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 
142: 718–24. 
Fu, J., Ji, H.L., Naren, A.P., and Kirk, K.L. (2001). A cluster of negative charges at the amino 
terminal tail of CFTR regulates ATP-dependent channel gating. J. Physiol. 536: 459–70. 
Galietta, L. V, Jayaraman, S., and Verkman,  a S. (2001a). Cell-based assay for high-
throughput quantitative screening of CFTR chloride transport agonists. Am. J. Physiol. Cell 
Physiol. 281: C1734–42. 
Galietta, L.J., Haggie, P.M., and Verkman,  a S. (2001b). Green fluorescent protein-based 
halide indicators with improved chloride and iodide affinities. FEBS Lett. 499: 220–4. 
Galietta, L.J., Springsteel, M.F., Eda, M., Niedzinski, E.J., By, K., Haddadin, M.J., et al. 
(2001c). Novel CFTR chloride channel activators identified by screening of combinatorial 
libraries based on flavone and benzoquinolizinium lead compounds. J. Biol. Chem. 276: 
19723–8. 
Garland, A.L., Walton, W.G., Coakley, R.D., Tan, C.D., Gilmore, R.C., Hobbs, C. a, et al. 
(2013). Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways. 
Proc. Natl. Acad. Sci. U. S. A. 110: 15973–8. 
Goktug, A.N., Chai, S.C., and Chen, T. (2013). Data analysis approaches in high throughput 
screening. In Drug Discovery, P.H. El-Shemy, ed. 
González, J.E., Oades, K., Leychkis, Y., Harootunian, A., and Negulescu, P.A. (1999). Cell-
 References 146 
based assays and instrumentation for screening ion-channel targets. Drug Discov. Today 4: 
431–439. 
Gregory, R.J., Rich, D.P., Cheng, S.H., Souza, D.W., Paul, S., Manavalan, P., et al. (1991). 
Maturation and function of cystic fibrosis transmembrane conductance regulator variants 
bearing mutations in putative nucleotide-binding domains 1 and 2. Mol. Cell. Biol. 11: 3886–
93. 
Groot-Kormelink, P.J., Beato, M., Finotti, C., Harvey, R.J., and Sivilotti, L.G. (2002). 
Achieving optimal expression for single channel recording: A plasmid ratio approach to the 
expression of ??1 glycine receptors in HEK293 cells. J. Neurosci. Methods 113: 207–214. 
Gunderson, K.L., and Kopito, R.R. (1995). Conformational states of CFTR associated with 
channel gating: the role ATP binding and hydrolysis. Cell 82: 231–9. 
Haws, C.M., Nepomuceno, I.B., Krouse, M.E., Wakelee, H., Law, T., Xia, Y., et al. (1996). 
Delta F508-CFTR channels : kinetics , activation by forskolin , and potentiation by xanthines. 
Am. J. Physiol. Cell Physiol. 270: C1544–1555. 
He, L., Kota, P., Aleksandrov, A. a, Cui, L., Jensen, T., Dokholyan, N. V, et al. (2013). 
Correctors of ΔF508 CFTR restore global conformational maturation without thermally 
stabilizing the mutant protein. FASEB J. 27: 536–45. 
Heda, G.D., Tanwani, M., and Marino, C.R. (2001). The Delta F508 mutation shortens the 
biochemical half-life of plasma membrane CFTR in polarized epithelial cells. Am. J. Physiol. 
Cell Physiol. 280: C166–74. 
Heim, R., Cubitt, A.B., and Tsien, R.Y. (1995). Improved green fluorescence. Nature 373: 
663–664. 
Heim, R., Prasher, D.C., and Tsien, R.Y. (1994). Wavelength mutations and 
posttranslational autoxidation of green fluorescent protein. Proc. Natl. Acad. Sci. U. S. A. 91: 
12501–4. 
Hildebrandt, E., Ding, H., Mulky, A., Dai, Q., Aleksandrov, A.A., Bajrami, B., et al. (2015). A 
Stable Human-Cell System Overexpressing Cystic Fibrosis Transmembrane Conductance 
Regulator Recombinant Protein at the Cell Surface. Mol. Biotechnol. 
Hoelen, H., Kleizen, B., Schmidt, A., Richardson, J., Charitou, P., Thomas, P.J., et al. 
(2010). The primary folding defect and rescue of ΔF508 CFTR emerge during translation of 
the mutant domain. PLoS One 5: e15458. 
 References 147 
Holleran, J.P., Glover, M.L., Peters, K.W., Bertrand, C. a, Watkins, S.C., Jarvik, J.W., et al. 
(2012). Pharmacological rescue of the mutant cystic fibrosis transmembrane conductance 
regulator (CFTR) detected by use of a novel fluorescence platform. Mol. Med. 18: 685–96. 
Howard, M., DuVall, M.D., Devor, D.C., Dong, J.Y., Henze, K., and Frizzell, R. a (1995). 
Epitope tagging permits cell surface detection of functional CFTR. Am. J. Physiol. 269: 
C1565–76. 
Irwin, J.J., Sterling, T., Mysinger, M.M., Bolstad, E.S., and Coleman, R.G. (2012). ZINC: A 
Free Tool to Discover Chemistry for Biology. J. Chem. Inf. Model. 52: 1757–1768. 
Jayaraman, S., Haggie, P., Wachter, R.M., Remington, S.J., and Verkman,  a S. (2000). 
Mechanism and cellular applications of a green fluorescent protein-based halide sensor. J. 
Biol. Chem. 275: 6047–50. 
Jih, K.-Y., and Hwang, T.-C. (2013). Vx-770 potentiates CFTR function by promoting 
decoupling between the gating cycle and ATP hydrolysis cycle. Proc. Natl. Acad. Sci. U. S. 
A. 1–6. 
Jih, K.-Y., Sohma, Y., and Hwang, T.-C. (2012a). Nonintegral stoichiometry in CFTR gating 
revealed by a pore-lining mutation. J. Gen. Physiol. 140: 347–59. 
Jih, K.-Y., Sohma, Y., Li, M., and Hwang, T.-C. (2012b). Identification of a novel post-
hydrolytic state in CFTR gating. J. Gen. Physiol. 139: 359–70. 
Kanelis, V., Hudson, R.P., Thibodeau, P.H., Thomas, P.J., and Forman-Kay, J.D. (2010). 
NMR evidence for differential phosphorylation-dependent interactions in WT and DeltaF508 
CFTR. EMBO J. 29: 263–77. 
Kopeikin, Z., Yuksek, Z., Yang, H.-Y., and Bompadre, S.G. (2014). Combined effects of VX-
770 and VX-809 on several functional abnormalities of F508del-CFTR channels. J. Cyst. 
Fibros. 
Larsen, M.B., Hu, J., Frizzell, R.A., and Watkins, S.C. (2015). Simple image-based no-wash 
method for quantitative detection of surface expressed CFTR. METHODS. 
Lazrak, A., Fu, L., Bali, V., Bartoszewski, R., Rab, A., Havasi, V., et al. (2013). The silent 
codon change I507-ATC->ATT contributes to the severity of the ΔF508 CFTR channel 
dysfunction. FASEB J. 27: 4630–45. 
Lewis, H. a, Zhao, X., Wang, C., Sauder, J.M., Rooney, I., Noland, B.W., et al. (2005). 
Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis 
 References 148 
transmembrane conductance regulator on domain folding and structure. J. Biol. Chem. 280: 
1346–53. 
Li, C., Ramjeesingh, M., Wang, W., Garami, E., Hewryk, M., Lee, D., et al. (1996). ATPase 
activity of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 271: 
28463–8. 
Li, Y., and Tsien, R.W. (2012). pHTomato, a red, genetically encoded indicator that enables 
multiplex interrogation of synaptic activity. Nat. Neurosci. 15: 1047–53. 
Lin, W.-Y., Jih, K.-Y., and Hwang, T.-C. (2014). A single amino acid substitution in CFTR 
converts ATP to an inhibitory ligand. J. Gen. Physiol. 144: 311–320. 
Linsdell, P., Tabcharani, J. a, Rommens, J.M., Hou, Y.X., Chang, X.B., Tsui, L.C., et al. 
(1997). Permeability of wild-type and mutant cystic fibrosis transmembrane conductance 
regulator chloride channels to polyatomic anions. J.Gen.Physiol. 110: 355–364. 
Loo, M. a, Jensen, T.J., Cui, L., Hou, Y., Chang, X.B., and Riordan, J.R. (1998). Perturbation 
of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its 
degradation by the proteasome. EMBO J. 17: 6879–87. 
Lozano, R., Mohsen Naghavi, Kyle Foreman, Stephen Lim, Kenji Shibuya, Victor Aboyans*, 
Jerry Abraham*, Timothy Adair*, Rakesh Aggarwal*, S.Y.A., Mohammad A AlMazroa*, 
Miriam Alvarado*, H Ross Anderson*, Laurie M Anderson*, Kathryn G Andrews*, Charles 
Atkinson*, Larry M Baddour*, S.B.-C., David H Bartels*, Michelle L Bell*, Emelia J 
Benjamin*, Derrick Bennett*, Kavi Bhalla*, Boris Bikbov*, Aref Bin Abdulhak*, Gretchen 
Birbeck*, Fiona Blyth*, I.B., Soufi ane Boufous*, Chiara Bucello*, Michael Burch*, Peter 
Burney*, Jonathan Carapetis*, Honglei Chen*, David Chou*, Sumeet S Chugh*, Luc E Coff 
eng*, S.D.C., Samantha Colquhoun*, K Ellicott Colson*, John Condon*, Myles D Connor*, 
Leslie T Cooper*, Matthew Corriere*, Monica Cortinovis*, Karen Courville de Vaccaro*, 
W.C., et al. (2012). Global and regional mortality from 235 causes of death for 20 age 
groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 
2010. Lancet 380: 2095–128. 
Lu, Y., Xiong, X., Helm, A., Kimani, K., Bragin, A., and Skach, W.R. (1998). Co- and 
Posttranslational Translocation Mechanisms Direct Cystic Fibrosis Transmembrane 
Conductance Regulator N Terminus Transmembrane Assembly. J. Biol. Chem. 273: 568–
576. 
Lubamba, B., Dhooghe, B., Noel, S., and Leal, T. (2012). Cystic fibrosis: insight into CFTR 
 References 149 
pathophysiology and pharmacotherapy. Clin. Biochem. 45: 1132–44. 
Lukacs, G.L., Chang, X.B., Bear, C.E., Kartner, N., Mohamed,  a, Riordan, J.R., et al. 
(1993). The DF508 mutation decreases the stability of cystic fibrosis transmembrane 
conductance regulator in the plasma membrane. J Biol Chem 268: 21592–21598. 
Ma, T., Thiagarajah, J.R., Yang, H., Sonawane, N.D., Folli, C., Galietta, L.J. V, et al. (2002). 
Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin – 
induced intestinal fluid secretion. J. Clin. Invest. 110: 1651–1658. 
Matthes, E., Goepp, J., Carlile, G.W., Luo, Y., Dejgaard, K., Billet, A., et al. (2015). Low free 
drug concentration prevents inhibition of F508del CFTR functional expression by the 
potentiator VX-770 (ivacaftor). Br. J. Pharmacol. 770: n/a–n/a. 
Meacham, G.C., Patterson, C., Zhang, W., Younger, J.M., and Cyr, D.M. (2001). The Hsc70 
co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat. Cell Biol. 3: 
100–5. 
Middleton, P.G., and House, H.H. (2010). Measurement of airway ion transport assists the 
diagnosis of cystic fibrosis. Pediatr. Pulmonol. 45: 789–795. 
Mihalyi, C., Torocsik, B., and Csanady, L. (2016). Obligate coupling of CFTR pore opening 
to tight nucleotide-binding domain dimerization. Elife 1.: 
Miki, H., Zhou, Z., Li, M., Hwang, T.-C., and Bompadre, S.G. (2010). Potentiation of disease-
associated cystic fibrosis transmembrane conductance regulator mutants by hydrolyzable 
ATP analogs. J. Biol. Chem. 285: 19967–75. 
Moyer, B.D., Loffing, J., Schwiebert, E.M., Loffing-cueni, D., Halpin, P.A., Karlson, K.H., et 
al. (1998). Membrane Trafficking of the Cystic Fibrosis Gene Product , Cystic Fibrosis 
Transmembrane Conductance Regulator , Tagged with Green Fluorescent Protein in Madin-
Darby Canine Kidney Cells *. J. Biol. Chem. 273: 21759–21768. 
Muanprasat, C., Sonawane, N.D., Salinas, D., Taddei, A., Galietta, L.J. V, and Verkman,  a 
S. (2004). Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, 
structure-activity analysis, and in vivo efficacy. J. Gen. Physiol. 124: 125–37. 
Mueller, C., Braag, S.A., Keeler, A., Hodges, C., Drumm, M., and Flotte, T.R. (2011). Lack of 
cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant 
cytokine secretion and hyperinflammatory adaptive immune responses. Am. J. Respir. Cell 
Mol. Biol. 44: 922–929. 
 References 150 
Munye, M.M., Ravi, J., Tagalakis, A.D., McCarthy, D., Ryadnov, M.G., and Hart, S.L. (2015). 
Role of liposome and peptide in the synergistic enhancement of transfection with a 
lipopolyplex vector. Sci. Rep. 5: 9292. 
Namkung, W., Park, J., Seo, Y., and Verkman, A.S. (2013). Novel Amino-Carbonitrile-
Pyrazole Identified in a Small Molecule Screen Activates Wild-Type and Δ F508 Cystic 
Fibrosis Transmembrane Conductance Regulator in the Absence of a cAMP Agonist. Mol. 
Pharmacol. 84: 384–392. 
Naren, A.P., Cormet-Boyaka, E., Fu, J., Villain, M., Blalock, J.E., Quick, M.W., et al. (1999). 
CFTR Chloride Channel Regulation by an Interdomain Interaction. Science (80-. ). 286: 544–
548. 
Oda, S., Fukami, T., Yokoi, T., and Nakajima, M. (2015). A comprehensive review of UDP-
glucuronosyltransferase and esterases for drug development. Drug Metab. Pharmacokinet. 
30: 30–51. 
Okiyoneda, T., Barrière, H., Bagdány, M., Rabeh, W.M., Du, K., Höhfeld, J., et al. (2010). 
Peripheral protein quality control removes unfolded CFTR from the plasma membrane. 
Science 329: 805–10. 
Okiyoneda, T., Veit, G., Dekkers, J.F., Bagdany, M., Soya, N., Xu, H., et al. (2013). 
Mechanism-based corrector combination restores deltaF508-CFTR folding and function. Nat. 
Chem. Biol. 
Ormo, M., Cubitt, A.B., Kallio, K., Gross, L.A., Tsien, R.Y., and Remington, S.J. (1996). 
Crystal structure of the Aequorea victoria green fluorescent protein. Science (80-. ). 273: 
1392–1395. 
Pasyk, S., Molinksi, S., Ahmadi, S., Ramjeesingh, M., Huan, L.-J., Chin, S., et al. (2015). 
The Major Cystic Fibrosis Causing Mutation Exhibits Defective Propensity for 
Phosphorylation. Proteomics 15: 447–461. 
Pedemonte, N., Lukacs, G.L., Du, K., Caci, E., Zegarra-moran, O., Galietta, L.J. V, et al. 
(2005a). Small-molecule correctors of defective ∆ F508-CFTR cellular processing identified 
by high-throughput screening. J. Clin. Invest. 115: 2564–2571. 
Pedemonte, N., Sonawane, N.D., Taddei, A., Hu, J., Zegarra-moran, O., Suen, Y.F., et al. 
(2005b). Phenylglycine and Sulfonamide Correctors of Defective delF508 and G551D Cystic 
Fibrosis Transmembrane Conductance Regulator Chloride-Channel Gating. Mol. Pharmacol. 
67: 1797–1807. 
 References 151 
Pezzulo, A.A., Tang, X.X., Hoegger, M.J., Alaiwa, M.H.A., Ramachandran, S., Moninger, 
T.O., et al. (2012). Reduced airway surface pH impairs bacterial killing in the porcine cystic 
fibrosis lung. Nature 487: 109–13. 
Phuan, P.-W., Veit, G., Tan, J., Finkbeiner, W.E., Lukacs, G.L., and Verkman, A.S. (2015). 
Potentiators of Defective ΔF508-CFTR Channel Gating that do not Interfere with Corrector 
Action. Mol. Pharmacol. 88: mol.115.099689–. 
Phuan, P.-W., Veit, G., Tan, J., Roldan, A., Finkbeiner, W.E., Lukacs, G., et al. (2014). 
Synergy-based Small-Molecule Screen Using a Human Lung Epithelial Cell Line Yields 
F508-CFTR Correctors that Augment VX-809 Maximal Efficacy. Mol. Pharmacol. 86: 42–51. 
Prince, L.S. (1999). Efficient Endocytosis of the Cystic Fibrosis Transmembrane 
Conductance Regulator Requires a Tyrosine-based Signal. J. Biol. Chem. 274: 3602–3609. 
Pyle, L.C., Ehrhardt, A., Mitchell, L.H., Fan, L., Ren, A., Naren, A.P., et al. (2011). 
Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute 
CFTR modulators. Am. J. Physiol. Lung Cell. Mol. Physiol. 301: L587–97. 
Rabeh, W.M., Bossard, F., Xu, H., Okiyoneda, T., Bagdany, M., Mulvihill, C.M., et al. (2012). 
Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR 
folding and function. Cell 148: 150–63. 
Rai, V., Gaur, M., Shukla, S., Shukla, S., Ambudkar, S. V., Komath, S.S., et al. (2006). 
Conserved Asp327 of Walker B motif in the N-terminal nucleotide binding domain (NBD-1) of 
Cdr1p of Candida albicans has acquired a new role in ATP hydrolysis. Biochemistry 45: 
14726–14739. 
Ramjeesingh, M., Li, C., Garami, E., Huan, L.J., Galley, K., Wang, Y., et al. (1999). Walker 
mutations reveal loose relationship between catalytic and channel-gating activities of purified 
CFTR (cystic fibrosis transmembrane conductance regulator). Biochemistry 38: 1463–1468. 
Ramsey, B.W., Jane, D., McElvaney, N.G., Tullis, E., Bell, S.C., Dřevínek, P., et al. (2011). A 
CFTR Potentiator in Patients with Cystic Fibrosis and the G155D mutation. N. Engl. J. Med. 
365: 1663–1672. 
Ratner, D., and Mueller, C. (2012). Immune responses in cystic fibrosis: Are they intrinsically 
defective? Am. J. Respir. Cell Mol. Biol. 46: 715–722. 
Robert, R., Carlile, G.W., Pavel, C., Liu, N., Anjos, S.M., Liao, J., et al. (2008). Structural 
Analog of Sildenafil Identified as a Novel Corrector of the F508del-CFTR Trafficking Defect. 
 References 152 
Mol. Pharmacol. 73: 478–489. 
Roxo-Rosa, M., Xu, Z., Schmidt, A., Neto, M., Cai, Z., Soares, C.M., et al. (2006). Revertant 
mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain 
of CFTR by different mechanisms. Proc. Natl. Acad. Sci. U. S. A. 103: 17891–6. 
Sabirzhanova, I., Lopes Pacheco, M., Rapino, D., Grover, R., Handa, J.T., Guggino, W.B., et 
al. (2015). Rescuing trafficking mutants of the ATP-binding cassette protein, ABCA4, with 
small molecule correctors as a treatment for Stargardt eye disease. J. Biol. Chem. 290: 
19743–19755. 
Schultz, B.D., Takahashi,  a, Liu, C., Frizzell, R. a, and Howard, M. (1997). FLAG epitope 
positioned in an external loop preserves normal biophysical properties of CFTR. Am. J. 
Physiol. 273: C2080–9. 
Serohijos, A.W.R., Aleksandrov, A.A., He, L., Cui, L., Dokholyan, N. V, and Riordan, J.R. 
(2008). Phenylalanine-508 mediates a cytoplasmic – membrane domain contact in the CFTR 
3D structure crucial to assembly and channel function. Proc. Natl. Acad. Sci. U. S. A. 105: 
3256–3261. 
Shah, K., Cheng, Y., Hahn, B., Bridges, R., Bradbury, N. a., and Mueller, D.M. (2015). 
Synonymous Codon Usage Affects the Expression of Wild Type and F508del CFTR. J. Mol. 
Biol. 427: 1464–1479. 
Sharma, M., Benharouga, M., Hu, W., and Lukacs, G.L. (2001). Conformational and 
temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane 
conductance regulator in post-endoplasmic reticulum compartments. J. Biol. Chem. 276: 
8942–50. 
Sharma, M., Pampinella, F., Nemes, C., Benharouga, M., So, J., Du, K., et al. (2004). 
Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J. 
Cell Biol. 164: 923–33. 
Shaw, G., Morse, S., Ararat, M., and Graham, F.L. (2002). Preferential transformation of 
human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J. 16: 
869–71. 
Sloane, P. a, Shastry, S., Wilhelm, A., Courville, C., Tang, L.P., Backer, K., et al. (2012). A 
pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator 
dysfunction in smoking related lung disease. PLoS One 7: e39809. 
 References 153 
Sorum, B., Czégé, D., and Csanády, L. (2015). Timing of CFTR Pore Opening and Structure 
of Its Transition State. Cell 163: 724–733. 
Stoltz, D.A., Meyerholz, D.K., Pezzulo, A.A., Ramachandran, S., Rogan, M.P., Davis, G.J., 
et al. (2010). Cystic Fibrosis Pigs Develop Lung Disease and Exhibit Defective Bacterial 
Eradication at Birth. Sci. Transl. Med. 2: 29ra31–29ra31. 
Stutts, M.J., Canessa, C.M., Olsen, J.C., Hamrick, M., Cohn, J.A., Rossier, B.C., et al. 
(1995). CFTR as a cAMP-Dependent Regulator of Sodium Channels. Science (80-. ). 269: 
847–850. 
Thibodeau, P.H., Richardson, J.M., Wang, W., Millen, L., Watson, J., Mendoza, J.L., et al. 
(2010). The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis 
transmembrane conductance regulator biogenesis. J. Biol. Chem. 285: 35825–35. 
Tirouvanziam, R., Bentzmann, S. De, Hubeau, C., Hinnrasky, J., Jacquot, J., Péault, B., et 
al. (2000). Inflammation and infection in naive human cystic fibrosis airway grafts. Am. J. 
Respir. Cell Mol. Biol. 23: 121–127. 
Tsai, M.-F., Li, M., and Hwang, T.-C. (2010). Stable ATP binding mediated by a partial NBD 
dimer of the CFTR chloride channel. J. Gen. Physiol. 135: 399–414. 
Urbatsch, I.L., Sankaran, B., Weber, J., and Senior, A.E. (1995). P-glycoprotein is stably 
inhibited by vandate-induced trapping of nucleotide at a single catalytic site. J. Biol. Chem. 
270: 19383–19390. 
Vais, H., Gao, G.-P., Yang, M., Tran, P., Louboutin, J.-P., Somanathan, S., et al. (2004). 
Novel adenoviral vectors coding for GFP-tagged wtCFTR and deltaF508-CFTR: 
characterization of expression and electrophysiological properties in A549 cells. Pflugers 
Arch. 449: 278–87. 
Van Goor, F., Hadida, S., Grootenhuis, P.D.J., Burton, B., Cao, D., Neuberger, T., et al. 
(2009). Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. 
Proc. Natl. Acad. Sci. U. S. A. 106: 18825–30. 
Van Goor, F., Hadida, S., Grootenhuis, P.D.J., Burton, B., Stack, J.H., Straley, K.S., et al. 
(2011). Correction of the F508del-CFTR protein processing defect in vitro by the 
investigational drug VX-809. Proc. Natl. Acad. Sci. U. S. A. 108: 18843–8. 
Van Goor, F., Straley, K.S., Cao, D., González, J., Hadida, S., Hazlewood, A., et al. (2006). 
Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary 
 References 154 
cultures by small molecules. Am. J. Physiol. Lung Cell. Mol. Physiol. 290: L1117–30. 
Van Goor, F., Yu, H., Burton, B., and Hoffman, B.J. (2013). Effect of ivacaftor on CFTR 
forms with missense mutations associated with defects in protein processing or function. J. 
Cyst. Fibros. 
Veit, G., Avramescu, R.G., Perdomo, D., Phuan, P.-W., Bagdany, M., Apaja, P.M., et al. 
(2014). Some gating potentiators, including VX-770, diminish  F508-CFTR functional 
expression. Sci. Transl. Med. 6: 246ra97–246ra97. 
Vergani, P., Lockless, S.W., Nairn, A.C., and Gadsby, D.C. (2005). CFTR channel opening 
by ATP-driven tight dimerization of its nucleotide-binding domains. Nature 433: 876–80. 
Vergani, P., Nairn, A.C., and Gadsby, D.C. (2003). On the Mechanism of MgATP-dependent 
Gating of CFTR Cl- Channels. J. Gen. Physiol. 120: 17–36. 
Wachter, R.M., Yarbrough, D., Kallio, K., and Remington, S.J. (2000). Crystallographic and 
energetic analysis of binding of selected anions to the yellow variants of green fluorescent 
protein. J. Mol. Biol. 301: 157–71. 
Wainwright, C.E., Elborn, J.S., Ramsey, B.W., Marigowda, G., Huang, X., Cipolli, M., et al. 
(2015). Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del 
CFTR. N. Engl. J. Med. 150517100015004. 
Wang, F., Zeltwanger, S., Hu, S., and Hwang, T.C. (2000). Deletion of phenylalanine 508 
causes attenuated phosphorylation-dependent activation of CFTR chloride channels. J. 
Physiol. 524 Pt 3: 637–48. 
Wang, X., Koulov, A. V, Kellner, W. a, Riordan, J.R., and Balch, W.E. (2008). Chemical and 
biological folding contribute to temperature-sensitive DeltaF508 CFTR trafficking. Traffic 9: 
1878–93. 
Wang, X., Matteson, J., An, Y., Moyer, B., Yoo, J.-S., Bannykh, S., et al. (2004). COPII-
dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses 
a di-acidic exit code. J. Cell Biol. 167: 65–74. 
Wellhauser, L., Chiaw, P.K., Pasyk, S., Li, C., Ramjeesingh, M., and Bear, C.E. (2009). A 
Small-Molecule Modulator Interacts Directly with Phe508- CFTR to Modify Its ATPase 
Activity and Conformational Stability. Mol. Pharmacol. 75: 1430–1438. 
Wu, M.M., Grabe, M., Adams, S., Tsien, R.Y., Moore, H.P.H., and Machen, T.E. (2001). 
Mechanisms of pH Regulation in the Regulated Secretory Pathway. J. Biol. Chem. 276: 
 References 155 
33027–33035. 
Xu, J., Chai, H., Ehinger, K., Egan, T.M., Srinivasan, R., Frick, M., et al. (2014). Imaging 
P2X4 receptor subcellular distribution, trafficking, and regulation using P2X4-pHluorin. J. 
Gen. Physiol. 144: 81–104. 
Yang, H., Shelat, A. a, Guy, R.K., Gopinath, V.S., Ma, T., Du, K., et al. (2003). Nanomolar 
affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J. 
Biol. Chem. 278: 35079–85. 
Yang, Y., Janich, S., Cohn, J.A., and Wilson, J.M. (1993). The Common Variant of Cystic 
Fibrosis Transmembrane Conductance Regulator is Recognized by hsp7O and Degraded in 
a Pre-Golgi Nonlysosomal Compartment. Proc. Natl. Acad. Sci. U. S. A. 90: 9480–9484. 
Yu, H., Burton, B., Huang, C.-J., Worley, J., Cao, D., Johnson, J.P., et al. (2012). Ivacaftor 
potentiation of multiple CFTR channels with gating mutations. J. Cyst. Fibros. 11: 237–45. 
Zhang, L., Aleksandrov, L.A., Riordan, J.R., and Ford, R.C. (2011). Do main location within 
the cystic fibrosis transmembrane conductance regulator protein investigated by electron 
microscopy and gold labelling. Biochim. Biophys. Acta - Biomembr. 1808: 399–404. 
Zhang, X.D. (2007). A pair of new statistical parameters for quality control in RNA 
interference high-throughput screening assays. Genomics 89: 552–561. 
Zhang, X.D. (2008). Novel analytic criteria and effective plate designs for quality control in 
genome-scale RNAi screens. J. Biomol. Screen.  Off. J. Soc. Biomol. Screen. 13: 363–377. 
Zhang, X.D. (2011). Illustration of SSMD, z score, SSMD*, z* score, and t statistic for hit 
selection in RNAi high-throughput screens. J. Biomol. Screen.  Off. J. Soc. Biomol. Screen. 
16: 775–785. 
Zhang, X.D., Ferrer, M., Espeseth, A.S., Marine, S.D., Stec, E.M., Crackower, M. a, et al. 
(2007). The use of strictly standardized mean difference for hit selection in primary RNA 
interference high-throughput screening experiments. J. Biomol. Screen.  Off. J. Soc. Biomol. 
Screen. 12: 497–509. 
Zhou, Z., Hu, S., and Hwang, T.C. (2001). Voltage-dependent flickery block of an open 
cystic fibrosis transmembrane conductance regulator (CFTR) channel pore. J. Physiol. 532: 
435–448. 
 
